

10/519,722

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10/519,722

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:44:50 ON 29 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:44:58 ON 29 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

DICTIONARY FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10519722.str



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom 21:CLASS  
22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

10/519,722

18:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

O,O0  
S,S0  
N,N0-3

Node 18: Limited

O,O0  
S,S0  
N,N1-2

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:45:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 336 TO ITERATE

100.0% PROCESSED 336 ITERATIONS

20 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5621 TO 7819

PROJECTED ANSWERS: 132 TO 668

L2 20 SEA SSS SAM L1


=> d scan

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-4-  
[(methyl-3-pyrrolidinylamino)methyl]- (9CI)

MF C29 H31 N7 O






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):19

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)  
 MF C29 H31 N7 O . x C5 H8 O4

CM 1




CM 2

10/519,722

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3S)-3-(diethylamino)-1-pyrrolidiny]methyl]-3-(trifluoromethyl)- (9CI)  
MF C32 H35 F3 N8 O  
CI COM


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3S)-3-(dimethylamino)-1-piperidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
MF C31 H33 F3 N8 O . Cl H


Absolute stereochemistry. Rotation (+).



● HCl

10/519,722


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI)  
MF C32 H33 F3 N6 O  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI)  
MF C30 H33 N7 O . C2 H4 O2

CM 1




CM 2




L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)  
MF C30 H31 Br N6 O

10/519,722



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[4-chloro-3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)-  
(9CI)  
MF C29 H28 Cl F3 N8 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2)  
(9CI)  
MF C29 H31 N7 O . 1/2 C5 H8 O4

CM 1




CM 2

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

10/519,722

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[{(2R,4S)-4-(dimethylamino)-2-methyl-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI)  
MF C31 H33 F3 N8 O  
CI COM


Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI)  
MF C30 H31 F3 N8 O2  
CI COM


PAGE 1-A






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-ethyl-4-  
 [(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI)  
 MF C30 H34 N8 O . Cl H



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)  
 MF C29 H31 N7 O  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


10/519,722

IN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-  
[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI)  
MF C26 H24 F3 N7 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI)  
MF C30 H31 F3 N8 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI)  
MF C29 H31 N7 O . Cl H

10/519,722



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)-1-azetidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
MF C29 H29 F3 N8 O . Cl H




● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-6-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
MF C29 H29 F3 N8 O . Cl H




10/519,722




● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI)  
MF C29 H31 N7 O . C17 H37 N7 O3  
CI MXS  
CM 1




CM 2

Absolute stereochemistry. Rotation (-).



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-nitro- (9CI)  
MF C29 H30 N8 O3

10/519,722



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful

FULL SEARCH INITIATED 13:45:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6526 TO ITERATE

100.0% PROCESSED 6526 ITERATIONS

325 ANSWERS

SEARCH TIME: 00.00.01

L3 325 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 13:46:03 ON 29 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15

FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 2002 L3

=> l4 and (pyridine or pyrimidine or pyrazine or pyridazine)

L4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

10/519,722

For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s 14 and (pyridine or pyridazine or pyrazine or pyrimidine)

211669 PYRIDINE

6728 PYRIDAZINE

12811 PYRAZINE

54368 PYRIMIDINE

L5 106 L4 AND (PYRIDINE OR PYRIDAZINE OR PYRAZINE OR PYRIMIDINE)

=> d 15 1-105 bib hitstr

L5 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:817911 CAPLUS

DN 145:249188

TI Preparation of tetrahydropyridothiophenes as antiproliferative agents for  
the treatment of cancer

IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,  
Bjoern

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 158pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084904	A1	20060817	WO 2006-EP50859	20060210
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-101007	A	20050211		
	EP 2005-104493	A	20050525		
	EP 2005-112159	A	20051214		


IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of tetrahydropyridothiophenes as antiproliferative and  
apoptosis-inducing agents useful in treatment of cancer)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




10/519,722

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:817524 CAPLUS  
DN 145:249187  
TI Preparation of tetrahydropyridothiophenes for the treatment of  
proliferative diseases such as cancer  
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,  
Bjoern  
PA Altana Pharma AG, Germany  
SO PCT Int. Appl., 154pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084869	A1	20060817	WO 2006-EP50782	20060208
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-100895	A	20050209		
	EP 2005-104488	A	20050525		
	EP 2005-112158	A	20051214		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of tetrahydropyridothiophenes with cell-cycle dependent, antiproliferative and apoptosis-inducing activity useful in treatment of hyperproliferative diseases such as cancer)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:768666 CAPLUS  
DN 145:188880  
TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and  
their preparation, pharmaceutical compositions and antiproliferative and

10/519,722

apoptosis inducing activity  
IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra;  
Beckers, Thomas; Schmidt, Mathias; Ciossek, Thomas; Nappe, Sandra  
PA Altana Pharma AG, Germany  
SO PCT Int. Appl., 56pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079644	A1	20060803	WO 2006-EP50465	20060126
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-100594	A	20050128		
	EP 2005-100913	A	20050209		
IT	152459-95-5				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)			
RN	152459-95-5	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:768650 CAPLUS  
DN 145:211060  
TI Preparation of substituted phenylaminopyrimidines as B-Raf inhibitors  
IN Aquila, Brian; Lyne, Paul; Pontz, Timothy  
PA AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SO PCT Int. Appl., 59pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

10/519,722

PI WO 2006079791 A1 20060803 WO 2006-GB223 20060124  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-646820P P 20050125

OS MARPAT 145:211060


IT 904326-67-6P 904326-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted phenylaminopyrimidines as B-Raf inhibitors for treating cancer)


RN 904326-67-6 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 904326-68-7 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768370 CAPLUS

DN 145:188879

TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and their preparation, pharmaceutical compositions and antiproliferative and apoptosis inducing activity

IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra

PA Altana Pharma AG, Germany

10/519,722

SO PCT Int. Appl., 61pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079645	A1	20060803	WO 2006-EP50467	20060126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-100526	A	20050127		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:729704 CAPLUS  
DN 145:159791  
TI 2-Phenylquinoxalines as inhibitors of MPP1 for treatment of proliferative diseases  
IN Nigg, Erich A.; Mayer, Thomas U.; Huenner, Stefan; Barr, Francis; Bormann, Jenny  
PA Max-Planck-Gesellschaft Zur Foerderung der Wissenschaften e.v., Germany  
SO Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1683523	A1	20060726	EP 2005-1419	20050125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				

BA, HR, IS, YU  
 WO 2006079478 A1 20060803 WO 2006-EP459 20060119  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 PRAI EP 2005-1419 A 20050125  
 IT 152459-95-5, Imatinib  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination with; phenylquinoxalines as inhibitors of human  
 phosphoprotein MPP1 for treatment of cancer and proliferative diseases)  
 RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:657352 CAPLUS  
 DN 145:124614  
 TI Multi-step process for preparing imatinib  
 IN Huang, Anli; Xing, Liu; Zelikovitch, Lior; Kaspi, Joseph  
 PA Peop. Rep. China  
 SO U.S. Pat. Appl. Publ., 11 pp.  
 CODEN: USXXCO

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006149061	A1	20060706	US 2005-318455	20051228
PRAI	US 2004-640013P	P	20041230		
OS	CASREACT 145:124614				
IT	152459-95-5P, Imatinib				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(multi-step process for preparing imatinib)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				






L5 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:655575 CAPLUS  
 DN 145:124558  
 TI Preparation of pyrazolyl phenyl ureas as enzyme modulators  
 IN Flynn, Daniel L.; Petillo, Peter A.  
 PA Deciphera Pharmaceuticals, LLC, USA  
 SO PCT Int. Appl., 974 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006071940	A2	20060706	WO 2005-US47270	20051223
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-638968P	P	20041223		
	US 2004-638986P	P	20041223		
	US 2004-638987P	P	20041223		
	US 2004-639087P	P	20041223		
OS	MARPAT 145:124558				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(co-drug; preparation of pyrazolyl Ph ureas as enzyme modulators for treating cancer and hyperproliferative diseases)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1

CRN 152459-95-5  
 CMF C29 H31 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:513267 CAPLUS  
DN 145:21160  
TI Methods and compositions for the treatment of graft failure  
IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 85 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006057951	A2	20060601	WO 2005-US42111	20051121
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-630242P	P	20041122		
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(comps. for treatment of graft failure)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:463553 CAPLUS  
DN 144:488677  
TI Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors  
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad  
PA Schering Corporation, USA  
SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006106023	A1	20060518	US 2005-272392	20051110
	US 2004063715	A1	20040401	US 2003-665005	20030919
	US 6919341	B2	20050719		
	US 2005130980	A1	20050616	US 2005-47524	20050131
PRAI	US 2002-412997P	P	20020923		
	US 2003-665005	A3	20030919		
	US 2005-47524	A2	20050131		

OS MARPAT 144:488677

IT 220127-57-1, Gleevec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors useful in treatment and prevention of various diseases)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:412038 CAPLUS  
DN 144:450735  
TI Preparation of novel aminopyridine derivatives having selective Aurora-A  
protein kinase inhibitory effect  
IN Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi;  
Shimomura, Toshiyasu  
PA Banyu Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 148 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006046734	A2	20060504	WO 2005-JP19957	20051025
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006106029	A1	20060518	US 2005-258447	20051025
PRAI	JP 2004-315152	A	20041029		
	JP 2005-161156	A	20050601		

10/519,722

US 2005-692537P P 20050621  
OS MARPAT 144:450735  
IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(novel aminopyridine derivs. having selective Aurora-A inhibitory  
effect)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:372184 CAPLUS  
DN 145:34047  
TI Anticancer implant compositions containing vasoinhibitor/  
pyrimidine derivative composite implant  
IN Kong, Qingzhong; Sun, Juan; Liu, Enxiang  
PA Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1733300	A	20060215	CN 2005-10044377	20050805
PRAI	CN 2005-10044377		20050805		
IT	220127-57-1, Imatinib mesylate				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (vasoinhibitor/pyrimidine derivative antitumor composite implant)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




10/519,722

CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:333442 CAPLUS

DN 144:370121

TI Preparation of pyrimidine derivatives as phosphatase and kinase inhibitors for treating a variety of diseases

IN Klebl, Bert; Baumann, Matthias; Hoppe, Edmund; Brehmer, Dirk; Daub, Henrik; Keri, Gyoergy; Varga, Zoltan; Marosfalvi, Jenoe; Oerfi, Laszlo

PA GPC Biotech A.-G., Germany

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021458	A2	20060302	WO 2005-EP9291	20050829
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-604685P P 20040827

OS MARPAT 144:370121


IT 152459-93-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-95-5P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-66-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 872672-74-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881676-19-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881677-62-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as phosphatase and kinase inhibitors for treating a variety of diseases)

RN 152459-93-3 CAPLUS


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-66-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 872672-74-7 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 881676-19-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722



RN 881677-62-9 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:333345 CAPLUS  
DN 144:350709  
TI Pyrazolopyrimidines as protein kinase B inhibitors, their preparation, pharmaceutical compositions, and use in therapy  
IN Maier, Thomas; Zuelch, Armin; Ciossek, Thomas; Baer, Thomas; Beckers, Thomas  
PA Altana Pharma AG, Germany  
SO PCT Int. Appl., 114 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006027346	A2	20060316	WO 2005-EP54366	20050905
	WO 2006027346	A3	20060803		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2004-104283 A 20040906

OS MARPAT 144:350709

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel pyrazolopyrimidine compds. useful in therapy of hyper-proliferative diseases and disorders responsive to induction of apoptosis)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-



10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:318488 CAPLUS

DN 144:369909

TI Preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors

IN Bold, Guido; Caravatti, Giorgio; Floersheimer, Andreas; Furet, Pascal;

Manley, Paul W.; Pissot Soldermann, Carole; Vaupel, Andrea

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034833	A1	20060406	WO 2005-EP10408	20050927
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI GB 2004-21525 A 20040928

OS MARPAT 144:369909

IT 220127-57-1, Glivec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(claimed drug for co-administration; preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:196073 CAPLUS  
DN 144:274310  
TI Preparation of benzotriazines, triazoles and oxadiazoles that affect the  
MAPK pathway and methods of use  
IN Wrasidlo, Wolfgang; Dneprovskaja, Elena  
PA Targen, Inc., USA  
SO PCT Int. Appl., 183 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024034	A1	20060302	WO 2005-US30614	20050824
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006079526	A1	20060413	US 2005-212064	20050824
PRAI	US 2004-604298P	P	20040825		
	US 2005-696168P	P	20050701		


OS MARPAT 144:274310

IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrug; preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use)

10/519,722

RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:176834 CAPLUS  
DN 144:370108  
TI Preparation and application of phenylamino pyrimidine derivatives  
IN Chen, Guoqing  
PA Chen Guoqing, Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 41 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1560050	A	20050105	CN 2004-10014093	20040218
PRAI	CN 2004-10014093		20040218		
IT	791609-82-0P 791609-84-2P 791609-85-3P 882166-67-8P				

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and application of phenylamino pyrimidine derivs.)


RN 791609-82-0 CAPLUS  
CN Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 791609-84-2 CAPLUS  
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [[(1-methyl-3-pyrrolidinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 791609-85-3 CAPLUS  
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [(3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



Me

RN 882166-67-8 CAPLUS  
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [(methyl-3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



Me

L5 ANSWER 18 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:167936 CAPLUS  
 DN 144:254145  
 TI Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors  
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.  
 PA Schering Corporation, USA  
 SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006041131	A1	20060223	US 2005-244772	20051006
	US 2004106624	A1	20040603	US 2003-653776	20030903
	US 7067661	B2	20060627		
	US 2006178371	A1	20060810	US 2006-395676	20060331
PRAI	US 2002-408029P	P	20020904		
	US 2003-653776	A2	20030903		

OS MARPAT 144:254145

IT 220127-57-1, Gleevec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of novel pyrazolopyrimidines as cyclin dependent kinase

10/519,722

inhibitors for treatment and prevention of diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:167588 CAPLUS

DN 144:254148

TI Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy

IN Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
	WO 2006018182	C1	20060608		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				




CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2006058311 A1 20060316 US 2005-189540 20050726  
PRAI EP 2004-19361 A 20040814  
EP 2004-19448 A 20040817

OS MARPAT 144:254148  
IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(preparation of aminopteridinones for use in combination therapy for  
treatment of cell proliferative diseases)

RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:117065 CAPLUS  
DN 144:184657  
TI Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-  
ylmethyl)-N-4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-  
ylamino]phenyl]benzamide  
IN Breedveld, Pauline; Cipriani, Greta; Pluim, Dick; Schellens, Johannes  
Henricus Matthias; Van Tellingena, Olaf; Wielinga, Pieter Roeland  
PA The Netherlands Cancer Institute, Neth.  
SO PCT Int. Appl., 13 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012958	A2	20060209	WO 2005-EP7090	20050630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-584825P	P	20040701		
IT 152459-95-5 220127-57-1				
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

10/519,722

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 874946-80-2 874946-81-3 874946-82-4

874946-83-5 874946-84-6 874946-85-7

875128-64-6 875128-67-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)

RN 874946-80-2 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 102625-70-7

CMF C16 H15 F2 N3 O4 S



RN 874946-81-3 CAPLUS


CN Benamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (3S,8aS)-hexahydro-3-[[[6-methoxy-2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]pyrrolo[1,2-a]pyrazine-1,4-dione (9CI) (CA INDEX NAME)

CM 1

CRN 171864-80-5

CMF C22 H27 N3 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 152459-95-5

CMF C29 H31 N7 O

10/519,722




RN 874946-82-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (5aS,12S,14aS)-1,2,3,5a,6,11,12,14a-octahydro-9-methoxy-12-(2-methyl-1-propenyl)-5H,14H-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,14-dione (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 118974-02-0

CMF C22 H25 N3 O3

Absolute stereochemistry.



RN 874946-83-5 CAPLUS

CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid, 1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxo-, 1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 461054-93-3

CMF C26 H35 N3 O5

10/519,722


Absolute stereochemistry. Rotation (-).



CM 2

CRN 152459-95-5

CMF C29 H31 N7 O




RN 874946-84-6 CAPLUS

CN 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 143664-11-3

CMF C34 H33 N3 O5




RN 874946-85-7 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 289499-45-2

CMF C24 H25 Cl F N5 O3 . 2 Cl H


10/519,722



●2 HCl

CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 875128-64-6 CAPLUS

CN Carbamic acid, [4-[(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl]butyl]-, 1,1-dimethylethyl ester, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)  
(CA INDEX NAME)

CM 1

CRN 329356-42-5  
CMF C27 H38 N4 O4


Absolute stereochemistry.



10/519,722

CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 875128-67-9 CAPLUS  
CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid,  
1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxo-,  
1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-  
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 329356-45-8  
CMF C25 H33 N3 O4

Absolute stereochemistry.



CM 2


CRN 152459-95-5  
CMF C29 H31 N7 O



L5 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:87941 CAPLUS  
DN 144:331390  
TI Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl  
kinase inhibitors  
AU Asaki, Tetsuo; Sugiyama, Yukiteru; Hamamoto, Taisuke; Higashioka, Masaya;




Umehara, Masato; Naito, Haruna; Niwa, Tomoko  
 CS Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Minami-ku,  
 Kyoto, Kisshoin, 601-8550, Japan  
 SO Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1421-1425  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier B.V.  
 DT Journal  
 LA English  
 OS CASREACT 144:331390  
 IT 641614-88-2P 859212-07-0P 859212-16-1P, NS-187  
 859212-47-8P 859212-49-0P 859212-51-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation N-[[[(bipyrimidinyl)amino](methyl)phenyl](trifluoromethyl)benzam  
 ide derivs. and study of their activity as Bcr-Abl kinase inhibitors)  
 RN 641614-88-2 CAPLUS  
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-  
 methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 859212-07-0 CAPLUS  
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[[(3R)-3-(dimethylamino)-1-pyrrolidinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 859212-16-1 CAPLUS

10/519,722


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3S)-3-(dimethylamino)-1-pyrrolidiny]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859212-47-8 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)-1-azetidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 859212-49-0 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3R)-3-[(dimethylamino)methyl]-1-pyrrolidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/519,722



● HCl

RN 859212-51-4 CAPLUS  
CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3S)-3-  
[(dimethylamino)methyl]-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


IT 641614-83-7P 641614-84-8P 641614-85-9P  
641614-86-0P 641614-87-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation halo[(piperazinyl)methyl][methyl[(pyridinyl)pyrimidinyl]amino]p  
henyl]benzamide derivs. and study of their activity as Bcr-Abl kinase  
inhibitors)

10/519,722


RN 641614-83-7 CAPLUS  
CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-84-8 CAPLUS  
CN Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS  
CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-86-0 CAPLUS  
CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-87-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 220127-57-1, STI-571

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(preparation substituted benzamide derivs., study of their activity as gene  
Bcr-Abl fusion protein- phosphorylating kinase (Bcr-Abl kinase)  
inhibitors and their activity against STI-571-resistant chronic myeloid  
leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:15086 CAPLUS

DN 144:108347

TI Preparation of pyrimidine urea derivatives as kinase inhibitors  
for use against proliferative diseases

IN Ding, Qiang; Gray, Nathanael Schiander; Li, Bing; Liu, Yi; Sim, Taebo;  
Uno, Tetsuo; Zhang, Guobao; Pissot Soldermann, Carole; Breitenstein,  
Werner; Bold, Guido; Caravatti, Giorgio; Furet, Pascal; Guagnano, Vito;  
Lang, Marc; Manley, Paul W.; Schoepfer, Joseph; Spanka, Carsten


10/519,722

PA Novartis AG, Switz.  
SO PCT Int. Appl., 327 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006000420	A1	20060105	WO 2005-EP6815	20050623
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-582425P	P	20040624		
	GB 2005-12324	A	20050616		
OS	MARPAT 144:108347				
IT	220127-57-1, Glivec				
	RL:	THU (Therapeutic use); BIOL (Biological study); USES (Uses) (codrug; preparation of pyrimidine urea derivs. as kinase inhibitors for use against proliferative diseases)			
RN	220127-57-1	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




10/519,722

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1329776 CAPLUS  
DN 144:45462  
TI Pharmacologically active substances in combination with radio waves for  
the treatment of cancer  
IN Kalbe, Jochen; Ludwig, Georg  
PA Germany  
SO PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005120638	A1	20051222	WO 2005-DE1028	20050609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004028156	A1	20060105	DE 2004-102004028156	20040609
PRAI	DE 2004-102004028156	A	20040609		
	US 2004-585061P	P	20040706		
IT	152459-95-5, Imatinib				
	RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug-radio wave combination for treatment of cancer)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1289902 CAPLUS  
DN 144:17212  
TI Use of c-kit inhibitors for treating fibrodysplasia  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA Ab Science, Fr.  
SO PCT Int. Appl., 66 pp.  
CODEN: PIXXD2

10/519,722

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115304	A2	20051208	WO 2005-IB1371	20050419
	WO 2005115304	A3	20060406		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2004-573345P	P	20040524		
OS	MARPAT 144:17212				
IT	152459-95-5				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (c-kit inhibitors for treating fibrodysplasia)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1289861 CAPLUS  
DN 144:17211  
TI Use of c-kit inhibitors for treating acne  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA Ab Science, Fr.  
SO PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115385	A1	20051208	WO 2005-IB1366	20050419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			



10/519,722

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRAI US 2004-573351P P 20040524


OS MARPAT 144:17211

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(c-kit inhibitors for treating acne)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1262399 CAPLUS

DN 144:22712

TI Triaryl compounds as PPAR modulators, their preparation, pharmaceutical  
compositions, and use in therapy

IN Epple, Robert; Azimioara, Mihai

PA Irm LLC, Bermuda

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113506	A1	20051201	WO 2005-US16747	20050513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-571004P P 20040514

OS MARPAT 144:22712

IT 152459-95-5, Imatinib


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of triaryl compds. as PPAR modulators and their use for  
treatment and prevention of diseases associated with PPARs activity)

RN 152459-95-5 CAPLUS

10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1239173 CAPLUS  
DN 143:477963  
TI Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful  
in the treatment of cancer  
IN Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying,  
Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum  
PA Bayer Pharmaceuticals Corporation, USA  
SO PCT Int. Appl., 215 pp.  
CODEN: PIXXD2  
DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005110994	A2	20051124	WO 2005-US15106	20050502
	WO 2005110994	A3	20060202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-566445P P 20040430

OS MARPAT 143:477963

IT 220127-57-1, Gleevec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(substituted pyrazolylurea derivs. useful for cancer treatment)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O

10/519,722



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170688 CAPLUS  
DN 143:432622  
TI Use of c-kit inhibitors for treating HIV-related diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 72 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102318	A1	20051103	WO 2005-IB1433	20050419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-563442P P 20040420

OS MARPAT 143:432622


IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of HIV-related diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170667 CAPLUS  
DN 143:432692  
TI Use of c-kit inhibitors for treating fibrosis  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 67 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102346	A2	20051103	WO 2005-IB1391	20050419
	WO 2005102346	A3	20060330		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-564569P P 20040423


OS MARPAT 143:432692

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of fibrosis)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170651 CAPLUS

10/519,722

DN 143:432621  
TI Use of c-kit inhibitors for treating plasmodium-related diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA Ab Science, Fr.  
SO PCT Int. Appl., 71 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102455	A1	20051103	WO 2005-IB1390	20050419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2004-564599P	P	20040423		
OS	MARPAT 143:432621				
IT	152459-95-5				
	RL:	(Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (c-kit inhibitors for treating plasmodium-related diseases)			
RN	152459-95-5	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170633 CAPLUS  
DN 143:432657  
TI Use of c-kit inhibitors for treating renal diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 69 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102326	A2	20051103	WO 2005-IB1370	20050419
	WO 2005102326	A3	20060330		

10/519,722

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-564586P P 20040423


OS MARPAT 143:432657

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of renal disease)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170607 CAPLUS

DN 143:432650

TI Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102325	A1	20051103	WO 2005-IB1367	20050419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-563460P P 20040420

OS MARPAT 143:432650

10/519,722

IT 152459-95-5  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(c-kit inhibitors for treatment of inflammatory muscle disorders  
including myositis and muscular dystrophy)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1006008 CAPLUS  
DN 143:260361  
TI Leptomycin B combination with chemotherapeutic agents for the treatment of  
proliferative diseases  
IN Santi, Daniel V.; Zhou, Yiqing  
PA Kosan Biosciences, Inc., USA  
SO U.S. Pat. Appl. Publ., 4 pp.  
CODEN: USXXCO

DT Patent  
LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005203174	A1	20050915	US 2005-58447	20050214
	WO 2005086944	A2	20050922	WO 2005-US8124	20050309
	WO 2005086944	A3	20051215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-551970P P 20040309  
US 2005-58447 A 20050214

IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(leptomycin B combination with chemotherapeutic agents for treatment of  
proliferative diseases)

RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:823686 CAPLUS

DN 143:216705

TI Preparation of salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide (imatinib)

IN Buerger, Hans Michael; Manley, Paul William; Mutz, Michael

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005075454	A2	20050818	WO 2005-EP1077	20050203
	WO 2005075454	A3	20060727		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			SM
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005211514	A1	20050818	AU 2005-211514	20050203
PRAI	US 2004-541817P	P	20040204		
	WO 2005-EP1077	W	20050203		
IT	152459-95-5DP, Imatinib, salts 862366-24-3P				
	862366-25-4P 862366-26-5P 862366-27-6P				
	862366-28-7P 862366-30-1P 862366-31-2P				
	862366-32-3P 862366-33-4P 862366-34-5P				
	862366-35-6P 862366-36-7P 862366-37-8P				
	862366-38-9P 862366-39-0P 862366-40-3P				
	862366-41-4P 862366-42-5P 862366-43-6P				
	862366-44-7P 862366-45-8P 862366-46-9P				
	862366-47-0P 862366-48-1P 862366-49-2P				
	862366-50-5P 862366-51-6P				
	RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of salt forms of imatinib)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




10/519,722



RN 862366-24-3 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



RN 862366-25-4 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/519,722




● HCl

RN 862366-26-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 77-92-9  
CMF C6 H8 O7




RN 862366-27-6 CAPLUS  
CN Butanedioic acid, hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O


10/519,722



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 862366-28-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2E)-2-butenedioate (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 862366-30-1 CAPLUS


CN Butanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O

10/519,722



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H


RN 862366-31-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 862366-32-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 862366-33-4 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with  
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 130-85-8  
CMF C23 H16 O6

10/519,722




RN 862366-34-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 862366-35-6 CAPLUS


CN Benzoic acid, 4-hydroxy-3-methoxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 121-34-6

CMF C8 H8 O4




RN 862366-36-7 CAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S




RN 862366-37-8 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 110-94-1  
CMF C5 H8 O4

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

RN 862366-38-9 CAPLUS  
CN Propanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 141-82-2  
CMF C3 H4 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CO<sub>2</sub>H

RN 862366-39-0 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5



10/519,722


CMF C29 H31 N7 O



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 862366-40-3 CAPLUS

CN Hexanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 124-04-9

CMF C6 H10 O4

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H


RN 862366-41-4 CAPLUS

CN Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

10/519,722


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 611-71-2  
CMF C8 H8 O3


Absolute stereochemistry. Rotation (-).



RN 862366-42-5 CAPLUS  
CN Butanedioic acid, hydroxy-, (2R)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 636-61-3  
CMF C4 H6 O5

Absolute stereochemistry.




RN 862366-43-6 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2S,3S)-2,3-dihydroxybutanedioate  
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 147-71-7  
CMF C4 H6 O6


Absolute stereochemistry.



RN 862366-44-7 CAPLUS  
CN Formic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-  
[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 64-18-6  
CMF C H2 O2

O=CH-OH

10/519,722


RN 862366-45-8 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




RN 862366-46-9 CAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 50-21-5

CMF C3 H6 O3

10/519,722




RN 862366-47-0 CAPLUS

CN Propanoic acid, 2-hydroxy-, (2S)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 79-33-4

CMF C3 H6 O3

Absolute stereochemistry. Rotation (+).




RN 862366-48-1 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

10/519,722


CRN 110-94-1  
CMF C5 H8 O4

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

RN 862366-49-2 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, compd. with 3,4-dihydroxy-3-cyclobutene-1,2-dione (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 2892-51-5  
CMF C4 H2 O4



RN 862366-50-5 CAPLUS  
CN Butanedioic acid, oxo-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




10/519,722

CM 2

CRN 328-42-7

CMF C4 H4 O5




RN 862366-51-6 CAPLUS

CN L-Ascorbic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.




IT 152459-95-5, Imatinib

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of salt forms of imatinib)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:729564 CAPLUS

DN 143:186693

TI Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

IN Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene

PA Emory University, USA

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005072826	A2	20050811	WO 2005-US1710	20050120
	WO 2005072826	A3	20060420		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005209231	A1	20050811	AU 2005-209231	20050120
	CA 2554201	AA	20050811	CA 2005-2554201	20050120
PRAI	US 2004-537960P	P	20040121		
	US 2004-553681P	P	20040316		
	US 2004-614203P	P	20040929		
	WO 2005-US1710	W	20050120		
OS	MARPAT 143:186693				
IT	152459-95-5 152459-95-5D, derivs. 220127-57-1, Imatinib mesylate 220127-57-1D, Imatinib mesylate, derivs. 593281-61-9, STI-X 593281-61-9D, derivs.				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(tyrosine kinase inhibitors for treatment of pathogenic infection)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




10/519,722



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O




CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 593281-61-9 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 593281-61-9 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:567125 CAPLUS  
DN 143:90993  
TI Combination of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one

hypusination inhibitor for the treatment of proliferative diseases, including leukemia

IN Bruemmendorf, Tim H.; Balabanov, Stefan; Hartmann, Ulrike; Kammer, Winfried; Nordheim, Alfred

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 27 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058320	A1	20050630	WO 2004-EP14439	20041217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004298761	A1	20050630	AU 2004-298761	20041217
	CA 2547196	AA	20050630	CA 2004-2547196	20041217
	EP 1696917	A1	20060906	EP 2004-804040	20041217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRAI	US 2003-531563P	P	20031219		
	WO 2004-EP14439	W	20041217		
IT	152459-95-5	220127-57-1	855843-70-8		
	855843-71-9	855843-72-0	855843-73-1		
	855843-74-2	855843-75-3	855843-76-4		
	855843-77-5	855843-78-6	855843-79-7		
	855843-80-0	855843-81-1			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pyrimidine-amine derivative-hypusination inhibitor combination for treatment of proliferative diseases, including leukemia)				
RN	152459-95-5	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-70-8 CAPLUS  
CN Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 70-51-9  
CMF C25 H48 N6 O8

PAGE 1-A



— (CH<sub>2</sub>)<sub>5</sub>—NH<sub>2</sub>


RN 855843-71-9 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 29342-05-0

CMF C12 H17 N O2



RN 855843-72-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O

10/519,722




CM 2

CRN 89149-10-0

CMF C17 H37 N7 O3

Absolute stereochemistry. Rotation (-).




RN 855843-73-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 30652-11-0

CMF C7 H9 N O2



10/519,722


RN 855843-74-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 150333-69-0

CMF C8 H20 N4



RN 855843-75-3 CAPLUS


CN Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 70-51-9

CMF C25 H48 N6 O8

PAGE 1-A



PAGE 1-B




CM 2

10/519,722

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 4


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-76-4 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 29342-05-0  
CMF C12 H17 N O2




CM 2

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S


CM 3



CRN 152459-95-5  
CMF C29 H31 N7 O



CRN 75-75-2  
CMF C H4 O3 S




CRN 89149-10-0  
CMF C17 H37 N7 O3

NCCCCNC(=O)[C@H](O)NC(=O)CCCCNC(=N)N

CRN 152459-95-5  
CMF C29 H31 N7 O


10/519,722



CM 4

CRN 75-75-2

CMF C H4 O3 S




RN 855843-78-6 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 30652-11-0

CMF C7 H9 N O2



CM 2

CRN 220127-57-1


CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 4

CRN 75-75-2

CMF C H4 O3 S




RN 855843-79-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CM 1

CRN 150333-69-0

CMF C8 H20 N4



CM 2


CRN 220127-57-1

CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5


CMF C29 H31 N7 O



CM 4

10/519,722


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-80-0 CAPLUS  
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.  
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 201530-41-8  
CMF C21 H15 N3 O4



CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 855843-81-1 CAPLUS  
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.  
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 201530-41-8

CMF C21 H15 N3 O4



CM 2


CRN 220127-57-1

CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5


CMF C29 H31 N7 O



CM 4

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2005:369277 CAPLUS

DN 142:430271

TI Preparation of substituted benzazoles as inhibitors of raf kinase

IN Ramurthy, Savithri; Subramanian, Sharadha; Verhagen, Joelle; Poon, Daniel J.; Hansen, Teresa; Shafer, Cynthia; McBride, Christopher; Levine, Barry H.; Costales, Abran; Renhowe, Paul A.

PA Chiron Corporation, USA

SO PCT Int. Appl., 185 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037273	A1	20050428	WO 2004-US34179	20041015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004281151	A1	20050428	AU 2004-281151	20041015
	CA 2542653	AA	20050428	CA 2004-2542653	20041015
	US 2005192287	A1	20050901	US 2004-967089	20041015
	EP 1682126	A1	20060726	EP 2004-795357	20041015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-511966P	P	20031016		
	WO 2004-US34179	W	20041015		
OS	MARPAT 142:430271				
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combination pharmaceutical; preparation of substituted benzazoles as inhibitors of raf kinase)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:369221 CAPLUS

DN 142:430024

TI Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis

IN Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc

10/519,722

PA Cytovia, Inc., USA  
SO PCT Int. Appl., 140 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037196	A2	20050428	WO 2004-US32570	20041005
	WO 2005037196	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-508290P P 20031006

OS MARPAT 142:430024

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy; preparation of 2-arylmethylene-N,N'-diarylmalonamides and analogs as activators of caspases and inducers of apoptosis)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:324144 CAPLUS

DN 142:392431

TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation

IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia; Liu, Yi; Schoepfer, Joseph; Steensma, Ruo

PA IRM LLC, Bermuda

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033086	A1	20050414	WO 2004-US32473	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004278413	A1	20050414	AU 2004-278413	20040930
	CA 2539339	AA	20050414	CA 2004-2539339	20040930
	US 2005171105	A1	20050804	US 2004-956412	20040930
	EP 1670771	A1	20060621	EP 2004-789483	20040930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRAI US 2003-507592P P 20030930

WO 2004-US32473 W 20040930

OS MARPAT 142:392431

IT 850087-62-6P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide  
 850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide  
 850087-74-0P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-(pyrimidin-4-yl)phenyl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)

RN 850087-62-6 CAPLUS

CN Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)  
 (CA INDEX NAME)



PAGE 1-A




PAGE 1-B

— Me

RN 850087-68-2 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI)  
 (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

— Me


RN 850087-74-0 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-(4-pyrimidinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:323779 CAPLUS  
DN 142:397824  
TI Biocompatibly coated medical implants  
IN Rathenow, Jorg; Ban, Andreas; Kunstmann, Jurgen; Mayer, Bernhard; Asgari, Soheil  
PA Germany  
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of Appl. No. PCT/EP04/04985.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005079200	A1	20050414	US 2004-938995	20040910
	DE 10322182	A1	20041202	DE 2003-10322182	20030516
	DE 10324415	A1	20041216	DE 2003-10324415	20030528
	DE 10333098	A1	20050210	DE 2003-10333098	20030721
	WO 2004101017	A2	20041125	WO 2004-EP4985	20040510
	WO 2004101017	A3	20050303		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DE 2003-10322182	A	20030516		
	DE 2003-10324415	A	20030528		
	DE 2003-10333098	A	20030721		
	WO 2004-EP4985	A2	20040510		
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(biocompatibly coated medical implants)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:158528 CAPLUS  
 DN 142:254620  
 TI Use of c-kit inhibitors for treating type II diabetes  
 IN Moussy, Alain; Kinet, Jean-Pierre  
 PA Ab Science, Fr.  
 SO PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016323	A2	20050224	WO 2004-IB2934	20040816
	WO 2005016323	A3	20050407		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2535242	AA	20050224	CA 2004-2535242	20040816
	EP 1653934	A2	20060510	EP 2004-769332	20040816
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-495088P	P	20030815		
	WO 2004-IB2934	W	20040816		
OS	MARPAT 142:254620				
IT	152459-95-5P, 4-[(4-Methylpiperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(c-kit inhibitor; use of potent, selective and non-toxic c-kit inhibitors for treating type diabetes, obesity and related diseases)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:99470 CAPLUS  
 DN 142:197889  
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf,  
 VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases  
 IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009961	A2	20050203	WO 2004-US23500	20040722
	WO 2005009961	A3	20050331		
	WO 2005009961	B1	20050602		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004259760	A1	20050203	AU 2004-259760	20040722
	CA 2532865	AA	20050203	CA 2004-2532865	20040722
	US 2005038080	A1	20050217	US 2004-895985	20040722
	EP 1663978	A2	20060607	EP 2004-786091	20040722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	NO 2006000870	A	20060407	NO 2006-870	20060222
PRAI	US 2003-489102P	P	20030723		
	US 2004-540326P	P	20040202		
	WO 2004-US23500	W	20040722		

IT 220127-57-1, STI-571

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph  
 urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated  
 diseases)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
 INDEX NAME)

CM 1

CRN 152459-95-5

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:17705 CAPLUS  
DN 142:148113  
TI Sole BCR-ABL inhibition is insufficient to eliminate all  
myeloproliferative disorder cell populations  
AU Wong, S.; McLaughlin, J.; Cheng, D.; Zhang, C.; Shokat, K. M.; Witte, O.  
N.  
CS Molecular Biology Interdepartmental Ph.D. Program, University of  
California, Los Angeles, CA, 90095, USA  
SO Proceedings of the National Academy of Sciences of the United States of  
America (2004), 101(50), 17456-17461  
CODEN: PNASA6; ISSN: 0027-8424  
PB National Academy of Sciences  
DT Journal  
LA English  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(Sole BCR-ABL inhibition is insufficient to eliminate all  
myeloproliferative disorder cell populations)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:1127387 CAPLUS

DN 142:74600

TI Heteroaryl-fused pyrimidinyl compounds, including thieno[3,2-d]  
pyrimidine derivatives, with KSP-inhibiting activity, and their  
preparation, pharmaceutical compositions, and use as anticancer agents

IN Wang, Weibo; Lagniton, Liana M.; Constantine, Ryan N.; Burger, Matthew T.

PA Chiron Corporation, USA

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004111058	A1	20041223	WO 2004-US16954	20040527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065169	A1	20050324	US 2004-850429	20040521
AU 2004247650	A1	20041223	AU 2004-247650	20040527
CA 2526217	AA	20041223	CA 2004-2526217	20040527
EP 1636238	A1	20060322	EP 2004-753729	20040527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1798749	A	20060705	CN 2004-80014819	20040527
PRAI US 2003-474684P	P	20030530		

10/519,722


WO 2004-US16954 W 20040527  
OS MARPAT 142:74600  
IT 152459-95-5, Imatinib 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic coadministration with; preparation of thieno[3,2-d]  
pyrimidine derivs. as KSP inhibitors for use as anticancer  
agents)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1080793 CAPLUS  
DN 142:32971  
TI Methods and compounds for the treatment of vascular stenosis using a  
combination of N-phenyl-2-pyrimidine derivatives and PI3K

10/519,722

inhibitors

IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 48 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108130	A1	20041216	WO 2004-US17273	20040601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2528032	AA	20041216	CA 2004-2528032	20040601
	EP 1635815	A1	20060322	EP 2004-753981	20040601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-475295P	P	20030603		
	WO 2004-US17273	W	20040601		
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Imatinib mesylate; methods and compds. for treatment of vascular stenosis using combination of N-phenyl-2-pyrimidine derivs. and PI3K inhibitors)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminolphenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2  
CMF C H4 O3 S





RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 46 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1060780 CAPLUS  
DN 142:38275  
TI Preparation of N-phenyl-2-pyrimidine-amine derivatives as  
anticancer agents and process for the preparation thereof  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim,  
Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-Chul; Lee, Sun-Ahe;  
Han, Byoung-Cheol  
PA Il Yang Pharm. Co., Ltd., S. Korea  
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 446,446,  
abandoned.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004248918	A1	20041209	US 2004-806834	20040322
PRAI	KR 2003-28669	A	20030506		
	US 2003-446446	B2	20030528		
OS	MARPAT 142:38275				
IT	796738-20-0P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-23-3P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl- 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-25-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-28-8P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[2-methyl-5- [4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-32-4P , 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2- yl]amino]phenyl]benzamide 796738-34-6P, 4-(4-Methylpiperazin-1- ylaminoethyl)-N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-40-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[4-methoxy-3- [4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-44-8P , 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3- yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-47-1P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin- 2-yl]aminophenyl]benzamide 796738-50-6P, 4-(4-Methylpiperazin-1- ylaminoethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin-2- yl]aminophenyl]benzamide 796738-54-0P, 4-(4-Methylpiperazin-1- ylmethyl)-N-[4-fluoro-3-[4-(pyridin-3-yl)pyrimidin-2- yl]aminophenyl]benzamide 796738-56-2P, 4-(4-Methylhomopiperazin- 1-ylmethyl)-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2- yl]amino]phenyl]benzamide 796738-58-4P, 4-(Piperidin-1-ylmethyl)- N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 804554-75-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 804554-76-5P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-				

3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-77-6P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-78-7P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-methyl-  
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-80-1P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-81-2P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-84-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-85-6P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methoxy-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-86-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-87-8P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[2-fluoro-5-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-88-9P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-fluoro-  
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-90-3P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-fluoro-3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-91-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-92-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-  
 yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-94-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 804554-95-8P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 804554-98-1P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)

RN 796738-20-0 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-  
 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS


CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-32-4 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-34-6 CAPLUS


10/519,722

CN Benzamide, 4-[[4-methyl-1-piperazinyl)amino)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl)amino)methyl]- (9CI) (CA INDEX NAME)



RN 796738-44-8 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



10/519,722


RN 796738-47-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS


CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

10/519,722

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 804554-75-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-76-5 CAPLUS


CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3

CMF C29 H32 N8 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-77-6 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RN 804554-78-7 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-80-1 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4

CMF C29 H31 N7 O




CM 2



10/519,722


CRN 75-75-2  
CMF C H4 O3 S



RN 804554-81-2 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6  
CMF C28 H30 N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 804554-84-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4  
CMF C30 H33 N7 O2


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-85-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-86-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-


10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate  
(9CI) (CA INDEX NAME)

CM 1

CRN 796738-44-8


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-87-8 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX  
NAME)

CM 1

CRN 796738-47-1

CMF C28 H28 F N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S


10/519,722



RN 804554-88-9 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 796738-50-6  
CMF C28 H29 F N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 804554-90-3 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX  
NAME)

CM 1

CRN 796738-54-0  
CMF C28 H28 F N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-91-4 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RN 804554-92-5 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-58-4


CMF C28 H28 N6 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-94-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0

CMF C30 H33 N7 O




CM 2

CRN 64-19-7

10/519,722


CMF C2 H4 O2



RN 804554-95-8 CAPLUS  
CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3  
CMF C29 H32 N8 O




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 804554-98-1 CAPLUS  
CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

10/519,722

AN 2004:1036851 CAPLUS  
DN 142:696  
TI Synergistic treatment of cancer using immunomers in conjunction with  
chemotherapeutic agents  
IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin  
PA Hybridon, Inc., USA  
SO PCT Int. Appl., 106 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103301	A2	20041202	WO 2004-US15313	20040514
	WO 2004103301	A3	20051103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004241093	A1	20041202	AU 2004-241093	20040514
	CA 2526212	AA	20041202	CA 2004-2526212	20040514
	US 2005009773	A1	20050113	US 2004-846167	20040514
	EP 1628531	A2	20060301	EP 2004-752345	20040514
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRAI	US 2003-471247P	P	20030516		
	WO 2004-US15313	W	20040514		
OS	MARPAT 142:696				
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(immunostimulatory oligonucleotide and/or immunomer combination with chemotherapeutic agent for synergistic cancer treatment)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2



CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:996162 CAPLUS  
DN 141:424205  
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib  
mesylate, useful as antitumor agents, and process for their preparation  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim,  
Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-chul; Lee, Sun-Ahe;  
Han, Byoung-Cheol  
PA Il Yang Pharm. Co. Ltd., S. Korea  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099187	A1	20041118	WO 2004-KR611	20040319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		

OS MARPAT 141:424205


IT 796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
796738-23-3P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722



RN 796738-23-3 CAPLUS  
CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)methyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-24-4P, 4-[[[(4-Methylpiperazin-1-yl)methyl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-22-2 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-20-0  
CMF C30 H33 N7 O

10/519,722



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-24-4 CAPLUS  
CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3  
CMF C29 H32 N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-28-8P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P  
 , 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,  
 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,  
 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,  
 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,  
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,  
 4-(Piperidin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-28-8 CAPLUS


CN Benzamide, 4-[[4-(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



10/519,722


RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-40-4 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-42-6 CAPLUS


CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-44-8 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-50-6 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)


10/519,722



RN 796738-56-2 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS  
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-27-7P, 4-[[4-(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-  
[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-29-9P, 4-[[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-33-5P, 4-[[4-(4-Methylhomopiperazin-1-  
yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-35-7P, 4-[[[4-(4-Methylpiperazin-1-  
yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P,  
4-[[4-(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-43-7P, 4-[[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-  
methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-45-9P, 4-[[4-(4-Methylhomopiperazin-1-  
yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P,  
4-[[4-(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-51-7P, 4-[[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-55-1P, 4-[[4-(4-Methylpiperazin-1-

yl)methyl}-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-62-0P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-65-3P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)  
 (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)




10/519,722

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-33-5 CAPLUS

CN Benamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4

CMF C29 H31 N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S


10/519,722



RN 796738-35-7 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6  
CMF C28 H30 N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 796738-41-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4  
CMF C30 H33 N7 O2


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl-, methanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-


10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-44-8


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-48-2 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1

CMF C28 H28 F N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S


10/519,722



RN 796738-51-7 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 796738-50-6  
CMF C28 H29 F N8 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-55-1 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-54-0  
CMF C28 H28 F N7 O



10/519,722

CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-57-3 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)


CM 1

CRN 796738-56-2  
CMF C29 H30 F N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 796738-59-5 CAPLUS  
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-58-4  
CMF C28 H28 N6 O

10/519,722



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-61-9 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0  
CMF C30 H33 N7 O



CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 796738-62-0 CAPLUS  
CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-


10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 796738-65-3 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic replacements for; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 220127-57-1 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5



10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:996161 CAPLUS  
DN 141:424204  
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib  
mesylate, useful as antitumor agents, and process for the preparation  
thereof  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jn; Lee, Gong-Yeal; Kim, Hong-Youb;  
Woo, Seok-Hun; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Ceol  
PA Il Yang Pharm Co., Ltd., S. Korea  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099186	A1	20041118	WO 2003-KR1029	20030526
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003232650	A1	20041126	AU 2003-232650	20030526
	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		
	WO 2003-KR1029	W	20030526		
OS	MARPAT 141:424204				
IT	796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-				

[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-23-3P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS

CN Benzamide, 4-[[4-(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 796738-24-4P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-22-2 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0

CMF C30 H33 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-24-4 CAPLUS.

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-  
[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
796738-28-8P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-  
(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P  
, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,  
4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,  
4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,  
4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,  
4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,  
4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,  
4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,  
4-[[[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,  
4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to  
imatinib mesylate as antitumor agents)

RN 796738-25-5 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-  
5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-28-8 CAPLUS


CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[4-(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS


CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS  
 CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-47-1 CAPLUS  
 CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS  
 CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS  
 CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-56-2 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-  
[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-29-9P, 4-[[[4-Methylpiperazin-1-yl]amino]methyl]-N-[2-  
methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-35-7P, 4-[[[4-Methylpiperazin-1-  
yl]amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P,  
4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-43-7P, 4-[[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-  
methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P,  
4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-51-7P, 4-[[[4-Methylpiperazin-1-yl]amino]methyl]-N-[2-  
fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

10/519,722

methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-62-0P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-65-3P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)




10/519,722

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-33-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4

CMF C29 H31 N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S

10/519,722




RN 796738-35-7 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6


CMF C28 H30 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-41-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4

CMF C30 H33 N7 O2




10/519,722

CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-44-8

CMF C29 H30 F N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-48-2 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1


CMF C28 H28 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-55-1 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-54-0

CMF C28 H28 F N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S

10/519,722




RN 796738-57-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-59-5 CAPLUS


CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-58-4

CMF C28 H28 N6 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-61-9 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 796738-62-0 CAPLUS


CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3  
CMF C29 H32 N8 O




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 796738-65-3 CAPLUS  
CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5



10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:995984 CAPLUS  
DN 141:389290  
TI New calcitriol analogs and therapeutic use in treating mast cell  
associated diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 70 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004098612	A2	20041118	WO 2004-IB1871	20040507
	WO 2004098612	A3	20050210		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-468295P	P	20030507		
	US 2003-480224P	P	20030623		
OS	MARPAT 141:389290				
IT	152459-95-5				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new calcitriol analogs and therapeutic use in treating mast cell associated diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965068 CAPLUS

DN 141:406114

TI Use of tyrosine kinase inhibitors for treating cerebral ischemia

IN Kinet, Jean-Pierre; Moussy, Alain

PA AB Science, Fr.

SO PCT Int. Appl., 117 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096225	A2	20041111	WO 2004-IB1874	20040428
	WO 2004096225	A3	20050310		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2523852	AA	20041111	CA 2004-2523852	20040428
	EP 1624873	A2	20060215	EP 2004-729952	20040428
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-465789P	P	20030428		
	WO 2004-IB1874	W	20040428		
OS	MARPAT 141:406114				
IT	152459-95-5				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(tyrosine kinase inhibitors for treating cerebral ischemia)			
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:965067 CAPLUS  
 DN 141:406039  
 TI Combinations for the treatment of diseases involving cell proliferation,  
 migration or apoptosis of myeloma cells, or angiogenesis  
 IN Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke;  
 Munzert, Gerd; Van Meel, Jacobus C. A.  
 PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim  
 Pharma G.m.b.H. & Co. K.-G.  
 SO PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
	WO 2004096224	A3	20041216		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
	GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
	LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO,				
	NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,				
	TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
EP	1473043	A1	20041103	EP 2003-9587	20030429
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU	2004233576	A1	20041111	AU 2004-233576	20040424
CA	2523868	AA	20041111	CA 2004-2523868	20040424
EP	1622619	A2	20060208	EP 2004-729366	20040424
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR	2004009919	A	20060425	BR 2004-9919	20040424
NO	2005005605	A	20051128	NO 2005-5605	20051128
PRAI	EP 2003-9587	A	20030429		
	EP 2004-508	A	20040113		
	EP 2004-1171	A	20040121		
	WO 2004-EP4363	W	20040424		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				
	(Biological study); USES (Uses)				
	(drug combinations for diseases involving cell proliferation and				
	migration or apoptosis or angiogenesis including protein tyrosine				
	kinase receptor antagonists and radiotherapy)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878151 CAPLUS

DN 141:366243

TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamilus; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PA Schering Corporation, USA; Pharmacopeia, Inc.

SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.  
CODEN: USXXCO

DT Patent

LA English


FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209878	A1	20041021	US 2004-776988	20040211
	AU 2005212409	A1	20050825	AU 2005-212409	20050208
	WO 2005077954	A2	20050825	WO 2005-US3859	20050208
	WO 2005077954	A3	20051013		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2006128725	A1	20060615	US 2005-245401	20051006
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	US 2003-654546	A2	20030903		
	US 2004-776988	A	20040211		
	WO 2005-US3859	W	20050208		
OS	MARPAT 141:366243				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer in combination of other anticancer agents)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

10/519,722


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756710 CAPLUS  
DN 141:277628  
TI Preparation of ureidophenoxycyanopyridines as anticancer drugs.  
IN Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming  
PA Bayer Pharmaceuticals Corporation, USA  
SO PCT Int. Appl., 127 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078747	A1	20040916	WO 2004-US6286	20040301
	WO 2004078747	C1	20041104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004235829	A1	20041125	US 2004-788029	20040227
	AU 2004217977	A1	20040916	AU 2004-217977	20040301
	CA 2517361	AA	20040916	CA 2004-2517361	20040301
	US 2004229937	A1	20041118	US 2004-789446	20040301
	US 2005032798	A1	20050210	US 2004-788405	20040301
	US 2005038031	A1	20050217	US 2004-788426	20040301
	EP 1599467	A1	20051130	EP 2004-716144	20040301


10/519,722

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
BR 2004007897 A 20060301 BR 2004-7897 20040301  
JP 2006519264 T2 20060824 JP 2006-508977 20040301  
PRAI US 2003-450323P P 20030228  
US 2003-450324P P 20030228  
US 2003-450348P P 20030228  
WO 2004-US6286 A 20040301  
OS MARPAT 141:277628  
IT 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer  
drugs)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]aminophenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
CM 1  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756044 CAPLUS  
DN 141:266048  
TI Medical implants with carbon-containing surfaces that are functionalized  
PA Blue Membranes GmbH, Germany  
SO Ger. Gebrauchsmusterschrift, 18 pp.  
CODEN: GGXXFR  
DT Patent  
LA German  
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----


10/519,722

PI DE 202004009061 U1 20040916 DE 2004-202004009061 20040528  
DE 10324415 A1 20041216 DE 2003-10324415 20030528  
DE 10333098 A1 20050210 DE 2003-10333098 20030721  
DE 10333099 A1 20050210 DE 2003-10333099 20030721  
PRAI DE 2003-10324415 A1 20030528  
DE 2003-10333098 A1 20030721  
DE 2003-10333099 A1 20030721  
IT 152459-95-5, Imatinib  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medical implants with carbon-containing surfaces that are functionalized)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756043 CAPLUS  
DN 141:266047  
TI Medical implants coated with biocompatible carbon-containing layers  
PA Blue Membranes GmbH, Germany  
SO Ger. Gebrauchsmusterschrift, 23 pp.  
CODEN: GGXXFR  
DT Patent  
LA German  
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 202004009060	U1	20040916	DE 2004-202004009060	20040510
	DE 10322182	A1	20041202	DE 2003-10322182	20030516
	DE 10324415	A1	20041216	DE 2003-10324415	20030528
	DE 10333098	A1	20050210	DE 2003-10333098	20030721
PRAI	DE 2003-10322182	A1	20030516		
	DE 2003-10324415	A1	20030528		
	DE 2003-10333098	A1	20030721		
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(medical implants coated with biocompatible carbon-containing layers)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2004:691283 CAPLUS

DN 141:207230

TI Preparation of imatinib and salts by reaction of N-(2-methyl-5-aminophenyl-4-(3-pyridyl)-2-pyrimidinamine with 4-(4-methylpiperazinylmethyl)benzoyl halides.

IN Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra

PA Cipla Limited, India

SO Brit. UK Pat. Appl., 34 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2398565	A1	20040825	GB 2003-3730	20030218
	AU 2004213616	A2	20040902	AU 2004-213616	20040108
	AU 2004213616	A1	20040902		
	CA 2516370	AA	20040902	CA 2004-2516370	20040108
	WO 2004074502	A2	20040902	WO 2004-GB18	20040108
	WO 2004074502	A3	20041028		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1599462	A2	20051130	EP 2004-700728	20040108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007672	A	20060301	BR 2004-7672	20040108
	JP 2006518360	T2	20060810	JP 2006-502181	20040108
	US 2006173182	A1	20060803	US 2005-546193	20051031
PRAI	GB 2003-3730	A	20030218		
	WO 2004-GB18	A	20040108		

OS CASREACT 141:207230


IT 152459-95-5P, Imatinib 220127-57-1P, Imatinib mesylate 744256-04-0P 744256-05-1P 744256-06-2P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imatinib and salts by reaction of methylaminophenylpyridylpyrimidinamine with methylpiperazinylmethylbenzoyl halides)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA




10/519,722

INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 744256-04-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



●x HBr


RN 744256-05-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 744256-06-2 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)



●3 HCl

● H<sub>2</sub>O

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:650874 CAPLUS  
 DN 141:167761  
 TI Sensitizing cells for apoptosis by selectively blocking cytokines  
 IN Stassi, Giorgio; Todaro, Matilde  
 PA Italy  
 SO Eur. Pat. Appl., 30 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1444989	A1	20040811	EP 2003-2603	20030207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004210432	A1	20040819	AU 2004-210432	20040209
CA 2515302	AA	20040819	CA 2004-2515302	20040209
WO 2004069274	A2	20040819	WO 2004-EP1177	20040209
WO 2004069274	A3	20041111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


EP 1592449 A2 20051109 EP 2004-709222 20040209  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006519190 T2 20060824 JP 2006-501781 20040209  
 PRAI EP 2003-2603 A 20030207  
 WO 2004-EP1177 W 20040209

IT 220127-57-1, STI571  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (CPG57148B; sensitizing cells for apoptosis by blocking cytokines)

RN 220127-57-1 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




L5 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:565086 CAPLUS  
 DN 141:123632  
 TI Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis  
 IN Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong; Kemnitzer, William E.  
 PA Cytovia, Inc., USA  
 SO PCT Int. Appl., 97 pp.

10/519,722


CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058253	A1	20040715	WO 2003-US40308	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004127521	A1	20040701	US 2003-737865	20031218
	CA 2509224	AA	20040715	CA 2003-2509224	20031218
	AU 2003303373	A1	20040722	AU 2003-303373	20031218
	EP 1581213	A1	20051005	EP 2003-808469	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1756547	A	20060405	CN 2003-80106440	20031218
	JP 2006516250	T2	20060629	JP 2004-563731	20031218
PRAI	US 2002-433953P	P	20021218		
	WO 2003-US40308	W	20031218		
OS	MARPAT 141:123632				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:559502 CAPLUS

DN 141:190802

TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors

IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-yu; James, Ray A.; Bishop, W. Robert; Wang, James J.-S.; Desai, Jagdish A.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 731 pp., Cont.-in-part of U.S. Ser. No. 85,896.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004122018	A1	20040624	US 2002-325896	20021219
	US 2002198216	A1	20021226	US 2001-940811	20010828
	US 2003229099	A1	20031211	US 2002-85896	20020227
	US 2004122018	A1	20040624	US 2002-325896	20021219
PRAI	US 2001-940811	A2	20010828		
	US 2002-85896	A2	20020227		
	US 2002-325896	A	20021219		
	US 2000-229183P	P	20000830		

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy; preparation of tricyclic antitumor agents as farnesyl protein transferase inhibitors for treatment of cancer and other proliferative diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5

CMF C29 H31 N7 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:513393 CAPLUS  
DN 141:71544  
TI Preparation of substituted benzazoles as Raf kinase inhibitors  
IN Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.;  
Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard  
PA USA  
SO U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004  
87,626.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004122237	A1	20040624	US 2003-675927	20030929
	US 2004087626	A1	20040506	US 2003-405945	20030331
	US 7071216	B2	20060704		
	AU 2004277405	A1	20050414	AU 2004-277405	20040929
	CA 2539748	AA	20050414	CA 2004-2539748	20040929
	WO 2005032548	A1	20050414	WO 2004-US32161	20040929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	EP 1675584	A1	20060705	EP 2004-789345	20040929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006193533	A2	20060727	JP 2006-96143	20060330
PRAI	US 2002-369066P	P	20020329		
	US 2003-405945	A2	20030331		
	JP 2003-579810	A3	20030331		
	US 2003-675927	A	20030929		
	WO 2004-US32161	W	20040929		
OS	MARPAT 141:71544				
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of substituted benzazoles as Raf kinase inhibitors for use in				
	combination with other antitumor agents)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:467883 CAPLUS  
 DN 141:38627  
 TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol  
 (pi) 3-kinase inhibitors and their use in the treatment of cancer  
 IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.  
 PA Chiron Corporation, USA  
 SO PCT Int. Appl., 151 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004048365	A1	20040610	WO 2003-US37294	20031121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507100	AA	20040610	CA 2003-2507100	20031121
AU 2003295776	A1	20040618	AU 2003-295776	20031121
US 2004176385	A1	20040909	US 2003-719896	20031121
EP 1575940	A1	20050921	EP 2003-786980	20031121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016485	A	20051011	BR 2003-16485	20031121
CN 1735607	A	20060215	CN 2003-80108239	20031121
JP 2006514118	T2	20060427	JP 2005-510381	20031121
NO 2005002927	A	20050708	NO 2005-2927	20050615
PRAI US 2002-428473P	P	20021121		
US 2003-438568P	P	20030107		
US 2003-523081P	P	20031119		
WO 2003-US37294	W	20031121		
OS MARPAT 141:38627				
IT 152459-95-5, Imatinib 220127-57-1, Gleevec				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(combination therapy; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)				
RN 152459-95-5 CAPLUS				
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				

10/519,722




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:452964 CAPLUS

DN 141:1206

TI Combination administration of an indolinone with a chemotherapeutic agent  
for cell proliferation disorders

IN Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.

PA Sugan, Inc., USA

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045523	A2	20040603	WO 2003-US36526	20031114
	WO 2004045523	A3	20040930		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				



CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 NL 1024779 A1 20040518 NL 2003-1024779 20031114  
 NL 1024779 C2 20041109  
 CA 2506308 AA 20040603 CA 2003-2506308 20031114  
 AU 2003290943 A1 20040615 AU 2003-290943 20031114  
 US 2004152759 A1 20040805 US 2003-712296 20031114  
 EP 1562600 A2 20050817 EP 2003-783527 20031114  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003015630 A 20050823 BR 2003-15630 20031114  
 CN 1711089 A 20051221 CN 2003-80103225 20031114  
 JP 2006508981 T2 20060316 JP 2004-553729 20031114  
 NO 2005002578 A 20050527 NO 2005-2578 20050527  
 PRAI US 2002-426386P P 20021115  
 WO 2003-US36526 W 20031114  
 OS MARPAT 141:1206  
 IT 152459-95-5, Imatinib  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as chemotherapeutic agent; cancer therapy using combination  
 administration of indolinone compds. with chemotherapeutic agents for  
 cell proliferation disorders)  
 RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:419904 CAPLUS  
 DN 142:70669  
 TI Characterization of a Conserved Structural Determinant Controlling Protein  
 Kinase Sensitivity to Selective Inhibitors  
 AU Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi,  
 Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik  
 CS Axxima Pharmaceuticals AG, Munchen, 81377, Germany  
 SO Chemistry & Biology (2004), 11(5), 691-701  
 CODEN: CBOLE2; ISSN: 1074-5521  
 PB Cell Press  
 DT Journal  
 LA English  
 IT 220127-57-1, STI571  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (characterization of a conserved structural determinant controlling  
 protein kinase inhibitor sensitivity)

10/519,722


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:331787 CAPLUS

DN 140:350538

TI Treatment of tuberous sclerosis associated neoplasms with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase inhibitors, especially N-phenyl-2-pyrimidineamines

IN Arbiser, Jack

PA USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004077661	A1	20040422	US 2003-655407	20030904
	CA 2439440	AA	20040305	CA 2003-2439440	20030903
PRAI	US 2002-408550P	P	20020905		

OS MARPAT 140:350538

IT 152459-95-5 152459-95-5D, acceptable salts  
220127-57-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(tuberous sclerosis-associated neoplasms treatment with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase)

10/519,722

inhibitors, especially N-Ph-2-pyrimidineamines)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722

L5 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:269996 CAPLUS

DN 140:303691

TI Preparation and pharmaceutical compositions of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon

PA Schering Corporation, USA; Pharmacoepia, Inc.

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026229	A2	20040401	WO 2003-US27491	20030903
	WO 2004026229	A3	20040617		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2497544	AA	20040401	CA 2003-2497544	20030903
	AU 2003298571	A1	20040408	AU 2003-298571	20030903
	EP 1534712	A2	20050601	EP 2003-796321	20030903
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1701073	A	20051123	CN 2003-824701	20030903
	JP 2006502184	T2	20060119	JP 2004-537708	20030903
	NZ 539161	A	20060526	NZ 2003-539161	20030903
	ZA 2005001846	A	20050912	ZA 2005-1846	20050303
PRAI	US 2002-408029P	P	20020904		
	WO 2003-US27491	W	20030903		
OS	MARPAT 140:303691				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyrimidines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:268055 CAPLUS

DN 140:385622

TI Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

AU Houghton, Peter J.; Germain, Glen S.; Harwood, Franklin C.; Schuetz, John D.; Stewart, Clinton F.; Buchdunger, Elisabeth; Traxler, Peter

CS Tennessee, Memphis, St. Jude Children's Research Hospital, Departments of Molecular Pharmacology, Memphis, TN, 38105-2794, USA

SO Cancer Research (2004), 64(7), 2333-2337

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

IT 220127-57-1, Imatinib Mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imatinib mesylate is a potent inhibitor of ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:267339 CAPLUS  
DN 140:303700  
TI Preparation and pharmaceutical compositions of novel imidazopyrazines as  
cyclin dependent kinase inhibitors  
IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.;  
Girijavallabhan, Viyyoor M.; Mallams, Alan K.  
PA Schering Corporation, USA  
SO PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026877	A1	20040401	WO 2003-US29209	20030919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499756	AA	20040401	CA 2003-2499756	20030919
	AU 2003272476	A1	20040408	AU 2003-272476	20030919
	EP 1543008	A1	20050622	EP 2003-754658	20030919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1694886	A	20051109	CN 2003-825177	20030919
	JP 2006507253	T2	20060302	JP 2004-537904	20030919
	ZA 2005002375	A	20050927	ZA 2005-2375	20050322
PRAI	US 2002-412997P	P	20020923		
	WO 2003-US29209	W	20030919		
OS	MARPAT 140:303700				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:267335 CAPLUS  
DN 140:287379  
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors  
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.  
PA Schering Corporation, USA  
SO PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026872	A1	20040401	WO 2003-US29841	20030917
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA,			ZM
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499593	AA	20040401	CA 2003-2499593	20030917
	AU 2003270846	A1	20040408	AU 2003-270846	20030917

10/519,722

US 2004097516 A1 20040520 US 2003-664337 20030917  
EP 1539750 A1 20050615 EP 2003-752559 20030917  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
CN 1681816 A 20051012 CN 2003-822011 20030917  
JP 2006503060 T2 20060126 JP 2004-538405 20030917  
NZ 538595 A 20060428 NZ 2003-538595 20030917  
ZA 2005002271 A 20050919 ZA 2005-2271 20050317  
PRAI US 2002-412138P P 20020919  
WO 2003-US29841 W 20030917  
OS MARPAT 140:287379  
IT 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(claimed codrugs for treatment of conditions mediated by cyclin  
dependent kinases in the presence of prepared pyrazolopyridines)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
  
CM 1  
  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
  
CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:267330 CAPLUS  
DN 140:303698  
TI Preparation and pharmaceutical compositions of novel imidazopyridines as  
cyclin dependent kinase inhibitors  
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.;  
Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.  
PA Schering Corporation, USA  
SO PCT Int. Appl., 78 pp.  
CODEN: PIXXD2



10/519,722


DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026867	A2	20040401	WO 2003-US29498	20030917
	WO 2004026867	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499639	AA	20040401	CA 2003-2499639	20030917
	AU 2003295332	A1	20040408	AU 2003-295332	20030917
	US 2004097517	A1	20040520	US 2003-664338	20030917
	US 6992080	B2	20060131		
	EP 1539756	A2	20050615	EP 2003-786514	20030917
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1703414	A	20051130	CN 2003-825047	20030917
	JP 2006507254	T2	20060302	JP 2004-538237	20030917
	US 2006030555	A1	20060209	US 2005-238597	20050929
PRAI	US 2002-412063P	P	20020919		
	US 2003-664338	A3	20030917		
	WO 2003-US29498	W	20030917		
OS	MARPAT 140:303698				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				




CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:267246 CAPLUS  
 DN 140:303696  
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors  
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.  
 PA Schering Corporation, USA  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026310	A1	20040401	WO 2003-US29456	20030919
	WO 2004026310	C1	20050630		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499874	AA	20040401	CA 2003-2499874	20030919
	AU 2003275031	A1	20040408	AU 2003-275031	20030919
	US 2004072835	A1	20040415	US 2003-666424	20030919
	EP 1542693	A1	20050622	EP 2003-759300	20030919
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1694706	A	20051109	CN 2003-825102	20030919
	JP 2006503838	T2	20060202	JP 2004-538213	20030919
	ZA 2005002380	A	20050927	ZA 2005-2380	20050322
PRAI	US 2002-412906P	P	20020923		
	WO 2003-US29456	W	20030919		
OS	MARPAT 140:303696				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:252622 CAPLUS

DN 140:283386

TI Crystal structure of human PIM-1 kinase and complexes with AMP-PNP and use  
in drug screening and design

IN Bremer, Ryan; Ibrahim, Prabha; Kumar, Abhinav; Mandiyan, Valsan; Milburn,  
Michael V.

PA Plexxikon, Inc., USA

SO PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024895	A2	20040325	WO 2003-US29415	20030916
	WO 2004024895	A3	20050609		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2503905	AA	20040325	CA 2003-2503905	20030916
	AU 2003272548	A1	20040430	AU 2003-272548	20030916
	US 2004142864	A1	20040722	US 2003-664421	20030916
	EP 1558751	A2	20050803	EP 2003-754735	20030916
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1701122	A	20051123	CN 2003-825157	20030916
PRAI	US 2002-411398P	P	20020916		

10/519,722

US 2002-412341P P 20020920  
WO 2003-US29415 W 20030916  
IT 220127-57-1, Imatinib mesylate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crystal structure of human PIM-1 kinase and complexes with AMP-PNP and  
use in drug screening and design)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
CM 1  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:252351 CAPLUS  
DN 140:264488  
TI Combination of a benzamide derivative and a histone deacetylase inhibitor  
for the treatment of leukemia  
IN Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong  
PA Virginia Commonwealth University, USA; McGuire Va Medical Center 111k  
SO PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024160	A1	20040325	WO 2003-IB4053	20030910
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			

10/519,722

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR


CA 2498210	AA	20040325	CA 2003-2498210	20030910
AU 2003259521	A1	20040430	AU 2003-259521	20030910
BR 2003014112	A	20050712	BR 2003-14112	20030910
EP 1553948	A1	20050720	EP 2003-795175	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681505	A	20051012	CN 2003-821763	20030910
JP 2006501267	T2	20060112	JP 2004-535791	20030910
US 2006100140	A1	20060511	US 2005-527553	20050909
PRAI US 2002-410286P	P	20020913		
US 2002-411344P	P	20020918		
WO 2003-IB4053	W	20030910		
IT 152459-95-5 220127-57-1, Glivec				
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)				
RN 152459-95-5 CAPLUS				
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:220336 CAPLUS

DN 140:270873

TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.;  
Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.;  
Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;  
Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min;  
James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs,  
Douglas Walsh

PA Schering Corporation, USA; Pharmacoepia, Inc.

SO PCT Int. Appl., 609 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022561	A1	20040318	WO 2003-US27555	20030903
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497440	AA	20040318	CA 2003-2497440	20030903
	AU 2003263071	A1	20040329	AU 2003-263071	20030903
	EP 1537116	A1	20050608	EP 2003-794592	20030903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003014001	A	20050705	BR 2003-14001	20030903
	JP 2006502163	T2	20060119	JP 2004-534487	20030903
	CN 1735614	A	20060215	CN 2003-824997	20030903
	NO 2005001647	A	20050603	NO 2005-1647	20050404
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	WO 2003-US27555	W	20030903		

OS MARPAT 140:270873

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent  
kinase inhibitors for treating cancer in combination of other  
anticancer agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:220335 CAPLUS  
DN 140:270872  
TI Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents  
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon  
PA Schering Corporation, USA; Pharmacopeia, Inc.; Pharmacopeia Drug Discovery, Inc.  
SO PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022560	A1	20040318	WO 2003-US27502	20030903
	WO 2004022560	C2	20050707		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2497450	AA	20040318	CA 2003-2497450	20030903

10/519,722

AU 2003268385 A1 20040329 AU 2003-268385 20030903  
US 2004116442 A1 20040617 US 2003-653868 20030903  
US 7074924 B2 20060711  
EP 1534710 A1 20050601 EP 2003-749347 20030903  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
CN 1701074 A 20051123 CN 2003-824779 20030903  
JP 2006502161 T2 20060119 JP 2004-534459 20030903  
NZ 539164 A 20060428 NZ 2003-539164 20030903  
ZA 2005001852 A 20050908 ZA 2005-1852 20050303  
US 2006173016 A1 20060803 US 2006-395824 20060331  
PRAI US 2002-407999P P 20020904  
US 2003-653868 A3 20030903  
WO 2003-US27502 W 20030903  
OS MARPAT 140:270872  
IT 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(anticancer agent, combination therapy; preparation of pyrazolo[1,5-  
a]pyrimidines as cyclin dependent kinase inhibitors and anticancer  
agents)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
CM 1  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:218528 CAPLUS  
DN 140:247038  
TI Use of specific inhibitors of tyrosine kinases for immunomodulation  
IN Zitvogel, Laurence; Auclair, Christian; Tursz, Thomas



10/519,722

PA Institut Gustave Roussy Igr, Fr.

SO Fr. Demande, 50 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI-	FR 2844452	A1	20040319	FR 2002-11545	20020918
	WO 2004026311	A2	20040401	WO 2003-FR2744	20030917
	WO 2004026311	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003276351	A1	20040408	AU 2003-276351	20030917
PRAI	FR 2002-11545	A	20020918		
	WO 2003-FR2744	W	20030917		

IT 220127-57-1, Gleevec

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of specific inhibitors of tyrosine kinases for immunomodulation)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




10/519,722

RE.CNT 9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5    ANSWER 77 OF 106    CAPLUS    COPYRIGHT 2006 ACS on STN  
AN    2004:100803    CAPLUS  
DN    140:139483  
TI    Method for enhancing the effectiveness of therapies of hyperproliferative  
      diseases  
IN    Chang, Yan; Sasak, Vodek  
PA    USA  
SO    U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.  
      CODEN: USXXCO  
DT    Patent  
LA    English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004023925	A1	20040205	US 2003-408723	20030407
	US 2003013681	A1	20030116	US 2002-176235	20020620
	US 6680306	B2	20040120		
	CN 1543351	A	20041103	CN 2002-816003	20020621
	US 2004043962	A1	20040304	US 2003-657383	20030908
	AU 2004229399	A1	20041028	AU 2004-229399	20040407
	CA 2521649	AA	20041028	CA 2004-2521649	20040407
	WO 2004091634	A1	20041028	WO 2004-US10675	20040407
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1617849	A1	20060125	EP 2004-759200	20040407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006522163	T2	20060928	JP 2006-509773	20040407
PRAI	US 2001-299991P	P	20010621		
	US 2002-176235	A2	20020620		
	US 2003-408723	A	20030407		
	US 2003-461006P	P	20030407		
	US 2003-474562P	P	20030530		
	WO 2004-US10675	W	20040407		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method for enhancing effectiveness of therapies of hyperproliferative diseases)				
RN	152459-95-5    CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)    (CA INDEX NAME)				




L5 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:20664 CAPLUS  
 DN 140:77165  
 TI Preparation of 4-[(4-methylpiperazin-1-yl)methyl]benzamide for treatment of leukemia  
 IN Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru  
 PA Nippon Shinyaku Co., Ltd., Japan  
 SO PCT Int. Appl., 102 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002963	A1	20040108	WO 2003-JP8192	20030627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490907	AA	20040108	CA 2003-2490907	20030627
	AU 2003246100	A1	20040119	AU 2003-246100	20030627
	BR 2003012288	A	20050412	BR 2003-12288	20030627
	EP 1533304	A1	20050525	EP 2003-738555	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678590	A	20051005	CN 2003-820146	20030627
	US 2006014742	A1	20060119	US 2004-519722	20041228
PRAI	JP 2002-189269	A	20020628		
	JP 2002-305146	A	20021018		
	JP 2002-377937	A	20021226		
	WO 2003-JP8192	W	20030627		
OS	MARPAT 140:77165				
IT	641614-84-8P 641614-88-2P 641614-92-8P 641614-95-1P 641615-19-2P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)				
RN	641614-84-8 CAPLUS				
CN	Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RN 641614-88-2 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-92-8 CAPLUS

CN Benzamide, N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-95-1 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 641615-19-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]amino]carbonyl]-2-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 641614-83-7P 641614-85-9P 641614-86-0P  
 641614-87-1P 641614-89-3P 641614-90-6P  
 641614-91-7P 641614-93-9P 641614-94-0P  
 641614-96-2P 641614-97-3P 641614-98-4P  
 641614-99-5P 641615-00-1P 641615-01-2P  
 641615-02-3P 641615-03-4P 641615-04-5P  
 641615-05-6P 641615-06-7P 641615-07-8P  
 641615-08-9P 641615-09-0P 641615-10-3P  
 641615-11-4P 641615-12-5P 641615-13-6P  
 641615-14-7P 641615-15-8P 641615-16-9P  
 641615-17-0P 641615-18-1P 641615-20-5P  
 641615-21-6P 641615-22-7P 641615-23-8P  
 641615-24-9P 641615-25-0P 641615-26-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)


RN 641614-83-7 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS

CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-86-0 CAPLUS

CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-87-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-89-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-90-6 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-91-7 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-93-9 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(1,2-dihydro-4-pyridazinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-94-0 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridazinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-96-2 CAPLUS

CN Benzamide, N-[3-((3,4'-bipyridin)-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-97-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(5-pyrimidinyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-98-4 CAPLUS

CN Benzamide, N-[3-([2,3'-bipyridin]-6-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-99-5 CAPLUS

CN Benzamide, N-[3-([3,3'-bipyridin]-5-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 641615-00-1 CAPLUS


CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(3-pyridinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-01-2 CAPLUS


CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[6-(3-pyridinyl)pyrazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 641615-02-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-1,2,4-triazin-3-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-03-4 CAPLUS

CN Benzamide, 3-methyl-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-04-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 641615-05-6 CAPLUS

CN Benzamide, 3-methoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-06-7 CAPLUS

CN Benzamide, 3,5-dibromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-07-8 CAPLUS

CN Benzamide, 3,5-dimethoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-08-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N3,N3-dimethyl-4-[(4-methyl-1-piperazinyl)methyl]-N1-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-09-0 CAPLUS

CN Benzamide, 3-bromo-4-[(4-ethyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-10-3 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-propyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-11-4 CAPLUS

CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-12-5 CAPLUS

CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-13-6 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-14-7 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-15-8 CAPLUS


CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-16-9 CAPLUS


CN Benzamide, 3-bromo-4-[[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 641615-17-0 CAPLUS

CN Benzamide, 3-bromo-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-18-1 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-20-5 CAPLUS


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-(1-piperazinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 641615-21-6 CAPLUS


10/519,722

CN Benzoic acid, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 641615-22-7 CAPLUS

CN Benzamide, 3-cyano-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-23-8 CAPLUS


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 641615-24-9 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)



● HCl

RN 641615-25-0 CAPLUS  
 CN Benzamide, N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 641615-26-1 CAPLUS  
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 641614-88-2  
 CMF C29 H29 F3 N8 O



CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:971730 CAPLUS  
DN 140:27844  
TI Preparation of tricyclic antitumor compounds as farnesyl protein  
transferase inhibitors  
IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane,  
Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor  
M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar,  
Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu;  
James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.  
PA USA  
SO U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S. Pat. Appl. 2002  
198,216.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003229099	A1	20031211	US 2002-85896	20020227
	US 2002198216	A1	20021226	US 2001-940811	20010828
	US 2004122018	A1	20040624	US 2002-325896	20021219
	CA 2477328	AA	20030904	CA 2003-2477328	20030225
	WO 2003072549	A1	20030904	WO 2003-US5479	20030225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,				
	ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,				
	MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK,				
	SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003215389	A1	20030909	AU 2003-215389	20030225
	BR 2003008071	A	20041221	BR 2003-8071	20030225
	EP 1492772	A1	20050105	EP 2003-711214	20030225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1630641	A	20050622	CN 2003-804720	20030225
	JP 2005525356	T2	20050825	JP 2003-571255	20030225
	ZA 2004006807	A	20050829	ZA 2004-6807	20040826
	NO 2004004053	A	20041126	NO 2004-4053	20040924
PRAI	US 2000-229183P	P	20000830		
	US 2001-940811	A2	20010828		
	US 2002-85896	A2	20020227		
	US 2002-325896	A	20021219		
	WO 2003-US5479	W	20030225		
OS	MARPAT 140:27844				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				



(co-administration; preparation of tricyclic compds. as farnesyl protein transferase inhibitors for treating cancer in combination with other agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:917665 CAPLUS

DN 140:156958

TI Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

AU Nimmanapalli, Ramadevi; Bali, Purva; O'Bryan, Erica; Fuino, Lianne; Guo, Fei; Wu, Jie; Houghton, Peter; Bhalla, Kapil

CS Interdisciplinary Oncology Program, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, FL, USA

SO Cancer Research (2003), 63(22), 7950-7958

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

IT 220127-57-1, Imatinib mesylate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:912990 CAPLUS  
DN 139:375014  
TI Methods and compositions with N-phenyl-2-pyrimidine compounds  
inhibiting platelet derived growth factor receptor for the treatment of  
graft failure  
IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 106 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003094904	A1	20031120	WO 2003-US314916	20030513
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003232115	A1	20031111	AU 2003-232115	20030513
	CA 2490989	AA	20031120	CA 2003-2490989	20030513
	EP 1509219	A1	20050302	EP 2003-750120	20030513
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

10/519,722


JP 2005533019 T2 20051104 JP 2004-502990 20030513  
US 2005261283 A1 20051124 US 2005-514322 20050719  
PRAI US 2002-380180P P 20020513  
US 2003-464023P P 20030418  
WO 2003-US14916 W 20030513  
OS MARPAT 139:375014  
IT 152459-95-5 220127-57-1, Imatinib mesylate  
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth  
factor receptor for treatment of graft failure)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2003:892800 CAPLUS

DN 139:395950

TI Preparation of substituted pyrazines as protein kinase modulators

IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PA Exelixis, Inc., USA

SO PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093297	A2	20031113	WO 2003-US13869	20030502
	WO 2003093297	A3	20040701		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2484209	AA	20031113	CA 2003-2484209	20030502
	AU 2003234464	A1	20031117	AU 2003-234464	20030502
	EP 1501514	A2	20050202	EP 2003-728690	20030502
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005530760	T2	20051013	JP 2004-501436	20030502
	US 2006211709	A1	20060921	US 2005-513081	20050727
PRAI	US 2002-377933P	P	20020503		
	WO 2003-US13869	W	20030502		

OS MARPAT 139:395950


IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 83 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:833884 CAPLUS

DN 139:317425


TI Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis  
 IN Debatin, Klaus Michael; Fulda, Simone  
 PA Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany  
 SO Eur. Pat. Appl., 19 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1354952	A1	20031022	EP 2002-8199	20020417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1354953	A1	20031022	EP 2002-15499	20020712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	WO 2003086470	A2	20031023	WO 2003-EP4039	20030417
	WO 2003086470	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003236211	A1	20031027	AU 2003-236211	20030417
	EP 1495124	A2	20050112	EP 2003-722503	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005536457	T2	20051202	JP 2003-583486	20030417
	US 2005222387	A1	20051006	US 2005-511037	20050119
PRAI	EP 2002-8199	A	20020417		
	EP 2002-15499	A	20020712		
	WO 2003-EP4039	W	20030417		
IT	220127-57-1, STI571				
	RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)				
	(therapeutic combination with SMAC peptide; Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:809105 CAPLUS  
DN 140:122306  
TI Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine  
-Type Small Molecule Kinase Inhibitors  
AU von Bubnoff, Nikolas; Veach, Darren R.; Miller, W. Todd; Li, Wanqing;  
Saenger, Jana; Peschel, Christian; Bornmann, William G.; Clarkson, Bayard;  
Duyster, Justus  
CS Department of Internal Medicine III, Technical University of Munich,  
Munich, Germany  
SO Cancer Research (2003), 63(19), 6395-6404  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
IT 220127-57-1, Glivec  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(inhibition of wild-type and mutant Bcr-Abl by pyrido-  
pyrimidine-type small mol. kinase inhibitors in relation to  
leukemia treatment)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:796477 CAPLUS

DN 139:307759

TI Preparation of substituted benzazoles as Raf kinase inhibitors

IN Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry  
Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl,  
Wendy

PA Chiron Corporation, USA

SO PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082272	A1	20031009	WO 2003-US10117	20030331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2480638	AA	20031009	CA 2003-2480638	20030331
	AU 2003226211	A1	20031013	AU 2003-226211	20030331
	EP 1499311	A1	20050126	EP 2003-745683	20030331
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008854	A	20050222	BR 2003-8854	20030331
	CN 1655779	A	20050817	CN 2003-812193	20030331
	JP 2005529089	T2	20050929	JP 2003-579810	20030331
	NO 2004004617	A	20041228	NO 2004-4617	20041026

10/519,722

JP 2006193533 A2 20060727 JP 2006-96143 20060330  
 PRAI US 2002-369066P P 20020329  
 JP 2003-579810 A3 20030331  
 WO 2003-US10117 W 20030331  
 OS MARPAT 139:307759  
 IT 152459-95-5, Imatinib  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (preparation of substituted benzazoles as Raf kinase inhibitors for use in  
 combination with other antitumor agents)  
 RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:696780 CAPLUS  
 DN 139:219397  
 TI N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-  
 pyridyl)-2-pyrimidine-amine coated stents  
 IN Prescott, Margaret Forney; Feldman, David Louis  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003072159	A1	20030904	WO 2003-EP2028	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
CA 2477558	AA	20030904	CA 2003-2477558	20030227
AU 2003214079	A1	20030909	AU 2003-214079	20030227
EP 1480688	A1	20041201	EP 2003-709729	20030227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008053	A	20041228	BR 2003-8053	20030227
JP 2005519080	T2	20050630	JP 2003-570902	20030227
CN 1638823	A	20050713	CN 2003-804788	20030227
NO 2004004093	A	20041124	NO 2004-4093	20040927
US 2005209244	A1	20050922	US 2005-505398	20050429
PRAI US 2002-360254P	P	20020228		
WO 2003-EP2028	W	20030227		
IT 152459-95-5				



RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(piperazino-methylbenzoylamido pyridylpyrimidineamine coated stents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:696536 CAPLUS

DN 139:207765

TI Combinations comprising N-(5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine and at least one telomerase inhibitor for treating proliferative diseases

IN Tauchi, Tetsuzo

PA Novartis AG, Switz.

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003166660	A1	20030904	US 2002-272837	20021017
	US 7045523	B2	20060516		
	US 2006111365	A1	20060525	US 2006-332406	20060113
PRAI	GB 2001-25105	A	20011018		
	GB 2002-15583	A	20020704		
	US 2002-272837	A3	20021017		


IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, salts  
220127-57-1

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations comprising imatinib and at least one telomerase inhibitor  
for treating proliferative diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:639686 CAPLUS

DN 140:139030

TI Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection

AU Savikko, Johanna; von Willebrand, Eva; Haeyry, Pekka

CS Transplantation Laboratory, Haartman Institute, Helsinki Univ. Central Hospital, Helsinki, Finland

SO Transplantation (2003), 76(3), 455-458

CODEN: TRPLAU; ISSN: 0041-1337


PB Lippincott Williams & Wilkins

DT Journal

LA English

10/519,722

IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(leflunomide analog FK778 is vasculoprotective independent of its immunosuppressive effect in relation to imatinib)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:633685 CAPLUS  
DN 139:180080  
TI Preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivatives  
IN Loiseleur, Olivier; Kaufmann, Daniel; Abel, Stephan; Buerger, Hans Michael; Meisenbach, Mark; Schmitz, Beat; Sedelmeier, Gottfried  
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SO PCT Int. Appl., 38 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066613	A1	20030814	WO 2003-EP1188	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2474738	AA	20030814	CA 2003-2474738	20030206
	AU 2003244444	A1	20030902	AU 2003-244444	20030206
	EP 1474408	A1	20041110	EP 2003-737319	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007529	A	20041221	BR 2003-7529	20030206
	CN 1630648	A	20050622	CN 2003-803556	20030206
	JP 2005528340	T2	20050922	JP 2003-565987	20030206
	NO 2004003685	A	20041105	NO 2004-3685	20040903
	US 2006142580	A1	20060629	US 2005-503538	20050120
PRAI	GB 2002-2873	A	20020207		
	WO 2003-EP1188	W	20030206		
OS	MARPAT 139:180080				
IT	152459-95-5p				

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)  
(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)

10/519,722

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610246 CAPLUS

DN 139:154937

TI Treatment of rheumatoid arthritis

IN Joensuu, Heikki

PA Hyks-Instituutti Oy, Finland

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063844	A2	20030807	WO 2003-EP802	20030127
	WO 2003063844	A3	20040401		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			
	RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR			
	CA 2473158	AA	20030807	CA 2003-2473158	20030127
	EP 1471916	A2	20041103	EP 2003-704474	20030127
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003007286	A	20041228	BR 2003-7286	20030127
	CN 1646130	A	20050727	CN 2003-802880	20030127
	JP 2005526022	T2	20050902	JP 2003-563538	20030127
	ZA 2004005323	A	20050620	ZA 2004-5323	20040705
	NO 2004003585	A	20041021	NO 2004-3585	20040827
PRAI	GB 2002-1882	A	20020128		
	WO 2003-EP802	W	20030127		
IT	152459-95-5 220127-57-1				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(treatment of rheumatoid arthritis with piperazinylmethylpyridinylpyrimidinylaminophenylbenzamide)			
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				


10/519,722



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 91 OF 106. CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:355612 CAPLUS  
DN 138:362649  
TI Treatment of cancer with anti-ErbB2 antibodies  
IN Sliwkowski, Mark X.  
PA Genentech, Inc., USA  
SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003086924	A1	20030508	US 2002-268501	20021010
	US 6949245	B1	20050927	US 2000-602812	20000623
	US 2004013667	A1	20040122	US 2003-608626	20030627
	US 2005208043	A1	20050922	US 2005-44749	20050127
	US 2005238640	A1	20051027	US 2005-154465	20050616

10/519,722

	US 2006034842	A1	20060216	US 2005-223361	20050909
	US 2006073143	A1	20060406	US 2005-222587	20050909
	AU 2005242195	A1	20060112	AU 2005-242195	20051207
	US 2006193854	A1	20060831	US 2006-429361	20060505
	US 2006198843	A1	20060907	US 2006-429043	20060505
	US 2006216285	A1	20060928	US 2006-429363	20060505
PRAI	US 1999-141316P	P	19990625		
	US 2000-602812	A2	20000623		
	AU 2000-57632	A3	20000623		
	US 2002-268501	A2	20021010		
	US 2005-44749	A1	20050127		
IT	220127-57-1, Imatinib mesylate				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(as tyrosine kinase inhibitor in combination with anti-ErbB2 antibodies; cancer treatment with anti-ErbB2 antibodies)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:334888 CAPLUS  
DN 138:358163  
TI Use of tyrosine kinase inhibitors for promoting hair growth  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035050	A2	20030501	WO 2002-IB4290	20020920
	WO 2003035050	A3	20040527		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2461182	AA	20030501	CA 2002-2461182	20020920
	EP 1461032	A2	20040929	EP 2002-801980	20020920
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005507917	T2	20050324	JP 2003-537617	20020920
	US 2004242612	A1	20041202	US 2004-490334	20040322
PRAI	US 2001-323314P	P	20010920		
	WO 2002-IB4290	W	20020920		
OS	MARPAT 138:358163				
IT	152459-95-5				
	RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of tyrosine kinase inhibitors for promoting hair growth)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:273844 CAPLUS  
 DN 139:345426  
 TI A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants  
 AU Huron, David R.; Gorre, Mercedes E.; Kraker, Alan J.; Sawyers, Charles L.; Rosen, Neal; Moasser, Mark M.  
 CS Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA  
 SO Clinical Cancer Research (2003), 9(4), 1267-1273  
 CODEN: CCREF4; ISSN: 1078-0432  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 IT 220127-57-1, STI571  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel pyridopyrimidine inhibitor (PD166326) of Bcr-abl tyrosine kinase

10/519,722

is effective against STI571-resistant Bcr-abl mutants in chronic myelogenous leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242116 CAPLUS

DN 138:265640

TI Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024386	A2	20030327	WO 2002-IB4236	20020920
	WO 2003024386	A3	20040205		
	WO 2003024386	C1	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW



RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2460845 AA 20030327 CA 2002-2460845 20020920  
 EP 1427379 A2 20040616 EP 2002-767812 20020920

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK


JP 2005511506 T2 20050428 JP 2003-528285 20020920  
 US 2004242601 A1 20041202 US 2004-490348 20040322

PRAI US 2001-323315P P 20010920  
 WO 2002-IB4236 W 20020920

OS MARPAT 138:265640  
 IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis)

RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:133053 CAPLUS  
 DN 138:163522  
 TI Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia  
 IN Donato, Nicholas J.; Fabbro, Dorian; Manley, Paul William; Mestan, Juergen; Warmuth, Markus; Hallek, Michael; Talpaz, Moshe; Wu, Ji  
 PA Novartis AG, Switz.; Novartis Pharma GmbH; GSF-National Research Institute for Environment and Health; The University of Texas System  
 SO PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003013540	A1	20030220	WO 2002-EP8941	20020809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2450777	AA	20030220	CA 2002-2450777	20020809
EP 1418917	A1	20040519	EP 2002-794592	20020809
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1523991	A	20040825	CN 2002-813696	20020809

10/519,722


	JP 2005502643	T2	20050127	JP 2003-518549	20020809
	US 2004248906	A1	20041209	US 2004-485803	20040729
	US 2006074094	A1	20060406	US 2005-285664	20051122
PRAI	US 2001-311690P	P	20010810		
	WO 2002-EP8941	W	20020809		
	US 2004-485803	A3	20040729		
IT	152459-95-5	220127-57-1			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of c-Src inhibitors alone or in combination with STI571 for leukemia treatment)				
RN	152459-95-5	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 96 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2003:10878 CAPLUS  
DN 138:395641  
TI Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)  
AU La Rosee, Paul; Corbin, Amie S.; Stoffregen, Eric P.; Deininger, Michael W.; Druker, Brian J.  
CS Division of Hematology and Medical Oncology, Oregon Health and Sciences University Cancer Institute, Portland, OR, 97239, USA  
SO Cancer Research (2002), 62(24), 7149-7153  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(activity of Bcr-Abl kinase inhibitor PD180970 against Abl kinase domain mutations that cause resistance to imatinib mesylate)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)  
  
CM 1  
  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
  
CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:977959 CAPLUS  
DN 138:51923  
TI Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571  
IN Sawyers, Charles L.; Gorre, Mercedes E.; Shah, Neil Pravin; Nicoll, John

10/519,722

PA The Regents of the University of California, USA

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102976	A2	20021227	WO 2002-US18729	20020614
	WO 2002102976	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2450473	AA	20021227	CA 2002-2450473	20020614
	US 2003158105	A1	20030821	US 2002-171889	20020614
	EP 1466174	A2	20041013	EP 2002-744318	20020614
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004537992	T2	20041224	JP 2003-506431	20020614
PRAI	US 2001-298728P	P	20010614		
	US 2001-331709P	P	20011120		
	WO 2002-US18729	W	20020614		
IT	220127-57-1, STI-571				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:946113 CAPLUS  
 DN 138:24647  
 TI Preparation of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and  
 analogs as activators of caspases and inducers of apoptosis for treatment  
 of cancer and other proliferative disorders  
 IN Cai, Sui Xiong; Zhang, Han-Zhong; Drewe, John; Kasibhatla, Shailaja  
 PA Cytovia, Inc., USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098425	A1	20021212	WO 2002-US17486	20020604
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1404329	A1	20040407	EP 2002-741817	20020604
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2005165053	A1	20050728	US 2003-477953	20031118
PRAI	US 2001-295007P	P	20010604		
	WO 2002-US17486	W	20020604		
OS	MARPAT 138:24647				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(coadministration agent; coadministration of (arylpropenoyl)-2(1H)-quinolinone caspases activators with known cancer therapeutic agents for treatment of cancer)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1


CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:946109 CAPLUS

DN 138:24718

TI Preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and  
4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases  
and inducers of apoptosis

IN Cai, Sui Xiong; Nguyen, Bao Ngoc; Drewe, John; Reddy, P. Sanjeeva;  
Kasibhatla, Shailaja; Pervin, Azra

PA Cytovia, Inc., USA

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098420	A1	20021212	WO 2002-US17108	20020531
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
	EP 1399159	A1	20040324	EP 2002-734605	20020531
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
	US 2003045581	A1	20030306	US 2002-158827	20020603
	US 6794400	B2	20040921		
PRAI	US 2001-294641P	P	20010601		
	WO 2002-US17108	W	20020531		
OS	MARPAT 138:24718				
IT	220127-57-1, Gleevec				

10/519,722

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and  
4-substituted-1-(arylcarbonyl)thiosemicarbazides for treating cancer in  
combination with)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:778718 CAPLUS

DN 137:289046

TI Methods and compositions for enhancing pharmaceutical treatments

IN Newman, Michael J.; Dixon, William Ross

PA USA

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002147197	A1	20021010	US 2002-104549	20020320
PRAI	US 1999-158322P	P	19991008		
	US 2000-684293	A2	20001006		
OS	MARPAT 137:289046				

IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, derivs.,  
analogs, and metabolites


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

10/519,722

(methods and compns. for enhancing pharmaceutical treatments)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:675840 CAPLUS

DN 137:226590

TI Use of epothilone derivatives and a signal transduction inhibitor for the treatment of cancer

IN Buchdunger, Elisabeth; Heldin, Carl-Henrik; Oestman, Arne; Pietras, Kristian; O'Reilly, Terence; Rothermel, John David; Traxler, Peter; Wartmann, Markus

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Brandt, Ralf

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067941	A2	20020906	WO 2002-EP2049	20020226
	WO 2002067941	A3	20031120		
	WO 2002067941	C1	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2439268	AA	20020906	CA 2002-2439268	20020226
	EP 1385522	A2	20040204	EP 2002-744903	20020226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007649	A	20040309	BR 2002-7649	20020226
	CN 1511036	A	20040707	CN 2002-805608	20020226




10/519,722

JP	2004527493	T2	20040909	JP	2002-567308	20020226
NZ	527764	A	20060127	NZ	2002-527764	20020226
ZA	2003006404	A	20040607	ZA	2003-6404	20030818
NO	2003003769	A	20030825	NO	2003-3769	20030825
US	2004132754	A1	20040708	US	2004-469367	20040218
PRAI	GB 2001-4840	A	20010227			
	US 2001-339040P	P	20011030			
	WO 2002-EP2049	W	20020226			
OS	MARPAT 137:226590					
IT	220127-57-1					
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)					
	(STI 571; use of epothilone derivs. and a signal transduction inhibitor for the treatment of cancer)					
RN	220127-57-1	CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)					


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:593669 CAPLUS  
DN 138:198235  
TI Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases  
AU Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel; Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas; Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard  
CS Molecular Pharmacology and Chemistry Program, New York, NY, 10021, USA  
SO Cancer Research (2002), 62(15), 4244-4255  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal

10/519,722

LA English  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(characterization of potent inhibitors of Bcr-Abl and the c-kit  
receptor tyrosine kinases and their antitumor effect)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:465821 CAPLUS  
DN 137:47211  
TI Substituted 2-aryl-4-arylamino pyrimidines and analogs as activators of  
caspases and inducers of apoptosis, their preparation, and the use thereof  
as, e.g., anticancer agents  
IN Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin,  
Azra  
PA Cytovia, Inc., USA  
SO PCT Int. Appl., 210 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047690	A1	20020620	WO 2001-US47498	20011212
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2002028922 A5 20020624 AU 2002-28922 20011212  
 US 2003069239 A1 20030410 US 2001-12444 20011212  
 US 6716851 B2 20040406  
 EP 1351691 A1 20031015 EP 2001-990048 20011212  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2004097503 A1 20040520 US 2003-704448 20031110  
 PRAI US 2000-254581P P 20001212  
 US 2001-12444 A3 20011212  
 WO 2001-US47498 W 20011212  
 OS MARPAT 137:47211  
 IT 438248-82-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[2-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)  
 RN 438248-82-9 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[2-(4-pyridinyl)-6-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:686951 CAPLUS  
 DN 136:111944  
 TI Bcr-Abl inhibition as a modality of CML therapeutics  
 AU Buchdunger, E.; Matter, A.; Druker, B. J.  
 CS Research Oncology, Novartis Pharma AG, Basel, CH-4002, Switz.  
 SO Biochimica et Biophysica Acta, Reviews on Cancer (2001), 1551(1), M11-M18  
 CODEN: BBACEU; ISSN: 0304-419X  
 PB Elsevier B.V.  
 DT Journal; General Review  
 LA English  
 IT 220127-57-1  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (STI 571; Bcr-Abl inhibition as modality of chronic myelogenous leukemia therapeutics)


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

379.57

547.16

STN INTERNATIONAL LOGOFF AT 13:50:07 ON 29 SEP 2006

10/519,722


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1996:380210 CAPLUS

DN 125:114681

TI Pyrimidine derivatives and processes for the preparation thereof

IN Zimmermann, Juerg

PA Ciba-Geigy Corporation, USA

SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521184	A	19960528	US 1994-234889	19940428
	CA 2148477	AA	19950413	CA 1994-2148477	19940921
PRAI	CH 1992-1083	A	19920403		
	US 1993-42322	B2	19930402		
	CH 1993-2966	A	19931001		



OS MARPAT 125:114681

IT 152459-93-3P 152459-95-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylaminopyrimidine derivs. as antitumor agents)

RN 152459-93-3 CAPLUS



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:Atom 12:Atom  
13:Atom 14:Atom 15:Atom 16:CLASS17:Atom 18:Atom 21:CLASS22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

18:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

O,O0

S,S0



N,N0-3

Node 18: Limited

O,O0

S,S0

N,N1-2



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:CLASS10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS17:Atom 18:Atom 21:CLASS22:CLASS

Generic attributes :



17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

18:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

Element Count :

Node 17: Limited

O,O0

S,S0

N,N0-3

Node 18: Limited

O,O0

S,S0

N,N1-2

10/519,722

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4	MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	5	MAY 11	KOREAPAT updates resume
NEWS	6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS	7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAPLUS and USPATFULL/USPAT2
NEWS	8	MAY 30	The F-Term thesaurus is now available in CA/CAPLUS
NEWS	9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS	10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS	11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS	12	JUL 11	CHEMSAFE reloaded and enhanced
NEWS	13	JUL 14	FSTA enhanced with Japanese patents
NEWS	14	JUL 19	Coverage of Research Disclosure reinstated in DWPI
NEWS	15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	17	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	18	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	20	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

10/519,722

result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:44:50 ON 29 SEP 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 13:44:58 ON 29 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

DICTIONARY FILE UPDATES: 28 SEP 2006 HIGHEST RN 909072-65-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10519722.str

10/519,722



chain nodes :

7 8 9 16 17 18 21

ring nodes :

1 2 3 4 5 6 10 11 12 13 14 15

ring/chain nodes :

22

chain bonds :

1-7 5-16 7-8 8-9 8-10 13-21 16-17 17-18 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-7 5-16 7-8 8-9 16-17 17-18

exact bonds :

8-10 13-21 21-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 10-11 10-15 11-12 12-13 13-14 14-15

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 18:Atom 21:CLASS

22:CLASS

Generic attributes :

17:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Type of Ring System : Monocyclic

10/519,722

18:  
Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic

Element Count :  
Node 17: Limited  
O,00  
S,S0  
N,N0-3

Node 18: Limited  
O,00  
S,S0  
N,N1-2

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam  
SAMPLE SEARCH INITIATED 13:45:22 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 336 TO ITERATE


100.0% PROCESSED 336 ITERATIONS 20 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 5621 TO 7819  
PROJECTED ANSWERS: 132 TO 668

L2 20 SEA SSS SAM L1

=> d scan

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(methyl-3-pyrrolidinylamino)methyl]- (9CI)  
MF C29 H31 N7 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):19

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)  
 MF C29 H31 N7 O . x C5 H8 O4

CM 1




CM 2

2

•

10/519,722


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-4-[(4-ethyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI)  
MF C32 H33 F3 N6 O  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI)  
MF C30 H33 N7 O . C2 H4 O2

CM 1




CM 2



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)  
MF C30 H31 Br N6 O



10/519,722




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Benamide, N-[4-chloro-3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI)

MF C29 H28 Cl F3 N8 O2




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI)

MF C29 H31 N7 O . 1/2 C5 H8 O4

CM 1




CM 2

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

10/519,722

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[4-(2R,4S)-4-(dimethylamino)-2-methyl-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI)  
MF C31 H33 F3 N8 O  
CI COM


Absolute stereochemistry. Rotation (-).




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-3-(trifluoromethyl)- (9CI)  
MF C30 H31 F3 N8 O2  
CI COM


PAGE 1-A






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-ethyl-4-  
 [(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI)  
 MF C30 H34 N8 O . Cl H



● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
 IN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)  
 MF C29 H31 N7 O  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN


10/519,722

IN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-  
[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI)  
MF C26 H24 F3 N7 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-[[1-[6-(cyclopropylamino)-4-pyrimidinyl]-1H-imidazol-2-yl]amino]-4-methylphenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (9CI)  
MF C30 H31 F3 N8 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI)  
MF C29 H31 N7 O . Cl H

10/519,722



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)-1-azetidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
MF C29 H29 F3 N8 O . Cl H



● HCl


L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, N-[3-([4,5'-bipyrimidin]-6-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
MF C29 H29 F3 N8 O . Cl H

10/519,722




● HCl

L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI)  
MF C29 H31 N7 O . C17 H37 N7 O3  
CI MXS  
CM 1




CM 2

Absolute stereochemistry. Rotation (-).



L2 20 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN  
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-nitro- (9CI)  
MF C29 H30 N8 O3

10/519,722



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 sss ful

FULL SEARCH INITIATED 13:45:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 6526 TO ITERATE

100.0% PROCESSED 6526 ITERATIONS

325 ANSWERS

SEARCH TIME: 00.00.01

L3 325 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

167.38

167.59

FILE 'CAPLUS' ENTERED AT 13:46:03 ON 29 SEP 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2006 VOL 145 ISS 15

FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13

L4 2002 L3

=> l4 and (pyridine or pyrimidine or pyrazine or pyridazine)

L4 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

10/519,722

For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s 14 and (pyridine or pyridazine or pyrazine or pyrimidine)

211669 PYRIDINE  
6728 PYRIDAZINE  
12811 PYRAZINE  
54368 PYRIMIDINE

L5 106 L4 AND (PYRIDINE OR PYRIDAZINE OR PYRAZINE OR PYRIMIDINE)

=> d 15 1-105 bib hitstr

L5 ANSWER 1 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:817911 CAPLUS

DN 145:249188

TI Preparation of tetrahydropyridothiophenes as antiproliferative agents for  
the treatment of cancer

IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,  
Bjoern

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 158pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084904	A1	20060817	WO 2006-EP50859	20060210
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI EP 2005-101007 A 20050211

EP 2005-104493 A 20050525

EP 2005-112159 A 20051214

IT 152459-95-5, Imatinib


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(preparation of tetrahydropyridothiophenes as antiproliferative and  
apoptosis-inducing agents useful in treatment of cancer)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






10/519,722

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:817524 CAPLUS  
DN 145:249187  
TI Preparation of tetrahydropyridothiophenes for the treatment of  
proliferative diseases such as cancer  
IN Pekari, Klaus; Schmidt, Mathias; Baer, Thomas; Beckers, Thomas; Bartels,  
Bjoern  
PA Altana Pharma AG, Germany  
SO PCT Int. Appl., 154pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006084869	A1	20060817	WO 2006-EP50782	20060208
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	EP 2005-100895	A	20050209		
	EP 2005-104488	A	20050525		
	EP 2005-112158	A	20051214		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of tetrahydropyridothiophenes with cell-cycle dependent, antiproliferative and apoptosis-inducing activity useful in treatment of hyperproliferative diseases such as cancer)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:768666 CAPLUS  
DN 145:188880  
TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and  
their preparation, pharmaceutical compositions and antiproliferative and

10/519,722

apoptosis inducing activity  
IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra;  
Beckers, Thomas; Schmidt, Mathias; Ciossek, Thomas; Nappe, Sandra  
PA Altana Pharma AG, Germany  
SO PCT Int. Appl., 56pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079644	A1	20060803	WO 2006-EP50465	20060126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-100594	A	20050128		
	EP 2005-100913	A	20050209		
IT	152459-95-5				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:768650 CAPLUS  
DN 145:211060  
TI Preparation of substituted phenylaminopyrimidines as B-Raf inhibitors  
IN Aquila, Brian; Lyne, Paul; Pontz, Timothy  
PA AstraZeneca AB, Swed.; AstraZeneca UK Limited  
SO PCT Int. Appl., 59pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

10/519,722

PI WO 2006079791 A1 20060803 WO 2006-GB223 20060124  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

PRAI US 2005-646820P P 20050125

OS MARPAT 145:211060


IT 904326-67-6P 904326-68-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted phenylaminopyrimidines as B-Raf inhibitors for  
treating cancer)


RN 904326-67-6 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-  
[(dimethylamino)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 904326-68-7 CAPLUS

CN Benzamide, N-[3-([2,5'-bipyrimidin]-4-ylamino)-4-methylphenyl]-4-[(4-  
methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:768370 CAPLUS

DN 145:188879

TI Novel indolopyridines, benzofuranopyridines and benzothienopyridines and  
their preparation, pharmaceutical compositions and antiproliferative and  
apoptosis inducing activity

IN Vennemann, Matthias; Baer, Thomas; Braunger, Juergen; Gimmnich, Petra

PA Altana Pharma AG, Germany

10/519,722

SO PCT Int. Appl., 61pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006079645	A1	20060803	WO 2006-EP50467	20060126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-100526	A	20050127		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of indolopyridines, benzofuranopyridines, and benzothienopyridines with antiproliferative and apoptosis inducing activity)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:729704 CAPLUS  
DN 145:159791  
TI 2-Phenylquinoxalines as inhibitors of MPPl for treatment of proliferative diseases  
IN Nigg, Erich A.; Mayer, Thomas U.; Huemmner, Stefan; Barr, Francis; Bormann, Jenny  
PA Max-Planck-Gesellschaft Zur Foerderung der Wissenschaften e.v., Germany  
SO Eur. Pat. Appl., 20 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1683523	A1	20060726	EP 2005-1419	20050125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				

BA, HR, IS, YU  
 WO 2006079478 A1 20060803 WO 2006-EP459 20060119  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,  
 KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,  
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
 VN, YU, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM


PRAI EP 2005-1419 A 20050125

IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combination with; phenylquinoxalines as inhibitors of human  
 phosphoprotein MPP1 for treatment of cancer and proliferative diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:657352 CAPLUS

DN 145:124614

TI Multi-step process for preparing imatinib

IN Huang, Anli; Xing, Liu; Zelikovitch, Lior; Kaspi, Joseph

PA Peop. Rep. China

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006149061	A1	20060706	US 2005-318455	20051228
PRAI	US 2004-640013P	P	20041230		


OS CASREACT 145:124614

IT 152459-95-5P, Imatinib

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (multi-step process for preparing imatinib)

RN 152459-95-5 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:655575 CAPLUS  
 DN 145:124558  
 TI Preparation of pyrazolyl phenyl ureas as enzyme modulators  
 IN Flynn, Daniel L.; Petillo, Peter A.  
 PA Deciphera Pharmaceuticals, LLC, USA  
 SO PCT Int. Appl., 974 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006071940	A2	20060706	WO 2005-US47270	20051223
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-638968P	P	20041223		
	US 2004-638986P	P	20041223		
	US 2004-638987P	P	20041223		
	US 2004-639087P	P	20041223		
OS	MARPAT 145:124558				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(co-drug; preparation of pyrazolyl Ph ureas as enzyme modulators for treating cancer and hyperproliferative diseases)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 9 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:513267 CAPLUS  
DN 145:21160  
TI Methods and compositions for the treatment of graft failure  
IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 85 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006057951	A2	20060601	WO 2005-US42111	20051121
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-630242P	P	20041122		
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(comps. for treatment of graft failure)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 10 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:463553 CAPLUS  
DN 144:488677  
TI Preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors  
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Zhao, Lianyun; Curran, Patrick J.; Belanger, David B.; Hamann, Blake; Reddy, Panduranga A.; Siddiqui, M. Arshad  
PA Schering Corporation, USA  
SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 47,524.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006106023	A1	20060518	US 2005-272392	20051110
	US 2004063715	A1	20040401	US 2003-665005	20030919
	US 6919341	B2	20050719		
	US 2005130980	A1	20050616	US 2005-47524	20050131
PRAI	US 2002-412997P	P	20020923		
	US 2003-665005	A3	20030919		
	US 2005-47524	A2	20050131		

OS MARPAT 144:488677

IT 220127-57-1, Gleevec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of novel imidazopyrazines as cyclin dependent kinase inhibitors  
useful in treatment and prevention of various diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)




CM 1

CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




L5 ANSWER 11 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:412038 CAPLUS  
 DN 144:450735  
 TI Preparation of novel aminopyridine derivatives having selective Aurora-A  
 protein kinase inhibitory effect  
 IN Ohkubo, Mitsuru; Kato, Tetsuya; Kawanishi, Nobuhiko; Mita, Takashi;  
 Shimomura, Toshiyasu  
 PA Banyu Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006046734	A2	20060504	WO 2005-JP19957	20051025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006106029	A1	20060518	US 2005-258447	20051025
PRAI JP 2004-315152	A	20041029		
JP 2005-161156	A	20050601		

10/519,722

US 2005-692537P P 20050621  
OS MARPAT 144:450735  
IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(novel aminopyridine derivs. having selective Aurora-A inhibitory  
effect)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 12 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:372184 CAPLUS  
DN 145:34047  
TI Anticancer implant compositions containing vasoinhibitor/  
pyrimidine derivative composite implant  
IN Kong, Qingzhong; Sun, Juan; Liu, Enxiang  
PA Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 18 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1733300	A	20060215	CN 2005-10044377	20050805
PRAI	CN 2005-10044377		20050805		

IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(vasoinhibitor/pyrimidine derivative antitumor composite implant)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




10/519,722

CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 13 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:333442 CAPLUS

DN 144:370121

TI Preparation of pyrimidine derivatives as phosphatase and kinase inhibitors for treating a variety of diseases

IN Klebl, Bert; Baumann, Matthias; Hoppe, Edmund; Brehmer, Dirk; Daub, Henrik; Keri, Gyoergy; Varga, Zoltan; Marosfalvi, Jenoe; Oerfi, Laszlo

PA GPC Biotech A.-G., Germany

SO PCT Int. Appl., 100 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021458	A2	20060302	WO 2005-EP9291	20050829
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-604685P P 20040827

OS MARPAT 144:370121

IT 152459-93-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 152459-95-5P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 475587-66-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 872672-74-7P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-2-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881676-19-3P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide 881677-62-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-4-yl)pyrimidin-2-yl]amino]phenyl]benzamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as phosphatase and kinase inhibitors for treating a variety of diseases)

RN 152459-93-3 CAPLUS


10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475587-66-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 872672-74-7 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(2-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 881676-19-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 881677-62-9 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(4-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:333345 CAPLUS  
 DN 144:350709  
 TI Pyrazolopyrimidines as protein kinase B inhibitors, their preparation,  
 pharmaceutical compositions, and use in therapy  
 IN Maier, Thomas; Zuelch, Armin; Ciossek, Thomas; Baer, Thomas; Beckers,  
 Thomas  
 PA Altana Pharma AG, Germany  
 SO PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006027346	A2	20060316	WO 2005-EP54366	20050905
	WO 2006027346	A3	20060803		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2004-104283 A 20040906

OS MARPAT 144:350709

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(novel pyrazolopyrimidine compds. useful in therapy of hyper-proliferative diseases and disorders responsive to induction of apoptosis)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:318488 CAPLUS  
DN 144:369909  
TI Preparation of cyclic diaryl ureas suitable as tyrosine kinase inhibitors  
IN Bold, Guido; Caravatti, Giorgio; Floersheimer, Andreas; Furet, Pascal;  
Manley, Paul W.; Pissot Soldermann, Carole; Vaupel, Andrea  
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SO PCT Int. Appl., 140 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034833	A1	20060406	WO 2005-EP10408	20050927
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI GB 2004-21525 A 20040928

OS MARPAT 144:369909

IT 220127-57-1, Glivec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(claimed drug for co-administration; preparation of cyclic diaryl ureas  
suitable as tyrosine kinase inhibitors)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 16 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:196073 CAPLUS  
DN 144:274310  
TI Preparation of benzotriazines, triazoles and oxadiazoles that affect the  
MAPK pathway and methods of use  
IN Wrasidlo, Wolfgang; Dneprovskaja, Elena  
PA Targen, Inc., USA  
SO PCT Int. Appl., 183 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006024034	A1	20060302	WO 2005-US30614	20050824
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006079526	A1	20060413	US 2005-212064	20050824
PRAI	US 2004-604298P	P	20040825		
	US 2005-696168P	P	20050701		
OS	MARPAT 144:274310				
IT	152459-95-5, Imatinib				

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(codrug; preparation of benzotriazines, triazoles and oxadiazoles that affect the MAPK pathway and methods of use)

10/519,722

RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:176834 CAPLUS  
DN 144:370108  
TI Preparation and application of phenylamino pyrimidine derivatives  
IN Chen, Guoqing  
PA Chen Guoqing, Peop. Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 41 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1560050	A	20050105	CN 2004-10014093	20040218
PRAI	CN 2004-10014093		20040218		
IT	791609-82-0P		791609-84-2P		791609-85-3P



882166-67-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and application of phenylamino pyrimidine derivs.)

RN 791609-82-0 CAPLUS  
CN Benzamide, 4-[[methyl(1-methyl-3-pyrrolidinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 791609-84-2 CAPLUS  
 CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
 [[(1-methyl-3-pyrrolidinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 791609-85-3 CAPLUS

CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



Me

RN 882166-67-8 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-4-  
[(methyl-3-pyrrolidinylamino)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2006:167936 CAPLUS  
 DN 144:254145  
 TI Preparation of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors  
 IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.  
 PA Schering Corporation, USA  
 SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 653,776.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006041131	A1	20060223	US 2005-244772	20051006
	US 2004106624	A1	20040603	US 2003-653776	20030903
	US 7067661	B2	20060627		
	US 2006178371	A1	20060810	US 2006-395676	20060331
PRAI	US 2002-408029P	P	20020904		
	US 2003-653776	A2	20030903		
OS	MARPAT 144:254145				
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of novel pyrazolopyrimidines as cyclin dependent kinase				


10/519,722

inhibitors for treatment and prevention of diseases)

RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 19 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:167588 CAPLUS  
DN 144:254148  
TI Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy  
IN Munzert, Gerd; Steegmaier, Martin; Baum, Anke  
PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.  
SO PCT Int. Appl., 158 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
	WO 2006018182	C1	20060608		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2006058311 A1 20060316 US 2005-189540 20050726  
PRAI EP 2004-19361 A 20040814  
EP 2004-19448 A 20040817  
OS MARPAT 144:254148  
IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(preparation of aminopteridinones for use in combination therapy for  
treatment of cell proliferative diseases)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:117065 CAPLUS  
DN 144:184657  
TI Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-  
ylmethyl)-N-4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-  
ylamino)phenyl]benzamide  
IN Breedveld, Pauline; Cipriani, Greta; Pluim, Dick; Schellens, Johannes  
Henricus Matthias; Van Tellingem, Olaf; Wielinga, Pieter Roeland  
PA The Netherlands Cancer Institute, Neth.  
SO PCT Int. Appl., 13 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006012958	A2	20060209	WO 2005-EP7090	20050630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-584825P P 20040701

IT 152459-95-5 220127-57-1


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)

10/519,722

(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



IT 874946-80-2 874946-81-3 874946-82-4  
874946-83-5 874946-84-6 874946-85-7  
875128-64-6 875128-67-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(BCRP inhibitor combination with pyrimidine deriv for cancer treatment)


RN 874946-80-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 102625-70-7  
CMF C16 H15 F2 N3 O4 S




RN 874946-81-3 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (3S,8aS)-hexahydro-3-[[6-methoxy-2-(3-methyl-2-butenyl)-1H-indol-3-yl]methyl]pyrrolo[1,2-alpyrazine-1,4-dione (9CI) (CA INDEX NAME)

CM 1

CRN 171864-80-5  
CMF C22 H27 N3 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O



10/519,722




RN 874946-82-4 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (5aS,12S,14aS)-1,2,3,5a,6,11,12,14a-octahydro-9-methoxy-12-(2-methyl-1-propenyl)-5H,14H-pyrrolo[1'',2'':4',5']pyrazino[1',2':1,6]pyrido[3,4-b]indole-5,14-dione (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 118974-02-0

CMF C22 H25 N3 O3

Absolute stereochemistry.



RN 874946-83-5 CAPLUS

CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid, 1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxo-, 1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 461054-93-3

CMF C26 H35 N3 O5

10/519,722


Absolute stereochemistry. Rotation (-).



CM 2

CRN 152459-95-5

CMF C29 H31 N7 O




RN 874946-84-6 CAPLUS

CN 4-Acridinecarboxamide, N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 143664-11-3

CMF C34 H33 N3 O5




RN 874946-85-7 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride (9CI) (CA INDEX NAME)

CM 1

CRN 289499-45-2

CMF C24 H25 Cl F N5 O3 . 2 Cl H


10/519,722



●2 HCl

CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 875128-64-6 CAPLUS  
CN Carbamic acid, [4-[(3S, 6S, 12aS)-1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indol-3-yl]butyl]-, 1,1-dimethylethyl ester, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI)  
(CA INDEX NAME)

CM 1

CRN 329356-42-5  
CMF C27 H38 N4 O4


Absolute stereochemistry.



10/519,722

CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 875128-67-9 CAPLUS  
CN Pyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid,  
1,2,3,4,6,7,12,12a-octahydro-6-(2-methylpropyl)-1,4-dioxo-,  
1,1-dimethylethyl ester, (3S,6S,12aS)-, mixt. with 4-[(4-methyl-1-  
piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 329356-45-8  
CMF C25 H33 N3 O4

Absolute stereochemistry.



CM 2


CRN 152459-95-5  
CMF C29 H31 N7 O



L5 ANSWER 21 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2006:87941 CAPLUS  
DN 144:331390  
TI Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl  
kinase inhibitors  
AU Asaki, Tetsuo; Sugiyama, Yukiteru; Hamamoto, Taisuke; Higashioka, Masaya;


10/519,722

Umehara, Masato; Naito, Haruna; Niwa, Tomoko  
CS Discovery Research Laboratories, Nippon Shinyaku Co, Ltd, Minami-ku,  
Kyoto, Kisshoin, 601-8550, Japan  
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1421-1425  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 144:331390  
IT 641614-88-2P 859212-07-0P 859212-16-1P, NS-187  
859212-47-8P 859212-49-0P 859212-51-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation N-[[ (bipyrimidinyl) amino] (methyl) phenyl] (trifluoromethyl) benzam  
ide derivs. and study of their activity as Bcr-Abl kinase inhibitors)  
RN 641614-88-2 CAPLUS  
CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-  
methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 859212-07-0 CAPLUS  
CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3R)-3-  
(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 859212-16-1 CAPLUS

10/519,722


CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 859212-47-8 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-(dimethylamino)-1-azetidiny]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 859212-49-0 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[3-[(dimethylamino)methyl]-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/519,722



● HCl

RN 859212-51-4 CAPLUS  
 CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[[ (3S)-3-  
 [(dimethylamino)methyl]-1-pyrrolidinyl]methyl]-3-(trifluoromethyl)-,  
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 641614-83-7P 641614-84-8P 641614-85-9P  
 641614-86-0P 641614-87-1P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation halo[(piperazinyl)methyl][methyl[(pyridinyl)pyrimidinyl]amino]p  
 henyl]benzamide derivs. and study of their activity as Bcr-Abl kinase  
 inhibitors)




10/519,722


RN 641614-83-7 CAPLUS  
CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-84-8 CAPLUS  
CN Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS  
CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-86-0 CAPLUS  
CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641614-87-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 220127-57-1, STI-571

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (preparation substituted benzamide derivs., study of their activity as gene  
 Bcr-Abl fusion protein- phosphorylating kinase (Bcr-Abl kinase)  
 inhibitors and their activity against STI-571-resistant chronic myeloid  
 leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
 INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:15086 CAPLUS

DN 144:108347

TI Preparation of pyrimidine urea derivatives as kinase inhibitors  
 for use against proliferative diseases

IN Ding, Qiang; Gray, Nathanael Schiander; Li, Bing; Liu, Yi; Sim, Taebo;  
 Uno, Tetsuo; Zhang, Guobao; Pissot Soldermann, Carole; Breitenstein,  
 Werner; Bold, Guido; Caravatti, Giorgio; Furet, Pascal; Guagnano, Vito;  
 Lang, Marc; Manley, Paul W.; Schoepfer, Joseph; Spanka, Carsten


10/519,722

PA Novartis AG, Switz.  
SO PCT Int. Appl., 327 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006000420	A1	20060105	WO 2005-EP6815	20050623
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2004-582425P	P	20040624		
	GB 2005-12324	A	20050616		
OS	MARPAT 144:108347				
IT	220127-57-1, Glivec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(codrug; preparation of pyrimidine urea derivs. as kinase inhibitors for use against proliferative diseases)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




10/519,722

RE.CNT 13      THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5    ANSWER 23 OF 106    CAPLUS    COPYRIGHT 2006 ACS on STN  
AN    2005:1329776    CAPLUS  
DN    144:45462  
TI    Pharmacologically active substances in combination with radio waves for  
the treatment of cancer  
IN    Kalbe, Jochen; Ludwig, Georg  
PA    Germany  
SO    PCT Int. Appl., 30 pp.  
CODEN: PIXXD2  
DT    Patent  
LA    German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005120638	A1	20051222	WO 2005-DE1028	20050609
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 102004028156	A1	20060105	DE 2004-102004028156	20040609
PRAI	DE 2004-102004028156	A	20040609		
	US 2004-585061P	P	20040706		
IT	152459-95-5, Imatinib				
	RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug-radio wave combination for treatment of cancer)				
RN	152459-95-5    CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)    (CA INDEX NAME)				




RE.CNT 7      THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5    ANSWER 24 OF 106    CAPLUS    COPYRIGHT 2006 ACS on STN  
AN    2005:1289902    CAPLUS  
DN    144:17212  
TI    Use of c-kit inhibitors for treating fibrodysplasia  
IN    Moussy, Alain; Kinet, Jean-Pierre  
PA    Ab Science, Fr.  
SO    PCT Int. Appl., 66 pp.  
CODEN: PIXXD2

10/519,722

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115304	A2	20051208	WO 2005-IB1371	20050419
	WO 2005115304	A3	20060406		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2004-573345P	P	20040524		
OS	MARPAT 144:17212				
IT	152459-95-5				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(c-kit inhibitors for treating fibrodysplasia)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 25 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1289861 CAPLUS  
DN 144:17211  
TI Use of c-kit inhibitors for treating acne  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA Ab Science, Fr.  
SO PCT Int. Appl., 73 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005115385	A1	20051208	WO 2005-IB1366	20050419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

10/519,722

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,  
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG

PRAI US 2004-573351P P 20040524


OS MARPAT 144:17211

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(c-kit inhibitors for treating acne)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1262399 CAPLUS

DN 144:22712

TI Triaryl compounds as PPAR modulators, their preparation, pharmaceutical  
compositions, and use in therapy

IN Epple, Robert; Azimioara, Mihai

PA Irm LLC, Bermuda

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005113506	A1	20051201	WO 2005-US16747	20050513
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-571004P P 20040514

OS MARPAT 144:22712

IT 152459-95-5, Imatinib


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(preparation of triaryl compds. as PPAR modulators and their use for  
treatment and prevention of diseases associated with PPARs activity)

RN 152459-95-5 CAPLUS

10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 27 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1239173 CAPLUS  
DN 143:477963  
TI Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful  
in the treatment of cancer  
IN Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying,  
Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum  
PA Bayer Pharmaceuticals Corporation, USA  
SO PCT Int. Appl., 215 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005110994	A2	20051124	WO 2005-US15106	20050502
	WO 2005110994	A3	20060202		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-566445P P 20040430

OS MARPAT 143:477963

IT 220127-57-1, Gleevec

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(substituted pyrazolylurea derivs. useful for cancer treatment)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 28 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170688 CAPLUS  
DN 143:432622  
TI Use of c-kit inhibitors for treating HIV-related diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 72 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102318	A1	20051103	WO 2005-IB1433	20050419
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2004-563442P P 20040420

OS MARPAT 143:432622


IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of HIV-related diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)





RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170667 CAPLUS  
DN 143:432692  
TI / Use of c-kit inhibitors for treating fibrosis  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 67 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102346	A2	20051103	WO 2005-IB1391	20050419
	WO 2005102346	A3	20060330		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-564569P P 20040423


OS MARPAT 143:432692

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of fibrosis)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 30 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170651 CAPLUS

10/519,722

DN 143:432621  
TI Use of c-kit inhibitors for treating plasmodium-related diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA Ab Science, Fr.  
SO PCT Int. Appl., 71 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102455	A1	20051103	WO 2005-IB1390	20050419
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-564599P P 20040423


OS MARPAT 143:432621

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treating plasmodium-related diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1170633 CAPLUS  
DN 143:432657  
TI Use of c-kit inhibitors for treating renal diseases  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 69 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102326	A2	20051103	WO 2005-IB1370	20050419
	WO 2005102326	A3	20060330		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-564586P P 20040423


OS MARPAT 143:432657

IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(c-kit inhibitors for treatment of renal disease)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 32 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1170607 CAPLUS

DN 143:432650

TI Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005102325	A1	20051103	WO 2005-IB1367	20050419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-563460P P 20040420

OS MARPAT 143:432650

10/519,722

IT 152459-95-5  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(c-kit inhibitors for treatment of inflammatory muscle disorders  
including myositis and muscular dystrophy)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 33 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1006008 CAPLUS  
DN 143:260361  
TI Leptomycin B combination with chemotherapeutic agents for the treatment of  
proliferative diseases  
IN Santi, Daniel V.; Zhou, Yiqing  
PA Kosan Biosciences, Inc., USA  
SO U.S. Pat. Appl. Publ., 4 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005203174	A1	20050915	US 2005-58447	20050214
	WO 2005086944	A2	20050922	WO 2005-US8124	20050309
	WO 2005086944	A3	20051215		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2004-551970P	P	20040309		
	US 2005-58447	A	20050214		

IT 152459-95-5, Imatinib  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(leptomycin B combination with chemotherapeutic agents for treatment of  
proliferative diseases)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 34 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:823686 CAPLUS

DN 143:216705

TI Preparation of salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]benzamide (imatinib)

IN Buerger, Hans Michael; Manley, Paul William; Mutz, Michael

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005075454	A2	20050818	WO 2005-EP1077	20050203
	WO 2005075454	A3	20060727		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005211514	A1	20050818	AU 2005-211514	20050203
PRAI	US 2004-541817P	P	20040204		
	WO 2005-EP1077	W	20050203		
IT	152459-95-5DP, Imatinib, salts 862366-24-3P				
	862366-25-4P 862366-26-5P 862366-27-6P				
	862366-28-7P 862366-30-1P 862366-31-2P				
	862366-32-3P 862366-33-4P 862366-34-5P				
	862366-35-6P 862366-36-7P 862366-37-8P				
	862366-38-9P 862366-39-0P 862366-40-3P				
	862366-41-4P 862366-42-5P 862366-43-6P				
	862366-44-7P 862366-45-8P 862366-46-9P				
	862366-47-0P 862366-48-1P 862366-49-2P				
	862366-50-5P 862366-51-6P				
	RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of salt forms of imatinib)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				


10/519,722



RN 862366-24-3 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 87-69-4  
CMF C4 H6 O6

Absolute stereochemistry.



RN 862366-25-4 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

10/519,722




● HCl

RN 862366-26-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 77-92-9  
CMF C6 H8 O7




RN 862366-27-6 CAPLUS  
CN Butanedioic acid, hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O


10/519,722



CM 2

CRN 6915-15-7

CMF C4 H6 O5




RN 862366-28-7 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2E)-2-butenedioate (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 862366-30-1 CAPLUS  
CN Butanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)  
(9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



10/519,722



CM 2

CRN 110-15-6

CMF C4 H6 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CH<sub>2</sub>-CO<sub>2</sub>H


RN 862366-31-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzoate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 65-85-0

CMF C7 H6 O2




RN 862366-32-3 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monobenzenesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 862366-33-4 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 130-85-8  
CMF C23 H16 O6

10/519,722




RN 862366-34-5 CAPLUS

CN Benzoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 69-72-7

CMF C7 H6 O3



RN 862366-35-6 CAPLUS


CN Benzoic acid, 4-hydroxy-3-methoxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 121-34-6

CMF C8 H8 O4




RN 862366-36-7 CAPLUS

CN Sulfamic acid, cyclohexyl-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 100-88-9

CMF C6 H13 N O3 S




RN 862366-37-8 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2)  
(9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 110-94-1  
CMF C5 H8 O4

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>3</sub>-CO<sub>2</sub>H

RN 862366-38-9 CAPLUS  
CN Propanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 141-82-2  
CMF C3 H4 O4

HO<sub>2</sub>C-CH<sub>2</sub>-CO<sub>2</sub>H


RN 862366-39-0 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, sulfate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 862366-40-3 CAPLUS

CN Hexanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

CRN 124-04-9

CMF C6 H10 O4

HO<sub>2</sub>C-(CH<sub>2</sub>)<sub>4</sub>-CO<sub>2</sub>H


RN 862366-41-4 CAPLUS

CN Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

10/519,722


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 611-71-2  
CMF C8 H8 O3


Absolute stereochemistry. Rotation (-).



RN 862366-42-5 CAPLUS  
CN Butanedioic acid, hydroxy-, (2R)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 636-61-3  
CMF C4 H6 O5

Absolute stereochemistry.




RN 862366-43-6 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, (2S,3S)-2,3-dihydroxybutanedioate  
(1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 147-71-7  
CMF C4 H6 O6


Absolute stereochemistry.



RN 862366-44-7 CAPLUS  
CN Formic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-  
[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (1:2) (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 64-18-6  
CMF C H2 O2





10/519,722


RN 862366-45-8 CAPLUS

CN 1,5-Naphthalenedisulfonic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 81-04-9

CMF C10 H8 O6 S2




RN 862366-46-9 CAPLUS

CN Propanoic acid, 2-hydroxy-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 50-21-5

CMF C3 H6 O3

10/519,722




RN 862366-47-0 CAPLUS

CN Propanoic acid, 2-hydroxy-, (2S)-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 79-33-4

CMF C3 H6 O3

Absolute stereochemistry. Rotation (+).




RN 862366-48-1 CAPLUS

CN Pentanedioic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O



CM 2

10/519,722


CRN 110-94-1  
CMF C5 H8 O4

$\text{HO}_2\text{C}-(\text{CH}_2)_3-\text{CO}_2\text{H}$

RN 862366-49-2 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, compd. with 3,4-dihydroxy-3-cyclobutene-1,2-dione (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 2892-51-5  
CMF C4 H2 O4



RN 862366-50-5 CAPLUS  
CN Butanedioic acid, oxo-, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




10/519,722

CM 2

CRN 328-42-7

CMF C4 H4 O5




RN 862366-51-6 CAPLUS

CN L-Ascorbic acid, compd. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O




CM 2

CRN 50-81-7

CMF C6 H8 O6

Absolute stereochemistry.




IT 152459-95-5, Imatinib

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of salt forms of imatinib)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 35 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:729564 CAPLUS

DN 143:186693

TI Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection

IN Kalman, Daniel; Bornmann, William Gerard; Sherman, Melanie Anne; Reeves, Patrick Michael; Swimm, Alyson Irene

PA Emory University, USA

SO PCT Int. Appl., 65 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005072826	A2	20050811	WO 2005-US1710	20050120
	WO 2005072826	A3	20060420		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005209231	A1	20050811	AU 2005-209231	20050120
	CA 2554201	AA	20050811	CA 2005-2554201	20050120
PRAI	US 2004-537960P	P	20040121		
	US 2004-553681P	P	20040316		
	US 2004-614203P	P	20040929		
	WO 2005-US1710	W	20050120		
OS	MARPAT 143:186693				
IT	152459-95-5 152459-95-5D, derivs. 220127-57-1, Imatinib mesylate 220127-57-1D, Imatinib mesylate, derivs. 593281-61-9, STI-X 593281-61-9D, derivs.				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(tyrosine kinase inhibitors for treatment of pathogenic infection)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				

10/519,722



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O




CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 593281-61-9 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 593281-61-9 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-(phenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 36 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:567125 CAPLUS  
DN 143:90993  
TI Combination of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one

hypusination inhibitor for the treatment of proliferative diseases,  
including leukemia

IN Bruemmendorf, Tim H.; Balabanov, Stefan; Hartmann, Ulrike; Kammer,  
Winfried; Nordheim, Alfred

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 27 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058320	A1	20050630	WO 2004-EP14439	20041217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004298761	A1	20050630	AU 2004-298761	20041217
	CA 2547196	AA	20050630	CA 2004-2547196	20041217
	EP 1696917	A1	20060906	EP 2004-804040	20041217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRAI	US 2003-531563P	P	20031219		
	WO 2004-EP14439	W	20041217		
IT	152459-95-5 220127-57-1 855843-70-8 855843-71-9 855843-72-0 855843-73-1 855843-74-2 855843-75-3 855843-76-4 855843-77-5 855843-78-6 855843-79-7 855843-80-0 855843-81-1				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(pyrimidine-amine derivative-hypusination inhibitor combination for treatment of proliferative diseases, including leukemia)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)




10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-70-8 CAPLUS  
CN Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, mixt. with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 70-51-9  
CMF C25 H48 N6 O8

PAGE 1-A



— (CH<sub>2</sub>)<sub>5</sub>—NH<sub>2</sub>


RN 855843-71-9 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 29342-05-0

CMF C12 H17 N O2



RN 855843-72-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O

10/519,722




CM 2

CRN 89149-10-0

CMF C17 H37 N7 O3

Absolute stereochemistry. Rotation (-).




RN 855843-73-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 30652-11-0

CMF C7 H9 N O2




RN 855843-74-2 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CRN 152459-95-5  
CMF C29 H31 N7 O



CRN 150333-69-0  
CMF C8 H20 N4



CRN 70-51-9  
CMF C25 H48 N6 O8

$$\text{Ac}-\overset{\text{OH}}{\underset{|}{\text{N}}}-(\text{CH}_2)_5-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\overset{\text{OH}}{\underset{|}{\text{N}}}-(\text{CH}_2)_5-\text{NH}-\overset{\text{O}}{\parallel}\text{C}-\text{CH}_2-\text{CH}_2-\overset{\text{O}}{\parallel}\text{C}-\overset{\text{OH}}{\underset{|}{\text{N}}}-$$
$$-(\text{CH}_2)_5-\text{NH}_2$$


CM 2

10/519,722

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 4


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-76-4 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 29342-05-0  
CMF C12 H17 N O2




CM 2

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S

CM 3


10/519,722

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 4

CRN 75-75-2  
CMF C H4 O3 S




RN 855843-77-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with 7-[(aminoiminomethyl)amino]-N-[(1S)-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide (9CI) (CA INDEX NAME)

CM 1

CRN 89149-10-0  
CMF C17 H37 N7 O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5  
CMF C29 H31 N7 O


10/519,722



CM 4

CRN 75-75-2

CMF C H4 O3 S




RN 855843-78-6 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone (9CI) (CA INDEX NAME)

CM 1

CRN 30652-11-0

CMF C7 H9 N O2



CM 2

CRN 220127-57-1


CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 4

CRN 75-75-2

CMF C H4 O3 S




RN 855843-79-7 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate, mixt. with (7-aminoheptyl)guanidine (9CI) (CA INDEX NAME)

CM 1

CRN 150333-69-0

CMF C8 H20 N4



CM 2


CRN 220127-57-1

CMF C29 H31 N7 O . C H4 O3 S

CM 3

CRN 152459-95-5

CMF C29 H31 N7 O




CM 4



10/519,722


CRN 75-75-2  
CMF C H4 O3 S



RN 855843-80-0 CAPLUS  
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.  
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide (9CI) (CA INDEX NAME)


CM 1

CRN 201530-41-8  
CMF C21 H15 N3 O4



CM 2

CRN 152459-95-5  
CMF C29 H31 N7 O




RN 855843-81-1 CAPLUS  
CN Benzoic acid, 4-[3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-, mixt.  
with 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722

CM 1

CRN 201530-41-8  
CMF C21 H15 N3 O4




CM 2

CRN 220127-57-1  
CMF C29 H31 N7 O . C H4 O3 S


CM 3

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 4

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2005:369277 CAPLUS  
DN 142:430271  
TI Preparation of substituted benzazoles as inhibitors of raf kinase  
IN Ramurthy, Savithri; Subramanian, Sharadha; Verhagen, Joelle; Poon, Daniel J.; Hansen, Teresa; Shafer, Cynthia; McBride, Christopher; Levine, Barry H.; Costales, Abran; Renhowe, Paul A.  
PA Chiron Corporation, USA  
SO PCT Int. Appl., 185 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037273	A1	20050428	WO 2004-US34179	20041015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004281151	A1	20050428	AU 2004-281151	20041015
	CA 2542653	AA	20050428	CA 2004-2542653	20041015
	US 2005192287	A1	20050901	US 2004-967089	20041015
	EP 1682126	A1	20060726	EP 2004-795357	20041015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-511966P	P	20031016		
	WO 2004-US34179	W	20041015		
OS	MARPAT 142:430271				
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of substituted benzazoles as inhibitors of raf kinase)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:369221 CAPLUS  
DN 142:430024  
TI Preparation of substituted 2-arylmethylene-N-aryl-N'-aryl-malonamides and analogs as activators of caspases and inducers of apoptosis  
IN Cai, Sui Xiong; Pervin, Azra; Kasibhatla, Shailaja; Nguyen, Bao Ngoc

10/519,722

PA Cytovia, Inc., USA  
SO PCT Int. Appl., 140 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037196	A2	20050428	WO 2004-US32570	20041005
	WO 2005037196	A3	20051013		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-508290P P 20031006

OS MARPAT 142:430024

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy; preparation of 2-arylmethylene-N,N'-diarylmalonamides and analogs as activators of caspases and inducers of apoptosis)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2


CMF C H4 O3 S



L5 ANSWER 39 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:324144 CAPLUS  
 DN 142:392431  
 TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase inhibitors and their preparation  
 IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia; Liu, Yi; Schoepfer, Joseph; Steensma, Ruo  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033086	A1	20050414	WO 2004-US32473	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004278413	A1	20050414	AU 2004-278413	20040930
	CA 2539339	AA	20050414	CA 2004-2539339	20040930
	US 2005171105	A1	20050804	US 2004-956412	20040930
	EP 1670771	A1	20060621	EP 2004-789483	20040930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-507592P	P	20030930		
	WO 2004-US32473	W	20040930		
OS	MARPAT 142:392431				
IT	850087-62-6P, N-[3-[[2-[6-(3-Dimethylaminophenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide				
	850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide				
	850087-74-0P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-(pyrimidin-4-yl)phenyl]amino]phenyl]benzamide				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(drug candidate; preparation of pyrimidine-containing arylamines and aryl benzamides as protein kinase inhibitors)				
RN	850087-62-6 CAPLUS				
CN	Benzamide, N-[3-[[2-[6-[[3-(dimethylamino)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI)				
	(CA INDEX NAME)				

PAGE 1-A




PAGE 1-B

Me

RN 850087-68-2 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Me

RN 850087-74-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-(4-pyrimidinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 40 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:323779 CAPLUS  
DN 142:397824  
TI Biocompatibly coated medical implants  
IN Rathenow, Jorg; Ban, Andreas; Kunstmann, Jurgen; Mayer, Bernhard; Asgari, Soheil  
PA Germany  
SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of Appl. No. PCT/EP04/04985.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 9


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005079200	A1	20050414	US 2004-938995	20040910
	DE 10322182	A1	20041202	DE 2003-10322182	20030516
	DE 10324415	A1	20041216	DE 2003-10324415	20030528
	DE 10333098	A1	20050210	DE 2003-10333098	20030721
	WO 2004101017	A2	20041125	WO 2004-EP4985	20040510
	WO 2004101017	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	DE 2003-10322182	A	20030516		
	DE 2003-10324415	A	20030528		
	DE 2003-10333098	A	20030721		
	WO 2004-EP4985	A2	20040510		
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(biocompatibly coated medical implants)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 41 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:158528 CAPLUS  
 DN 142:254620  
 TI Use of c-kit inhibitors for treating type II diabetes  
 IN Moussy, Alain; Kinet, Jean-Pierre  
 PA Ab Science, Fr.  
 SO PCT Int. Appl., 126 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016323	A2	20050224	WO 2004-IB2934	20040816
	WO 2005016323	A3	20050407		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2535242	AA	20050224	CA 2004-2535242	20040816
	EP 1653934	A2	20060510	EP 2004-769332	20040816
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-495088P	P	20030815		
	WO 2004-IB2934	W	20040816		
OS	MARPAT 142:254620				
IT	152459-95-5P, 4-((4-Methylpiperazin-1-yl)methyl)-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide				
RL:	PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(c-kit inhibitor; use of potent, selective and non-toxic c-kit inhibitors for treating type diabetes, obesity and related diseases)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				






L5 ANSWER 42 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2005:99470 CAPLUS  
 DN 142:197889  
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf,  
 VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases  
 IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott  
 PA Bayer Pharmaceuticals Corporation, USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009961	A2	20050203	WO 2004-US23500	20040722
	WO 2005009961	A3	20050331		
	WO 2005009961	B1	20050602		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004259760	A1	20050203	AU 2004-259760	20040722
	CA 2532865	AA	20050203	CA 2004-2532865	20040722
	US 2005038080	A1	20050217	US 2004-895985	20040722
	EP 1663978	A2	20060607	EP 2004-786091	20040722
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	NO 2006000870	A	20060407	NO 2006-870	20060222
PRAI	US 2003-489102P	P	20030723		
	US 2004-540326P	P	20040202		
	WO 2004-US23500	W	20040722		
IT	220127-57-1, STI-571				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 43 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:17705 CAPLUS

DN 142:148113

TI Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations

AU Wong, S.; McLaughlin, J.; Cheng, D.; Zhang, C.; Shokat, K. M.; Witte, O. N.

CS Molecular Biology Interdepartmental Ph.D. Program, University of California, Los Angeles, CA, 90095, USA

SO Proceedings of the National Academy of Sciences of the United States of America (2004), 101(50), 17456-17461

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

IT 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1127387 CAPLUS  
DN 142:74600  
TI Heteroaryl-fused pyrimidinyl compounds, including thieno[3,2-d]pyrimidine derivatives, with KSP-inhibiting activity, and their preparation, pharmaceutical compositions, and use as anticancer agents  
IN Wang, Weibo; Lagniton, Liana M.; Constantine, Ryan N.; Burger, Matthew T.  
PA Chiron Corporation, USA  
SO PCT Int. Appl., 59 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004111058	A1	20041223	WO 2004-US16954	20040527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065169	A1	20050324	US 2004-850429	20040521
AU 2004247650	A1	20041223	AU 2004-247650	20040527
CA 2526217	AA	20041223	CA 2004-2526217	20040527
EP 1636238	A1	20060322	EP 2004-753729	20040527
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1798749	A	20060705	CN 2004-80014819	20040527
PRAI US 2003-474684P	P	20030530		

10/519,722


WO 2004-US16954 W 20040527  
OS MARPAT 142:74600  
IT 152459-95-5, Imatinib 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic coadministration with; preparation of thieno[3,2-d]  
pyrimidine derivs. as KSP inhibitors for use as anticancer  
agents)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1080793 CAPLUS  
DN 142:32971  
TI Methods and compounds for the treatment of vascular stenosis using a  
combination of N-phenyl-2-pyrimidine derivatives and PI3K


10/519,722

inhibitors  
IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 48 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004108130	A1	20041216	WO 2004-US17273	20040601
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2528032	AA	20041216	CA 2004-2528032	20040601
	EP 1635815	A1	20060322	EP 2004-753981	20040601
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-475295P	P	20030603		
	WO 2004-US17273	W	20040601		
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Imatinib mesylate; methods and compds. for treatment of vascular stenosis using combination of N-phenyl-2-pyrimidine derivs. and PI3K inhibitors)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2  
CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 46 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:1060780 CAPLUS  
DN 142:38275  
TI Preparation of N-phenyl-2-pyrimidine-amine derivatives as  
anticancer agents and process for the preparation thereof  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim,  
Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-Chul; Lee, Sun-Ahe;  
Han, Byoung-Cheol  
PA Il Yang Pharm. Co., Ltd., S. Korea  
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 446,446,  
abandoned.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004248918	A1	20041209	US 2004-806834	20040322
PRAI	KR 2003-28669	A	20030506		
	US 2003-446446	B2	20030528		
OS	MARPAT 142:38275				
IT	796738-20-0P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-23-3P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl- 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-25-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-28-8P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[2-methyl-5- [4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-32-4P , 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2- yl]amino]phenyl]benzamide 796738-34-6P, 4-(4-Methylpiperazin-1- ylaminomethyl)-N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-40-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P, 4-(4-Methylpiperazin-1-ylaminomethyl)-N-[4-methoxy-3- [4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-44-8P , 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3- yl)pyrimidin-2-yl]aminophenyl]benzamide 796738-47-1P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin- 2-yl]aminophenyl]benzamide 796738-50-6P, 4-(4-Methylpiperazin-1- ylaminomethyl)-N-[2-fluoro-5-[4-(pyridin-3-yl)pyrimidin-2- yl]aminophenyl]benzamide 796738-54-0P, 4-(4-Methylpiperazin-1- ylmethyl)-N-[4-fluoro-3-[4-(pyridin-3-yl)pyrimidin-2- yl]aminophenyl]benzamide 796738-56-2P, 4-(4-Methylhomopiperazin- 1-ylmethyl)-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2- yl]amino]phenyl]benzamide 796738-58-4P, 4-(Piperidin-1-ylmethyl)- N-[3-[4-(pyridin-3-yl)pyrimidin-2-yl]aminophenyl]benzamide 804554-75-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3- [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 804554-76-5P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-				

3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-77-6P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-methyl-5-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-78-7P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-methyl-  
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-80-1P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-81-2P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-84-5P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methoxy-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-85-6P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methoxy-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-86-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[2-fluoro-5-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-87-8P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[2-fluoro-5-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-88-9P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[2-fluoro-  
 5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-90-3P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[4-fluoro-3-[[4-  
 (pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-91-4P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-fluoro-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-92-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-  
 yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 804554-94-7P, 4-(4-Methylhomopiperazin-1-ylmethyl)-N-[4-methyl-3-  
 [[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 804554-95-8P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 804554-98-1P, 4-[(4-Methylpiperazin-1-ylamino)methyl]-N-[4-methyl-  
 3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of N-phenylpyrimidine-2-amine derivs. as anticancer agents)

RN 796738-20-0 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-  
 3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS


CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-28-8 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS




10/519,722

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 796738-44-8 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



10/519,722


RN 796738-47-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS


CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-58-4 CAPLUS

10/519,722

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 804554-75-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-76-5 CAPLUS


CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3

CMF C29 H32 N8 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-77-6 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RN 804554-78-7 CAPLUS

CN Benzamide, 4-[[ (4-methyl-1-piperazinyl) amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-28-8


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-80-1 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-32-4


CMF C29 H31 N7 O



CM 2

10/519,722


CRN 75-75-2  
CMF C H4 O3 S



RN 804554-81-2 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6  
CMF C28 H30 N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 804554-84-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4  
CMF C30 H33 N7 O2


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-85-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 804554-86-7 CAPLUS


CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-

10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate  
(9CI) (CA INDEX NAME)


CM 1

CRN 796738-44-8  
CMF C29 H30 F N7 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 804554-87-8 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX  
NAME)

CM 1

CRN 796738-47-1  
CMF C28 H28 F N7 O




CM 2

CRN 75-75-2  
CMF C H4 O3 S




10/519,722



RN 804554-88-9 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl)amino]methyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 796738-50-6  
CMF C28 H29 F N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 804554-90-3 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl)methyl]-, monomethanesulfonate (9CI) (CA INDEX  
NAME)

CM 1

CRN 796738-54-0  
CMF C28 H28 F N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 804554-91-4 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, monomethanesulfonate  
(9CI) (CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




10/519,722

RN 804554-92-5 CAPLUS  
CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-58-4  
CMF C28 H28 N6 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 804554-94-7 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0  
CMF C30 H33 N7 O




CM 2

CRN 64-19-7

10/519,722


CMF C2 H4 O2



RN 804554-95-8 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3  
CMF C29 H32 N8 O




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 804554-98-1 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

10/519,722

AN 2004:1036851 CAPLUS  
 DN 142:696  
 TI Synergistic treatment of cancer using immunomers in conjunction with  
 chemotherapeutic agents  
 IN Kandimalla, Ekambar R.; Agrawal, Sudhir; Wang, Daqin  
 PA Hybridon, Inc., USA  
 SO PCT Int. Appl., 106 pp.  
 CODEN: PIXXD2


DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103301	A2	20041202	WO 2004-US15313	20040514
	WO 2004103301	A3	20051103		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004241093	A1	20041202	AU 2004-241093	20040514
	CA 2526212	AA	20041202	CA 2004-2526212	20040514
	US 2005009773	A1	20050113	US 2004-846167	20040514
	EP 1628531	A2	20060301	EP 2004-752345	20040514
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-471247P	P	20030516		
	WO 2004-US15313	W	20040514		
OS	MARPAT 142:696				
IT	220127-57-1, Gleevec				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL				
	(Biological study); USES (Uses)				
	(immunostimulatory oligonucleotide and/or immunomer combination with				
	chemotherapeutic agent for synergistic cancer treatment)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				
	pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA				
	INDEX NAME)				


CM 1

CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 48 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:996162 CAPLUS  
DN 141:424205  
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib  
mesylate, useful as antitumor agents, and process for their preparation  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jin; Lee, Gong-Yeal; Kim,  
Hong-Youb; Woo, Seok-Hun; Kim, Yong-Seok; Bae, Woo-chul; Lee, Sun-Ahe;  
Han, Byoung-Cheol  
PA Il Yang Pharm. Co. Ltd., S. Korea  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099187	A1	20041118	WO 2004-KR611	20040319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		

OS MARPAT 141:424205

IT 796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

796738-23-3P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722



RN 796738-23-3 CAPLUS  
 CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




IT 796738-22-2P, 4-[[4-Methylhomopiperazin-1-yl]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 796738-24-4P, 4-[[4-Methylpiperazin-1-yl]amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)  
 RN 796738-22-2 CAPLUS  
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0  
 CMF C30 H33 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-24-4 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S






IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-28-8P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P  
 , 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,  
 4-[[[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,  
 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,  
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,  
 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,  
 4-[[[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,  
 4-(Piperidin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-25-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-28-8 CAPLUS


CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



10/519,722


RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-40-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[[(4-methyl-1-piperazinyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-44-8 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 796738-54-0 CAPLUS


CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 796738-56-2 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 796738-58-4 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-  
[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-29-9P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-35-7P, 4-[[[(4-Methylpiperazin-1-  
yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P,  
4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-43-7P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-  
methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P,  
4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-51-7P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-

yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 796738-62-0P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate  
 796738-65-3P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI)  
 (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 796738-28-8  
CMF C29 H32 N8 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-33-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-32-4  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S


10/519,722



RN 796738-35-7 CAPLUS  
CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-34-6  
CMF C28 H30 N8 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 796738-41-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4  
CMF C30 H33 N7 O2


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-




10/519,722

[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-44-8


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-48-2 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1

CMF C28 H28 F N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S

10/519,722




RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-55-1 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-54-0

CMF C28 H28 F N7 O




10/519,722

CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-57-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-59-5 CAPLUS


CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-  
pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-58-4


CMF C28 H28 N6 O

10/519,722



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-61-9 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-20-0  
CMF C30 H33 N7 O



CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 796738-62-0 CAPLUS  
CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-


10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3


CMF C29 H32 N8 O



CM 2


CRN 64-19-7

CMF C2 H4 O2



RN 796738-65-3 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 220127-57-1, Imatinib mesylate

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic replacements for; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 49 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:996161 CAPLUS  
DN 141:424204  
TI New N-phenyl-2-pyrimidine-amine derivatives related to imatinib  
mesylate, useful as antitumor agents, and process for the preparation  
thereof  
IN Kim, Dong-Yeon; Kim, Jae-Gun; Cho, Dae-Jn; Lee, Gong-Yeal; Kim, Hong-Youb;  
Woo, Seok-Hun; Bae, Woo-chul; Lee, Sun-Ahe; Han, Byoung-Ceol  
PA Il Yang Pharm Co., Ltd., S. Korea  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004099186	A1	20041118	WO 2003-KR1029	20030526
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003232650	A1	20041126	AU 2003-232650	20030526
	KR 2004095155	A	20041112	KR 2004-17594	20040316
PRAI	KR 2003-28669	A	20030506		
	WO 2003-KR1029	W	20030526		
OS	MARPAT 141:424204				
IT	796738-20-0P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-				

[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-23-3P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-20-0 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-23-3 CAPLUS

CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-22-2P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate

796738-24-4P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)

RN 796738-22-2 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0

CMF C30 H33 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-24-4 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-23-3

CMF C29 H32 N8 O




CM 2


CRN 75-75-2

CMF C H4 O3 S






- IT 796738-25-5P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-28-8P, 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 796738-32-4P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-34-6P  
 , 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-40-4P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-42-6P,  
 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-44-8P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-47-1P,  
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-50-6P,  
 4-[[[(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-54-0P,  
 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-56-2P,  
 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide 796738-58-4P,  
 4-(Piperidin-1-yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)
- RN 796738-25-5 CAPLUS  
 CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




- RN 796738-28-8 CAPLUS  
 CN Benzamide, 4-[[[(4-methyl-1-piperazinyl)amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 796738-32-4 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-34-6 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 796738-40-4 CAPLUS


CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 796738-42-6 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)


10/519,722




RN 796738-44-8 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-47-1 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-50-6 CAPLUS  
CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 796738-54-0 CAPLUS  
CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 796738-56-2 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]- (9CI) (CA INDEX NAME)

RN 796738-58-4 CAPLUS

CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



IT 796738-27-7P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[2-methyl-5-  
[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-29-9P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
methyl-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-33-5P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-35-7P, 4-[[4-(4-Methylpiperazin-1-  
yl)amino]methyl]-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-41-5P,  
4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methoxy-3-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-43-7P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-  
methoxy-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide  
methanesulfonate 796738-45-9P, 4-[(4-Methylhomopiperazin-1-  
yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-  
yl]amino]phenyl]benzamide methanesulfonate 796738-48-2P,  
4-[(4-Methylpiperazin-1-yl)methyl]-N-[2-fluoro-5-[[4-(pyridin-3-  
yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate  
796738-51-7P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[2-  
fluoro-5-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide

methanesulfonate 796738-55-1P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-57-3P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-fluoro-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-59-5P, 4-(Piperidin-1-ylmethyl)-N-[3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide methanesulfonate 796738-61-9P, 4-[(4-Methylhomopiperazin-1-yl)methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-62-0P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide acetate 796738-65-3P, 4-[[4-(4-Methylpiperazin-1-yl)amino]methyl]-N-[4-methyl-3-[[4-(pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 796738-27-7 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-25-5


CMF C30 H33 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-29-9 CAPLUS

CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[2-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 796738-28-8  
CMF C29 H32 N8 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 796738-33-5 CAPLUS  
CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 796738-32-4  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S

10/519,722




RN 796738-35-7 CAPLUS

CN Benzamide, 4-[[[4-methyl-1-piperazinyl)amino)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-34-6


CMF C28 H30 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-41-5 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-40-4

CMF C30 H33 N7 O2




10/519,722

CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-43-7 CAPLUS

CN Benzamide, N-[4-methoxy-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-42-6


CMF C29 H32 N8 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-45-9 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-44-8

CMF C29 H30 F N7 O




10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-48-2 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-47-1


CMF C28 H28 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



10/519,722


RN 796738-51-7 CAPLUS

CN Benzamide, N-[2-fluoro-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]amino]methyl]-, methanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 796738-50-6


CMF C28 H29 F N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-55-1 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[[4-methyl-1-piperazinyl]methyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-54-0

CMF C28 H28 F N7 O




CM 2

CRN 75-75-2

CMF C H4 O3 S

10/519,722




RN 796738-57-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-  
[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-, methanesulfonate (9CI)  
(CA INDEX NAME)

CM 1

CRN 796738-56-2


CMF C29 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 796738-59-5 CAPLUS


CN Benzamide, 4-(1-piperidinylmethyl)-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-58-4

CMF C28 H28 N6 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 796738-61-9 CAPLUS

CN Benzamide, 4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 796738-20-0


CMF C30 H33 N7 O



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 796738-62-0 CAPLUS


CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 796738-23-3  
CMF C29 H32 N8 O




CM 2

CRN 64-19-7  
CMF C2 H4 O2



RN 796738-65-3 CAPLUS  
CN Benzamide, 4-[[4-methyl-1-piperazinyl]amino]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(therapeutic replacements for; preparation of phenylpyrimidinamine derivs. related to imatinib mesylate as antitumor agents)


RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[[4-methyl-1-piperazinyl]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

10/519,722


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 50 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:995984 CAPLUS

DN 141:389290

TI New calcitriol analogs and therapeutic use in treating mast cell associated diseases

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004098612	A2	20041118	WO 2004-IB1871	20040507
	WO 2004098612	A3	20050210		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2003-468295P	P	20030507		
	US 2003-480224P	P	20030623		
OS	MARPAT 141:389290				
IT	152459-95-5				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(new calcitriol analogs and therapeutic use in treating mast cell associated diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 51 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965068 CAPLUS

DN 141:406114

TI Use of tyrosine kinase inhibitors for treating cerebral ischemia

IN Kinet, Jean-Pierre; Moussy, Alain

PA AB Science, Fr.

SO PCT Int. Appl., 117 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096225	A2	20041111	WO 2004-IB1874	20040428
	WO 2004096225	A3	20050310		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2523852	AA	20041111	CA 2004-2523852	20040428
	EP 1624873	A2	20060215	EP 2004-729952	20040428
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
PRAI	US 2003-465789P	P	20030428		
	WO 2004-IB1874	W	20040428		
OS	MARPAT 141:406114				
IT	152459-95-5				
	RL:	PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
		(tyrosine kinase inhibitors for treating cerebral ischemia)			
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 52 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:965067 CAPLUS

DN 141:406039

TI Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis

IN Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
	WO 2004096224	A3	20041216		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1473043	A1	20041103	EP 2003-9587	20030429
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	AU 2004233576	A1	20041111	AU 2004-233576	20040424
	CA 2523868	AA	20041111	CA 2004-2523868	20040424
	EP 1622619	A2	20060208	EP 2004-729366	20040424
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	BR 2004009919	A	20060425	BR 2004-9919	20040424
	NO 2005005605	A	20051128	NO 2005-5605	20051128
PRAI	EP 2003-9587	A	20030429		
	EP 2004-508	A	20040113		
	EP 2004-1171	A	20040121		
	WO 2004-EP4363	W	20040424		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				



pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 53 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:878151 CAPLUS

DN 141:366243

TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamilus; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PA Schering Corporation, USA; Pharmacopeia, Inc.

SO U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004209878	A1	20041021	US 2004-776988	20040211
	AU 2005212409	A1	20050825	AU 2005-212409	20050208
	WO 2005077954	A2	20050825	WO 2005-US3859	20050208
	WO 2005077954	A3	20051013		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2006128725	A1	20060615	US 2005-245401	20051006
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	US 2003-654546	A2	20030903		
	US 2004-776988	A	20040211		
	WO 2005-US3859	W	20050208		

OS MARPAT 141:366243

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer in combination of other anticancer agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 54 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756710 CAPLUS  
DN 141:277628  
TI Preparation of ureidophenoxycyanopyridines as anticancer drugs.  
IN Scott, William J.; Dumas, Jacques; Boyer, Stephen; Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma, Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei; Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu, Qingming  
PA Bayer Pharmaceuticals Corporation, USA  
SO PCT Int. Appl., 127 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004078747	A1	20040916	WO 2004-US6286	20040301
	WO 2004078747	C1	20041104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004235829	A1	20041125	US 2004-788029	20040227
	AU 2004217977	A1	20040916	AU 2004-217977	20040301
	CA 2517361	AA	20040916	CA 2004-2517361	20040301
	US 2004229937	A1	20041118	US 2004-789446	20040301
	US 2005032798	A1	20050210	US 2004-788405	20040301
	US 2005038031	A1	20050217	US 2004-788426	20040301
	EP 1599467	A1	20051130	EP 2004-716144	20040301

10/519,722

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK  
BR 2004007897 A 20060301 BR 2004-7897 20040301  
JP 2006519264 T2 20060824 JP 2006-508977 20040301  
PRAI US 2003-450323P P 20030228  
US 2003-450324P P 20030228  
US 2003-450348P P 20030228  
WO 2004-US6286 A 20040301  
OS MARPAT 141:277628  
IT 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer  
drugs)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
CM 1  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756044 CAPLUS  
DN 141:266048  
TI Medical implants with carbon-containing surfaces that are functionalized  
PA Blue Membranes GmbH, Germany  
SO Ger. Gebrauchsmusterschrift, 18 pp.  
CODEN: GGXXFR  
DT Patent  
LA German  
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

10/519,722


PI DE 202004009061 U1 20040916 DE 2004-202004009061 20040528  
DE 10324415 A1 20041216 DE 2003-10324415 20030528  
DE 10333098 A1 20050210 DE 2003-10333098 20030721  
DE 10333099 A1 20050210 DE 2003-10333099 20030721  
PRAI DE 2003-10324415 A1 20030528  
DE 2003-10333098 A1 20030721  
DE 2003-10333099 A1 20030721  
IT 152459-95-5, Imatinib  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medical implants with carbon-containing surfaces that are functionalized)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 56 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:756043 CAPLUS  
DN 141:266047  
TI Medical implants coated with biocompatible carbon-containing layers  
PA Blue Membranes GmbH, Germany  
SO Ger. Gebrauchsmusterschrift, 23 pp.  
CODEN: GGXXFR  
DT Patent  
LA German  
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 202004009060	U1	20040916	DE 2004-202004009060	20040510
	DE 10322182	A1	20041202	DE 2003-10322182	20030516
	DE 10324415	A1	20041216	DE 2003-10324415	20030528
	DE 10333098	A1	20050210	DE 2003-10333098	20030721
PRAI	DE 2003-10322182	A1	20030516		
	DE 2003-10324415	A1	20030528		
	DE 2003-10333098	A1	20030721		

IT 152459-95-5, Imatinib  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(medical implants coated with biocompatible carbon-containing layers)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 57 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:691283 CAPLUS

DN 141:207230

TI Preparation of imatinib and salts by reaction of N-(2-methyl-5-aminophenyl)-4-(3-pyridyl)-2-pyrimidinamine with 4-(4-methylpiperazinylmethyl)benzoyl halides.

IN Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra

PA Cipla Limited, India

SO Brit. UK Pat. Appl., 34 pp.


CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2398565	A1	20040825	GB 2003-3730	20030218
	AU 2004213616	A2	20040902	AU 2004-213616	20040108
	AU 2004213616	A1	20040902		
	CA 2516370	AA	20040902	CA 2004-2516370	20040108
	WO 2004074502	A2	20040902	WO 2004-GB18	20040108
	WO 2004074502	A3	20041028		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1599462	A2	20051130	EP 2004-700728	20040108
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004007672	A	20060301	BR 2004-7672	20040108
	JP 2006518360	T2	20060810	JP 2006-502181	20040108
	US 2006173182	A1	20060803	US 2005-546193	20051031
PRAI	GB 2003-3730	A	20030218		
	WO 2004-GB18	A	20040108		
OS	CASREACT 141:207230				
IT	152459-95-5P, Imatinib 220127-57-1P, Imatinib mesylate 744256-04-0P 744256-05-1P 744256-06-2P				
	RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of imatinib and salts by reaction of methylaminophenylpyridylpyrimidinamine with methylpiperazinylmethylbenzoyl halides)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA


10/519,722

INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 744256-04-0 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrobromide (9CI) (CA INDEX NAME)



● x HBr


RN 744256-05-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 744256-06-2 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, trihydrochloride, monohydrate (9CI) (CA INDEX NAME)



●3 HCl

● H<sub>2</sub>O


RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:650874 CAPLUS  
 DN 141:167761  
 TI Sensitizing cells for apoptosis by selectively blocking cytokines  
 IN Stassi, Giorgio; Todaro, Matilde  
 PA Italy  
 SO Eur. Pat. Appl., 30 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English


FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1444989	A1	20040811	EP 2003-2603	20030207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004210432	A1	20040819	AU 2004-210432	20040209
CA 2515302	AA	20040819	CA 2004-2515302	20040209
WO 2004069274	A2	20040819	WO 2004-EP1177	20040209
WO 2004069274	A3	20041111		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 EP 1592449 A2 20051109 EP 2004-709222 20040209  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2006519190 T2 20060824 JP 2006-501781 20040209  
 PRAI EP 2003-2603 A 20030207  
 WO 2004-EP1177 W 20040209  
 IT 220127-57-1, STI571  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (CPG57148B; sensitizing cells for apoptosis by blocking cytokines)  
 RN 220127-57-1 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2  
 CRN 75-75-2  
 CMF C H4 O3 S



L5 ANSWER 59 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:565086 CAPLUS  
 DN 141:123632  
 TI Preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis  
 IN Cai, Sui Xiong; Zhang, Han-zhong; Kuemmerle, Jared D.; Zhang, Hong; Kemnitzer, William E.  
 PA Cytovia, Inc., USA  
 SO PCT Int. Appl., 97 pp.



10/519,722


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058253	A1	20040715	WO 2003-US40308	20031218
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004127521	A1	20040701	US 2003-737865	20031218
	CA 2509224	AA	20040715	CA 2003-2509224	20031218
	AU 2003303373	A1	20040722	AU 2003-303373	20031218
	EP 1581213	A1	20051005	EP 2003-808469	20031218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1756547	A	20060405	CN 2003-80106440	20031218
	JP 2006516250	T2	20060629	JP 2004-563731	20031218
PRAI	US 2002-433953P	P	20021218		
	WO 2003-US40308	W	20031218		
OS	MARPAT 141:123632				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 60 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:559502 CAPLUS

DN 141:190802

TI Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors

IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-yu; James, Ray A.; Bishop, W. Robert; Wang, James J.-S.; Desai, Jagdish A.

PA Schering Corporation, USA

SO U.S. Pat. Appl. Publ., 731 pp., Cont.-in-part of U.S. Ser. No. 85,896.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004122018	A1	20040624	US 2002-325896	20021219
	US 2002198216	A1	20021226	US 2001-940811	20010828
	US 2003229099	A1	20031211	US 2002-85896	20020227
	US 2004122018	A1	20040624	US 2002-325896	20021219
PRAI	US 2001-940811	A2	20010828		
	US 2002-85896	A2	20020227		
	US 2002-325896	A	20021219		
	US 2000-229183P	P	20000830		

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy; preparation of tricyclic antitumor agents as farnesyl protein transferase inhibitors for treatment of cancer and other proliferative diseases)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 152459-95-5

CMF C29 H31 N7 O



CM 2


CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 61 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:513393 CAPLUS  
DN 141:71544  
TI Preparation of substituted benzazoles as Raf kinase inhibitors  
IN Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.;  
Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard  
PA USA  
SO U.S. Pat. Appl. Publ., 476 pp., Cont.-in-part of U.S. Pat. Appl. 2004  
87,626.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004122237	A1	20040624	US 2003-675927	20030929
	US 2004087626	A1	20040506	US 2003-405945	20030331
	US 7071216	B2	20060704		
	AU 2004277405	A1	20050414	AU 2004-277405	20040929
	CA 2539748	AA	20050414	CA 2004-2539748	20040929
	WO 2005032548	A1	20050414	WO 2004-US32161	20040929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1675584	A1	20060705	EP 2004-789345	20040929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006193533	A2	20060727	JP 2006-96143	20060330
PRAI	US 2002-369066P	P	20020329		
	US 2003-405945	A2	20030331		
	JP 2003-579810	A3	20030331		
	US 2003-675927	A	20030929		
	WO 2004-US32161	W	20040929		
OS	MARPAT 141:71544				
IT	152459-95-5, Imatinib				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(preparation of substituted benzazoles as Raf kinase inhibitors for use in combination with other antitumor agents)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-				

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 62 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:467883 CAPLUS

DN 141:38627

TI Preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

IN Nuss, John M.; Pecchi, Sabina; Renhowe, Paul A.

PA Chiron Corporation, USA

SO PCT Int. Appl., 151 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004048365	A1	20040610	WO 2003-US37294	20031121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507100	AA	20040610	CA 2003-2507100	20031121
AU 2003295776	A1	20040618	AU 2003-295776	20031121
US 2004176385	A1	20040909	US 2003-719896	20031121
EP 1575940	A1	20050921	EP 2003-786980	20031121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016485	A	20051011	BR 2003-16485	20031121
CN 1735607	A	20060215	CN 2003-80108239	20031121
JP 2006514118	T2	20060427	JP 2005-510381	20031121
NO 2005002927	A	20050708	NO 2005-2927	20050615
PRAI US 2002-428473P	P	20021121		
US 2003-438568P	P	20030107		
US 2003-523081P	P	20031119		
WO 2003-US37294	W	20031121		
OS MARPAT 141:38627				
IT 152459-95-5, Imatinib 220127-57-1, Gleevec				
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(combination therapy; preparation of 2,4,6-trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors for treating neoplasm)				
RN 152459-95-5 CAPLUS				
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				

10/519,722




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 63 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:452964 CAPLUS

DN 141:1206

TI Combination administration of an indolinone with a chemotherapeutic agent  
for cell proliferation disorders

IN Abrams, Tinya; Murray, Lesley; Pryer, Nancy; Cherrington, Julie M.

PA Sugen, Inc., USA

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004045523	A2	20040603	WO 2003-US36526	20031114
	WO 2004045523	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,  
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 NL 1024779 A1 20040518 NL 2003-1024779 20031114  
 NL 1024779 C2 20041109  
 CA 2506308 AA 20040603 CA 2003-2506308 20031114  
 AU 2003290943 A1 20040615 AU 2003-290943 20031114  
 US 2004152759 A1 20040805 US 2003-712296 20031114  
 EP 1562600 A2 20050817 EP 2003-783527 20031114  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003015630 A 20050823 BR 2003-15630 20031114  
 CN 1711089 A 20051221 CN 2003-80103225 20031114  
 JP 2006508981 T2 20060316 JP 2004-553729 20031114  
 NO 2005002578 A 20050527 NO 2005-2578 20050527  
 PRAI US 2002-426386P P 20021115  
 WO 2003-US36526 W 20031114  
 OS MARPAT 141:1206  
 IT 152459-95-5, Imatinib  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);  
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as chemotherapeutic agent; cancer therapy using combination  
 administration of indolinone compds. with chemotherapeutic agents for  
 cell proliferation disorders)  
 RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 64 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:419904 CAPLUS  
 DN 142:70669  
 TI Characterization of a Conserved Structural Determinant Controlling Protein  
 Kinase Sensitivity to Selective Inhibitors  
 AU Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi,  
 Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik  
 CS Axxima Pharmaceuticals AG, Munchen, 81377, Germany  
 SO Chemistry & Biology (2004), 11(5), 691-701  
 CODEN: CBOLE2; ISSN: 1074-5521  
 PB Cell Press  
 DT Journal  
 LA English  
 IT 220127-57-1, STI571  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (characterization of a conserved structural determinant controlling  
 protein kinase inhibitor sensitivity)

10/519,722


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 65 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:331787 CAPLUS

DN 140:350538

TI Treatment of tuberous sclerosis associated neoplasms with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase inhibitors, especially N-phenyl-2-pyrimidineamines

IN Arbiser, Jack

PA USA

SO U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004077661	A1	20040422	US 2003-655407	20030904
	CA 2439440	AA	20040305	CA 2003-2439440	20030903
PRAI	US 2002-408550P	P	20020905		
OS	MARPAT 140:350538				
IT	152459-95-5 152459-95-5D, acceptable salts				
	220127-57-1				

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(tuberous sclerosis-associated neoplasms treatment with platelet-derived growth factor receptor tyrosine kinase or bcr-abl tyrosine kinase)

10/519,722

inhibitors, especially N-Ph-2-pyrimidineamines)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S





10/519,722

L5 ANSWER 66 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:269996 CAPLUS

DN 140:303691

TI Preparation and pharmaceutical compositions of novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Alvarez, Carmen S.; Chan, Tin-Yau; Knutson, Chad; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon

PA Schering Corporation, USA; Pharmacoepia, Inc.

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026229	A2	20040401	WO 2003-US27491	20030903
	WO 2004026229	A3	20040617		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2497544	AA	20040401	CA 2003-2497544	20030903
	AU 2003298571	A1	20040408	AU 2003-298571	20030903
	EP 1534712	A2	20050601	EP 2003-796321	20030903
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1701073	A	20051123	CN 2003-824701	20030903
	JP 2006502184	T2	20060119	JP 2004-537708	20030903
	NZ 539161	A	20060526	NZ 2003-539161	20030903
	ZA 2005001846	A	20050912	ZA 2005-1846	20050303
PRAI	US 2002-408029P	P	20020904		
	WO 2003-US27491	W	20030903		

OS MARPAT 140:303691

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared pyrazolopyrimidines)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]aminophenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5

CMF C29 H31 N7 O


10/519,722



CM 2

CRN 75-75-2

CMF C H4 O3 S




L5 ANSWER 67 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:268055 CAPLUS  
DN 140:385622  
TI Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter  
and Reverses Resistance to Topotecan and SN-38 in Vitro  
AU Houghton, Peter J.; Germain, Glen S.; Harwood, Franklin C.; Schuetz, John  
D.; Stewart, Clinton F.; Buchdunger, Elisabeth; Traxler, Peter  
CS Tennessee, Memphis, St. Jude Children's Research Hospital, Departments of  
Molecular Pharmacology, Memphis, TN, 38105-2794, USA  
SO Cancer Research (2004), 64(7), 2333-2337  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
IT 220127-57-1; Imatinib Mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(imatinib mesylate is a potent inhibitor of ABCG2 (BCRP) transporter  
and reverses resistance to topotecan and SN-38 in vitro)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 68 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:267339 CAPLUS

DN 140:303700

TI Preparation and pharmaceutical compositions of novel imidazopyrazines as cyclin dependent kinase inhibitors

IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan K.

PA Schering Corporation, USA

SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026877	A1	20040401	WO 2003-US29209	20030919
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499756	AA	20040401	CA 2003-2499756	20030919
	AU 2003272476	A1	20040408	AU 2003-272476	20030919
	EP 1543008	A1	20050622	EP 2003-754658	20030919
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1694886	A	20051109	CN 2003-825177	20030919
	JP 2006507253	T2	20060302	JP 2004-537904	20030919
	ZA 2005002375	A	20050927	ZA 2005-2375	20050322
PRAI	US 2002-412997P	P	20020923		
	WO 2003-US29209	W	20030919		

OS MARPAT 140:303700

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)

RN 220127-57-1 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:267335 CAPLUS  
DN 140:287379  
TI Preparation and pharmaceutical compositions of novel pyrazolopyridines as cyclin dependent kinase inhibitors  
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.; Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.  
PA Schering Corporation, USA  
SO PCT Int. Appl., 68 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026872	A1	20040401	WO 2003-US29841	20030917
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2499593	AA	20040401	CA 2003-2499593	20030917
	AU 2003270846	A1	20040408	AU 2003-270846	20030917

10/519,722

US 2004097516 A1 20040520 US 2003-664337 20030917  
EP 1539750 A1 20050615 EP 2003-752559 20030917  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
CN 1681816 A 20051012 CN 2003-822011 20030917  
JP 2006503060 T2 20060126 JP 2004-538405 20030917  
NZ 538595 A 20060428 NZ 2003-538595 20030917  
ZA 2005002271 A 20050919 ZA 2005-2271 20050317  
PRAI US 2002-412138P P 20020919  
WO 2003-US29841 W 20030917  
OS MARPAT 140:287379  
IT 220127-57-1, Gleevec  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(claimed codrugs for treatment of conditions mediated by cyclin  
dependent kinases in the presence of prepared pyrazolopyridines)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 70 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:267330 CAPLUS  
DN 140:303698  
TI Preparation and pharmaceutical compositions of novel imidazopyridines as  
cyclin dependent kinase inhibitors  
IN Dwyer, Michael P.; Guzi, Timothy J.; Paruch, Kamil; Doll, Ronald J.;  
Keertikar, Kartik M.; Girijavallabhan, Viyyoor M.  
PA Schering Corporation, USA  
SO PCT Int. Appl., 78 pp.  
CODEN: PIXXD2

10/519,722

DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026867	A2	20040401	WO 2003-US29498	20030917
	WO 2004026867	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499639	AA	20040401	CA 2003-2499639	20030917
	AU 2003295332	A1	20040408	AU 2003-295332	20030917
	US 2004097517	A1	20040520	US 2003-664338	20030917
	US 6992080	B2	20060131		
	EP 1539756	A2	20050615	EP 2003-786514	20030917
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1703414	A	20051130	CN 2003-825047	20030917
	JP 2006507254	T2	20060302	JP 2004-538237	20030917
	US 2006030555	A1	20060209	US 2005-238597	20050929
PRAI	US 2002-412063P	P	20020919		
	US 2003-664338	A3	20030917		
	WO 2003-US29498	W	20030917		
OS	MARPAT 140:303698				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2


CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 71 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:267246 CAPLUS  
 DN 140:303696  
 TI Preparation and pharmaceutical compositions of novel imidazopyrazines as  
 cyclin dependent kinase inhibitors  
 IN Paruch, Kamil; Guzi, Timothy J.; Dwyer, Michael P.; Doll, Ronald J.;  
 Girijavallabhan, Viyyoor M.  
 PA Schering Corporation, USA  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004026310	A1	20040401	WO 2003-US29456	20030919
	WO 2004026310	C1	20050630		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2499874	AA	20040401	CA 2003-2499874	20030919
	AU 2003275031	A1	20040408	AU 2003-275031	20030919
	US 2004072835	A1	20040415	US 2003-666424	20030919
	EP 1542693	A1	20050622	EP 2003-759300	20030919
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	CN 1694706	A	20051109	CN 2003-825102	20030919
	JP 2006503838	T2	20060202	JP 2004-538213	20030919
	ZA 2005002380	A	20050927	ZA 2005-2380	20050322
PRAI	US 2002-412906P	P	20020923		
	WO 2003-US29456	W	20030919		
OS	MARPAT 140:303696				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(claimed codrugs for treatment of conditions mediated by cyclin dependent kinases in the presence of prepared imidazopyrazines)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 72 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:252622 CAPLUS

DN 140:283386

TI Crystal structure of human PIM-1 kinase and complexes with AMP-PNP and use in drug screening and design

IN Bremer, Ryan; Ibrahim, Prabha; Kumar, Abhinav; Mandiyan, Valsan; Milburn, Michael V.

PA Plexxikon, Inc., USA

SO PCT Int. Appl., 217 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024895	A2	20040325	WO 2003-US29415	20030916
	WO 2004024895	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2503905	AA	20040325	CA 2003-2503905	20030916
	AU 2003272548	A1	20040430	AU 2003-272548	20030916
	US 2004142864	A1	20040722	US 2003-664421	20030916
	EP 1558751	A2	20050803	EP 2003-754735	20030916
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1701122	A	20051123	CN 2003-825157	20030916
PRAI	US 2002-411398P	P	20020916		




10/519,722

US 2002-412341P P 20020920  
WO 2003-US29415 W 20030916  
IT 220127-57-1, Imatinib mesylate  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(crystal structure of human PIM-1 kinase and complexes with AMP-PNP and  
use in drug screening and design)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)  
  
CM 1  
  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
  
CRN 75-75-2  
CMF C H4 O3 S




L5 ANSWER 73 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:252351 CAPLUS  
DN 140:264488  
TI Combination of a benzamide derivative and a histone deacetylase inhibitor  
for the treatment of leukemia  
IN Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong  
PA Virginia Commonwealth University, USA; Mcquire Va Medical Center 111k  
SO PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004024160	A1	20040325	WO 2003-IB4053	20030910
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW			

10/519,722

RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR


CA 2498210	AA	20040325	CA 2003-2498210	20030910
AU 2003259521	A1	20040430	AU 2003-259521	20030910
BR 2003014112	A	20050712	BR 2003-14112	20030910
EP 1553948	A1	20050720	EP 2003-795175	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681505	A	20051012	CN 2003-821763	20030910
JP 2006501267	T2	20060112	JP 2004-535791	20030910
US 2006100140	A1	20060511	US 2005-527553	20050909
PRAI US 2002-410286P	P	20020913		
US 2002-411344P	P	20020918		
WO 2003-IB4053	W	20030910		
IT 152459-95-5 220127-57-1, Glivec				
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)				
RN 152459-95-5 CAPLUS				
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3- pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 74 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:220336 CAPLUS

DN 140:270873

TI Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.;  
Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.;  
Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent;  
Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min;  
James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs,  
Douglas Walsh

PA Schering Corporation, USA; Pharmacoepia, Inc.

SO PCT Int. Appl., 609 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022561	A1	20040318	WO 2003-US27555	20030903
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2497440	AA	20040318	CA 2003-2497440	20030903
	AU 2003263071	A1	20040329	AU 2003-263071	20030903
	EP 1537116	A1	20050608	EP 2003-794592	20030903
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003014001	A	20050705	BR 2003-14001	20030903
	JP 2006502163	T2	20060119	JP 2004-534487	20030903
	CN 1735614	A	20060215	CN 2003-824997	20030903
	NO 2005001647	A	20050603	NO 2005-1647	20050404
PRAI	US 2002-408027P	P	20020904		
	US 2002-421959P	P	20021029		
	WO 2003-US27555	W	20030903		

OS MARPAT 140:270873

IT 220127-57-1, Gleevec

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent  
kinase inhibitors for treating cancer in combination of other  
anticancer agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

10/519,722


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 75 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:220335 CAPLUS  
DN 140:270872  
TI Preparation of pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors and anticancer agents  
IN Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon  
PA Schering Corporation, USA; Pharmacoopia, Inc.; Pharmacoopia Drug Discovery, Inc.  
SO PCT Int. Appl., 82 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004022560	A1	20040318	WO 2003-US27502	20030903
	WO 2004022560	C2	20050707		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2497450	AA	20040318	CA 2003-2497450	20030903

AU 2003268385 A1 20040329 AU 2003-268385 20030903  
 US 2004116442 A1 20040617 US 2003-653868 20030903  
 US 7074924 B2 20060711  
 EP 1534710 A1 20050601 EP 2003-749347 20030903  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 CN 1701074 A 20051123 CN 2003-824779 20030903  
 JP 2006502161 T2 20060119 JP 2004-534459 20030903  
 NZ 539164 A 20060428 NZ 2003-539164 20030903  
 ZA 2005001852 A 20050908 ZA 2005-1852 20050303  
 US 2006173016 A1 20060803 US 2006-395824 20060331  
 PRAI US 2002-407999P P 20020904  
 US 2003-653868 A3 20030903  
 WO 2003-US27502 W 20030903  
 OS MARPAT 140:270872  
 IT 220127-57-1, Gleevec  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (anticancer agent, combination therapy; preparation of pyrazolo[1,5-  
 a]pyrimidines as cyclin dependent kinase inhibitors and anticancer  
 agents)  
 RN 220127-57-1 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
 INDEX NAME)  
 CM 1  
 CRN 152459-95-5  
 CMF C29 H31 N7 O



CM 2  
 CRN 75-75-2  
 CMF C H4 O3 S



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:218528 CAPLUS  
 DN 140:247038  
 TI Use of specific inhibitors of tyrosine kinases for immunomodulation  
 IN Zitvogel, Laurence; Auclair, Christian; Tursz, Thomas

10/519,722

PA Institut Gustave Roussy Igr, Fr.  
SO Fr. Demande, 50 pp.  
CODEN: FRXXBL

DT Patent  
LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI-	FR 2844452	A1	20040319	FR 2002-11545	20020918
	WO 2004026311	A2	20040401	WO 2003-FR2744	20030917
	WO 2004026311	A3	20040812		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2003276351	A1	20040408	AU 2003-276351	20030917
PRAI	FR 2002-11545	A	20020918		
	WO 2003-FR2744	W	20030917		

IT 220127-57-1, Gleevec

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of specific inhibitors of tyrosine kinases for immunomodulation)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




10/519,722

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 77 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:100803 CAPLUS  
DN 140:139483  
TI Method for enhancing the effectiveness of therapies of hyperproliferative diseases  
IN Chang, Yan; Sasak, Vodek  
PA USA  
SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004023925	A1	20040205	US 2003-408723	20030407
	US 2003013681	A1	20030116	US 2002-176235	20020620
	US 6680306	B2	20040120		
	CN 1543351	A	20041103	CN 2002-816003	20020621
	US 2004043962	A1	20040304	US 2003-657383	20030908
	AU 2004229399	A1	20041028	AU 2004-229399	20040407
	CA 2521649	AA	20041028	CA 2004-2521649	20040407
	WO 2004091634	A1	20041028	WO 2004-US10675	20040407
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1617849	A1	20060125	EP 2004-759200	20040407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	JP 2006522163	T2	20060928	JP 2006-509773	20040407
PRAI	US 2001-299991P	P	20010621		
	US 2002-176235	A2	20020620		
	US 2003-408723	A	20030407		
	US 2003-461006P	P	20030407		
	US 2003-474562P	P	20030530		
	WO 2004-US10675	W	20040407		
IT	152459-95-5, Imatinib				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(method for enhancing effectiveness of therapies of hyperproliferative diseases)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 78 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:20664 CAPLUS

DN 140:77165

TI Preparation of 4-[(4-methylpiperazin-1-yl)methyl]benzamide for treatment of leukemia

IN Asaki, Tetsuo; Hamamoto, Taisuke; Sugiyama, Yukiteru

PA Nippon Shinyaku Co., Ltd., Japan

SO PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004002963	A1	20040108	WO 2003-JP8192	20030627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2490907	AA	20040108	CA 2003-2490907	20030627
	AU 2003246100	A1	20040119	AU 2003-246100	20030627
	BR 2003012288	A	20050412	BR 2003-12288	20030627
	EP 1533304	A1	20050525	EP 2003-738555	20030627
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1678590	A	20051005	CN 2003-820146	20030627
	US 2006014742	A1	20060119	US 2004-519722	20041228
PRAI	JP 2002-189269	A	20020628		
	JP 2002-305146	A	20021018		
	JP 2002-377937	A	20021226		
	WO 2003-JP8192	W	20030627		

OS MARPAT 140:77165

IT 641614-84-8P 641614-88-2P 641614-92-8P  
641614-95-1P 641615-19-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)

RN 641614-84-8 CAPLUS


CN Benzamide, 3-iodo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)






RN 641614-88-2 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-92-8 CAPLUS

CN Benzamide, N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-95-1 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 641615-19-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]amino]carbonyl]-2-(trifluoromethyl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 641614-83-7P 641614-85-9P 641614-86-0P  
 641614-87-1P 641614-89-3P 641614-90-6P  
 641614-91-7P 641614-93-9P 641614-94-0P  
 641614-96-2P 641614-97-3P 641614-98-4P  
 641614-99-5P 641615-00-1P 641615-01-2P  
 641615-02-3P 641615-03-4P 641615-04-5P  
 641615-05-6P 641615-06-7P 641615-07-8P  
 641615-08-9P 641615-09-0P 641615-10-3P  
 641615-11-4P 641615-12-5P 641615-13-6P  
 641615-14-7P 641615-15-8P 641615-16-9P  
 641615-17-0P 641615-18-1P 641615-20-5P  
 641615-21-6P 641615-22-7P 641615-23-8P  
 641615-24-9P 641615-25-0P 641615-26-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(piperazinyl)methyl]benzamides for treatment of leukemia)


RN 641614-83-7 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-85-9 CAPLUS

CN Benzamide, 3-chloro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-86-0 CAPLUS

CN Benzamide, 3-fluoro-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-87-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641614-89-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-90-6 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(6-chloro-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-91-7 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-93-9 CAPLUS

CN Benzamide, 3-bromo-N-[3-[[4-(1,2-dihydro-4-pyridazinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-94-0 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridazinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-96-2 CAPLUS

CN Benzamide, N-[3-([3,4'-bipyridin]-2'-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-97-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(5-pyrimidinyl)-2-pyridinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641614-98-4 CAPLUS

CN Benzamide, N-[3-([2,3'-bipyridin]-6-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641614-99-5 CAPLUS

CN Benzamide, N-[3-([3,3'-bipyridin]-5-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-00-1 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(3-pyridinyl)phenyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-01-2 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[6-(3-pyridinyl)pyrazinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-02-3 CAPLUS

CN Benzamide, 3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[5-(3-pyridinyl)-1,2,4-triazin-3-yl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-03-4 CAPLUS

CN Benzamide, 3-methyl-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-04-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 641615-05-6 CAPLUS

CN Benzamide, 3-methoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-06-7 CAPLUS

CN Benzamide, 3,5-dibromo-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-07-8 CAPLUS

CN Benzamide, 3,5-dimethoxy-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-08-9 CAPLUS

CN 1,3-Benzenedicarboxamide, N3,N3-dimethyl-4-[(4-methyl-1-piperazinyl)methyl]-N1-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-09-0 CAPLUS

CN Benzamide, 3-bromo-4-[(4-ethyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-10-3 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-[(4-propyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 641615-11-4 CAPLUS

CN Benzamide, 3-bromo-4-[(dimethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-12-5 CAPLUS


CN Benzamide, 3-bromo-4-[(diethylamino)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-13-6 CAPLUS


CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)






RN 641615-14-7 CAPLUS

CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-15-8 CAPLUS


CN Benzamide, 3-bromo-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(4-morpholinylmethyl)- (9CI) (CA INDEX NAME)



RN 641615-16-9 CAPLUS


CN Benzamide, 3-bromo-4-[[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 641615-17-0 CAPLUS

CN Benzamide, 3-bromo-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 641615-18-1 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-(1-piperazinylmethyl)- (9CI) (CA INDEX NAME)




RN 641615-20-5 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-(1-piperazinylmethyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 641615-21-6 CAPLUS

CN Benzoic acid, 2-[(4-methyl-1-piperazinyl)methyl]-5-[[[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]amino]carbonyl]-, methyl ester (9CI)  
(CA INDEX NAME)




RN 641615-22-7 CAPLUS

CN Benzamide, 3-cyano-4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 641615-23-8 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-3-bromo-4-[(4-methyl-1-piperazinyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 641615-24-9 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)


10/519,722



● HCl

RN 641615-25-0 CAPLUS

CN Benzamide, N-[3-[[4-(5-bromo-3-pyridinyl)-2-pyrimidinyl]amino]-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 641615-26-1 CAPLUS

CN Benzamide, N-[3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl]-4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 641614-88-2


CMF C29 H29 F3 N8 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:971730 CAPLUS  
DN 140:27844  
TI Preparation of tricyclic antitumor compounds as farnesyl protein  
transferase inhibitors  
IN Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane,  
Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor  
M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar,  
Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu;  
James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.  
PA USA  
SO U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S. Pat. Appl. 2002  
198,216.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003229099	A1	20031211	US 2002-85896	20020227
	US 2002198216	A1	20021226	US 2001-940811	20010828
	US 2004122018	A1	20040624	US 2002-325896	20021219
	CA 2477328	AA	20030904	CA 2003-2477328	20030225
	WO 2003072549	A1	20030904	WO 2003-US5479	20030225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU,				
	ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD,				
	MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK,				
	SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003215389	A1	20030909	AU 2003-215389	20030225
	BR 2003008071	A	20041221	BR 2003-8071	20030225
	EP 1492772	A1	20050105	EP 2003-711214	20030225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1630641	A	20050622	CN 2003-804720	20030225
	JP 2005525356	T2	20050825	JP 2003-571255	20030225
	ZA 2004006807	A	20050829	ZA 2004-6807	20040826
	NO 2004004053	A	20041126	NO 2004-4053	20040924
PRAI	US 2000-229183P	P	20000830		
	US 2001-940811	A2	20010828		
	US 2002-85896	A2	20020227		
	US 2002-325896	A	20021219		
	WO 2003-US5479	W	20030225		
OS	MARPAT 140:27844				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)				

10/519,722

(co-administration; preparation of tricyclic compds. as farnesyl protein transferase inhibitors for treating cancer in combination with other agents)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 80 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:917665 CAPLUS

DN 140:156958

TI Arsenic Trioxide Inhibits Translation of mRNA of bcr-abl, Resulting in Attenuation of Bcr-Abl Levels and Apoptosis of Human Leukemia Cells

AU Nimmanapalli, Ramadevi; Bali, Purva; O'Bryan, Erica; Fuino, Lianne; Guo, Fei; Wu, Jie; Houghton, Peter; Bhalla, Kapil

CS Interdisciplinary Oncology Program, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, FL, USA

SO Cancer Research (2003), 63(22), 7950-7958

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

IT 220127-57-1, Imatinib mesylate

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells)

RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:912990 CAPLUS  
DN 139:375014  
TI Methods and compositions with N-phenyl-2-pyrimidine compounds  
inhibiting platelet derived growth factor receptor for the treatment of  
graft failure  
IN Sukhatme, Vikas P.  
PA Beth Israel Deaconess Medical Center, USA  
SO PCT Int. Appl., 106 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003094904	A1	20031120	WO 2003-US314916	20030513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003232115	A1	20031111	AU 2003-232115	20030513
CA 2490989	AA	20031120	CA 2003-2490989	20030513
EP 1509219	A1	20050302	EP 2003-750120	20030513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

10/519,722


	JP 2005533019	T2	20051104	JP 2004-502990	20030513
	US 2005261283	A1	20051124	US 2005-514322	20050719
PRAI	US 2002-380180P	P	20020513		
	US 2003-464023P	P	20030418		
	WO 2003-US14916	W	20030513		
OS	MARPAT 139:375014				
IT	152459-95-5 220127-57-1, Imatinib mesylate				
	RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);				
	THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(N-Ph-2-pyrimidine compds. inhibiting platelet derived growth				
	factor receptor for treatment of graft failure)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 82 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN



10/519,722

AN 2003:892800 CAPLUS

DN 139:395950

TI Preparation of substituted pyrazines as protein kinase modulators

IN Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tesfai, Zerom; Wang, Longcheng; Co, Erick Wang; Epshteyn, Sergey; Kennedy, Abigail R.; Chen, Baili; Dubenko, Larisa; Anand, Neel Kumar; Tsang, Tsze H.; Nuss, John M.; Peto, Csaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy

PA Exelixis, Inc., USA

SO PCT Int. Appl., 468 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093297	A2	20031113	WO 2003-US13869	20030502
	WO 2003093297	A3	20040701		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2484209	AA	20031113	CA 2003-2484209	20030502
	AU 2003234464	A1	20031117	AU 2003-234464	20030502
	EP 1501514	A2	20050202	EP 2003-728690	20030502
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005530760	T2	20051013	JP 2004-501436	20030502
	US 2006211709	A1	20060921	US 2005-513081	20050727
PRAI	US 2002-377933P	P	20020503		
	WO 2003-US13869	W	20030502		

OS MARPAT 139:395950


IT 152459-95-5, Imatinib

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of substituted pyrazines as protein kinase modulators for use in combination with other cancer therapeutic agents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 83 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:833884 CAPLUS

DN 139:317425

10/519,722

TI Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis

IN Debatin, Klaus Michael; Fulda, Simone

PA Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany

SO Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1354952	A1	20031022	EP 2002-8199	20020417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1354953	A1	20031022	EP 2002-15499	20020712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	WO 2003086470	A2	20031023	WO 2003-EP4039	20030417
	WO 2003086470	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003236211	A1	20031027	AU 2003-236211	20030417
	EP 1495124	A2	20050112	EP 2003-722503	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005536457	T2	20051202	JP 2003-583486	20030417
	US 2005222387	A1	20051006	US 2005-511037	20050119
PRAI	EP 2002-8199	A	20020417		
	EP 2002-15499	A	20020712		
	WO 2003-EP4039	W	20030417		
IT	220127-57-1, STI571				
	RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)				
	(therapeutic combination with SMAC peptide; Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 84 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:809105 CAPLUS  
DN 140:122306  
TI Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine  
-Type Small Molecule Kinase Inhibitors  
AU von Bubnoff, Nikolas; Veach, Darren R.; Miller, W. Todd; Li, Wanqing;  
Saenger, Jana; Peschel, Christian; Bornmann, William G.; Clarkson, Bayard;  
Duyster, Justus  
CS Department of Internal Medicine III, Technical University of Munich,  
Munich, Germany  
SO Cancer Research (2003), 63(19), 6395-6404  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
IT 220127-57-1, Glivec  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(inhibition of wild-type and mutant Bcr-Abl by pyrido-  
pyrimidine-type small mol. kinase inhibitors in relation to  
leukemia treatment)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 85 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:796477 CAPLUS

DN 139:307759

TI Preparation of substituted benzazoles as Raf kinase inhibitors

IN Renhowe, Paul A.; Ramurthy, Savithri; Amiri, Payman; Levine, Barry  
Haskell; Poon, Daniel J.; Subramanian, Sharadha; Sung, Leonard; Fantl,  
Wendy

PA Chiron Corporation, USA

SO PCT Int. Appl., 259 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082272	A1	20031009	WO 2003-US10117	20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2480638	AA	20031009	CA 2003-2480638	20030331
AU 2003226211	A1	20031013	AU 2003-226211	20030331
EP 1499311	A1	20050126	EP 2003-745683	20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008854	A	20050222	BR 2003-8854	20030331
CN 1655779	A	20050817	CN 2003-812193	20030331
JP 2005529089	T2	20050929	JP 2003-579810	20030331
NO 2004004617	A	20041228	NO 2004-4617	20041026

10/519,722

JP 2006193533 A2 20060727 JP 2006-96143 20060330  
PRAI US 2002-369066P P 20020329  
JP 2003-579810 A3 20030331  
WO 2003-US10117 W 20030331  
OS MARPAT 139:307759  
IT 152459-95-5, Imatinib  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of substituted benzazoles as Raf kinase inhibitors for use in  
combination with other antitumor agents)  
RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 86 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:696780 CAPLUS  
DN 139:219397  
TI N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-  
pyridyl)-2-pyrimidine-amine coated stents  
IN Prescott, Margaret Forney; Feldman, David Louis  
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
SO PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072159	A1	20030904	WO 2003-EP2028	20030227
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW	
	RW:			AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR	
	CA 2477558	AA	20030904	CA 2003-2477558	20030227
	AU 2003214079	A1	20030909	AU 2003-214079	20030227
	EP 1480688	A1	20041201	EP 2003-709729	20030227
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
	BR 2003008053	A	20041228	BR 2003-8053	20030227
	JP 2005519080	T2	20050630	JP 2003-570902	20030227
	CN 1638823	A	20050713	CN 2003-804788	20030227
	NO 2004004093	A	20041124	NO 2004-4093	20040927
	US 2005209244	A1	20050922	US 2005-505398	20050429
PRAI	US 2002-360254P	P	20020228		
	WO 2003-EP2028	W	20030227		
IT	152459-95-5				

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(piperazino-methylbenzoylamido pyridylpyrimidineamine coated stents)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 87 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:696536 CAPLUS

DN 139:207765

TI Combinations comprising N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine and at least one telomerase inhibitor for treating proliferative diseases

IN Tauchi, Tetsuzo

PA Novartis AG, Switz.

SO U.S. Pat. Appl. Publ., 8 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003166660	A1	20030904	US 2002-272837	20021017
	US 7045523	B2	20060516		
	US 2006111365	A1	20060525	US 2006-332406	20060113
PRAI	GB 2001-25105	A	20011018		
	GB 2002-15583	A	20020704		
	US 2002-272837	A3	20021017		
IT	152459-95-5, Imatinib 152459-95-5D, Imatinib, salts				
	220127-57-1				


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);

THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations comprising imatinib and at least one telomerase inhibitor for treating proliferative diseases)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-

10/519,722

pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 88 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:639686 CAPLUS

DN 140:139030

TI Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection

AU Savikko, Johanna; von Willebrand, Eva; Haeyry, Pekka

CS Transplantation Laboratory, Haartman Institute, Helsinki Univ. Central Hospital, Helsinki, Finland

SO Transplantation (2003), 76(3), 455-458

CODEN: TRPLAU; ISSN: 0041-1337

PB Lippincott Williams & Wilkins

DT Journal

LA English


10/519,722

IT 152459-95-5, Imatinib

RL: PAC (Pharmacological activity); BIOL (Biological study)  
(leflunomide analog FK778 is vasculoprotective independent of its immunosuppressive effect in relation to imatinib)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 89 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:633685 CAPLUS

DN 139:180080

TI Preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivatives

IN Loiseleur, Olivier; Kaufmann, Daniel; Abel, Stephan; Buerger, Hans Michael; Meisenbach, Mark; Schmitz, Beat; Sedelmeier, Gottfried

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066613	A1	20030814	WO 2003-EP1188	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2474738	AA	20030814	CA 2003-2474738	20030206
	AU 2003244444	A1	20030902	AU 2003-244444	20030206
	EP 1474408	A1	20041110	EP 2003-737319	20030206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007529	A	20041221	BR 2003-7529	20030206
	CN 1630648	A	20050622	CN 2003-803556	20030206
	JP 2005528340	T2	20050922	JP 2003-565987	20030206
	NO 2004003685	A	20041105	NO 2004-3685	20040903
	US 2006142580	A1	20060629	US 2005-503538	20050120
PRAI	GB 2002-2873	A	20020207		
	WO 2003-EP1188	W	20030206		

OS MARPAT 139:180080

IT 152459-95-5P


RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of N-(pyridin-3-ylpyrimidin-2-ylaminophenyl)benzamide derivs.)



10/519,722

RN 152459-95-5 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 90 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:610246 CAPLUS

DN 139:154937

TI Treatment of rheumatoid arthritis

IN Joensuu, Heikki

PA Hyks-Instituutti Oy, Finland

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063844	A2	20030807	WO 2003-EP802	20030127
	WO 2003063844	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
	CA 2473158	AA	20030807	CA 2003-2473158	20030127
	EP 1471916	A2	20041103	EP 2003-704474	20030127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007286	A	20041228	BR 2003-7286	20030127
	CN 1646130	A	20050727	CN 2003-802880	20030127
	JP 2005526022	T2	20050902	JP 2003-563538	20030127
	ZA 2004005323	A	20050620	ZA 2004-5323	20040705
	NO 2004003585	A	20041021	NO 2004-3585	20040827
PRAI	GB 2002-1882	A	20020128		
	WO 2003-EP802	W	20030127		

IT 152459-95-5 220127-57-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL


(Biological study); USES (Uses)

(treatment of rheumatoid arthritis with piperazinylmethylpyridinylpyrimidinylaminophenylbenzamide)

RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)

10/519,722




RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 91 OF 106. CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:355612 CAPLUS

DN 138:362649

TI Treatment of cancer with anti-ErbB2 antibodies

IN Sliwkowski, Mark X.

PA Genentech, Inc., USA

SO U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 602,812.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003086924	A1	20030508	US 2002-268501	20021010
	US 6949245	B1	20050927	US 2000-602812	20000623
	US 2004013667	A1	20040122	US 2003-608626	20030627
	US 2005208043	A1	20050922	US 2005-44749	20050127
	US 2005238640	A1	20051027	US 2005-154465	20050616

10/519,722

US 2006034842 A1 20060216 US 2005-223361 20050909  
US 2006073143 A1 20060406 US 2005-222587 20050909  
AU 2005242195 A1 20060112 AU 2005-242195 20051207  
US 2006193854 A1 20060831 US 2006-429361 20060505  
US 2006198843 A1 20060907 US 2006-429043 20060505  
US 2006216285 A1 20060928 US 2006-429363 20060505  
PRAI US 1999-141316P P 19990625  
US 2000-602812 A2 20000623  
AU 2000-57632 A3 20000623  
US 2002-268501 A2 20021010  
US 2005-44749 A1 20050127  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(as tyrosine kinase inhibitor in combination with anti-ErbB2  
antibodies; cancer treatment with anti-ErbB2 antibodies)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 92 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2003:334888 CAPLUS  
DN 138:358163  
TI Use of tyrosine kinase inhibitors for promoting hair growth  
IN Moussy, Alain; Kinet, Jean-Pierre  
PA AB Science, Fr.  
SO PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003035050	A2	20030501	WO 2002-IB4290	20020920
	WO 2003035050	A3	20040527		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2461182	AA	20030501	CA 2002-2461182	20020920
	EP 1461032	A2	20040929	EP 2002-801980	20020920
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK		
	JP 2005507917	T2	20050324	JP 2003-537617	20020920
	US 2004242612	A1	20041202	US 2004-490334	20040322
PRAI	US 2001-323314P	P	20010920		
	WO 2002-IB4290	W	20020920		
OS	MARPAT 138:358163				
IT	152459-95-5				
	RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of tyrosine kinase inhibitors for promoting hair growth)				
RN	152459-95-5 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



L5 ANSWER 93 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:273844 CAPLUS  
 DN 139:345426  
 TI A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants  
 AU Huron, David R.; Gorre, Mercedes E.; Kraker, Alan J.; Sawyers, Charles L.; Rosen, Neal; Moasser, Mark M.  
 CS Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA  
 SO Clinical Cancer Research (2003), 9(4), 1267-1273  
 CODEN: CCRE44; ISSN: 1078-0432  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 IT 220127-57-1, STI571  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel pyridopyrimidine inhibitor (PD166326) of Bcr-abl tyrosine kinase

10/519,722

is effective against STI571-resistant Bcr-abl mutants in chronic myelogenous leukemia)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:242116 CAPLUS

DN 138:265640

TI Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis

IN Moussy, Alain; Kinet, Jean-Pierre

PA AB Science, Fr.

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024386	A2	20030327	WO 2002-IB4236	20020920
	WO 2003024386	A3	20040205		
	WO 2003024386	C1	20040624		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2460845 AA 20030327 CA 2002-2460845 20020920  
 EP 1427379 A2 20040616 EP 2002-767812 20020920

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK


JP 2005511506 T2 20050428 JP 2003-528285 20020920  
 US 2004242601 A1 20041202 US 2004-490348 20040322

PRAI US 2001-323315P P 20010920  
 WO 2002-IB4236 W 20020920

OS MARPAT 138:265640  
 IT 152459-95-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis)

RN 152459-95-5 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 95 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2003:133053 CAPLUS  
 DN 138:163522  
 TI Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia  
 IN Donato, Nicholas J.; Fabbro, Dorian; Manley, Paul William; Mestan, Jürgen; Warmuth, Markus; Hallek, Michael; Talpaz, Moshe; Wu, Ji  
 PA Novartis AG, Switz.; Novartis Pharma GmbH; GSF-National Research Institute for Environment and Health; The University of Texas System  
 SO PCT Int. Appl., 25 pp.  
 CODEN: PIXXD2


DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003013540	A1	20030220	WO 2002-EP8941	20020809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	CA 2450777	AA	20030220	CA 2002-2450777	20020809
	EP 1418917	A1	20040519	EP 2002-794592	20020809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	CN 1523991	A	20040825	CN 2002-813696	20020809

10/519,722


	JP 2005502643	T2	20050127	JP 2003-518549	20020809
	US 2004248906	A1	20041209	US 2004-485803	20040729
	US 2006074094	A1	20060406	US 2005-285664	20051122
PRAI	US 2001-311690P	P	20010810		
	WO 2002-EP8941	W	20020809		
	US 2004-485803	A3	20040729		
IT	152459-95-5	220127-57-1			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(use of c-Src inhibitors alone or in combination with STI571 for leukemia treatment)				
RN	152459-95-5	CAPLUS			
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)				



RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 96 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

10/519,722

AN 2003:10878 CAPLUS  
DN 138:395641  
TI Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)  
AU La Rosee, Paul; Corbin, Amie S.; Stoffregen, Eric P.; Deininger, Michael W.; Druker, Brian J.  
CS Division of Hematology and Medical Oncology, Oregon Health and Sciences University Cancer Institute, Portland, OR, 97239, USA  
SO Cancer Research (2002), 62(24), 7149-7153  
CODEN: CNREA8; ISSN: 0008-5472  
PB American Association for Cancer Research  
DT Journal  
LA English  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(activity of Bcr-Abl kinase inhibitor PD180970 against Abl kinase domain mutations that cause resistance to imatinib mesylate)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)  
  
CM 1  
  
CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2  
  
CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 97 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:977959 CAPLUS  
DN 138:51923  
TI Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571  
IN Sawyers, Charles L.; Gorre, Mercedes E.; Shah, Neil Pravin; Nicoll, John



10/519,722

PA The Regents of the University of California, USA  
SO PCT Int. Appl., 129 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002102976	A2	20021227	WO 2002-US18729	20020614
	WO 2002102976	A3	20040805		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2450473	AA	20021227	CA 2002-2450473	20020614
	US 2003158105	A1	20030821	US 2002-171889	20020614
	EP 1466174	A2	20041013	EP 2002-744318	20020614
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004537992	T2	20041224	JP 2003-506431	20020614
PRAI	US 2001-298728P	P	20010614		
	US 2001-331709P	P	20011120		
	WO 2002-US18729	W	20020614		


IT 220127-57-1, STI-571  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571)

RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O




CM 2

CRN 75-75-2  
CMF C H4 O3 S



L5 ANSWER 98 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2002:946113 CAPLUS  
 DN 138:24647  
 TI Preparation of 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1H)-quinolinones and  
 analogs as activators of caspases and inducers of apoptosis for treatment  
 of cancer and other proliferative disorders  
 IN Cai, Sui Xiong; Zhang, Han-Zhong; Drewe, John; Kasibhatla, Shailaja  
 PA Cytovia, Inc., USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098425	A1	20021212	WO 2002-US17486	20020604
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1404329	A1	20040407	EP 2002-741817	20020604
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2005165053	A1	20050728	US 2003-477953	20031118
PRAI	US 2001-295007P	P	20010604		
	WO 2002-US17486	W	20020604		
OS	MARPAT 138:24647				
IT	220127-57-1, Gleevec				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration agent; coadministration of (arylpropenoyl)-2(1H)-quinolinone caspases activators with known cancer therapeutic agents for treatment of cancer)				
RN	220127-57-1 CAPLUS				
CN	Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)				
CM	1				
CRN	152459-95-5				
CMF	C29 H31 N7 O				



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 99 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:946109 CAPLUS

DN 138:24718

TI Preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and  
4-substituted-1-(arylcarbonyl)thiosemicarbazides as activators of caspases  
and inducers of apoptosis

IN Cai, Sui Xiong; Nguyen, Bao Ngoc; Drewe, John; Reddy, P. Sanjeeva;  
Kasibhatla, Shailaja; Pervin, Azra

PA Cytovia, Inc., USA

SO PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002098420	A1	20021212	WO 2002-US17108	20020531
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1399159	A1	20040324	EP 2002-734605	20020531
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003045581	A1	20030306	US 2002-158827	20020603
	US 6794400	B2	20040921		
PRAI	US 2001-294641P	P	20010601		
	WO 2002-US17108	W	20020531		
OS	MARPAT 138:24718				
IT	220127-57-1, Gleevec				

10/519,722

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(preparation of 4-substituted-1-(arylmethylidene)thiosemicarbazides and  
4-substituted-1-(arylcarbonyl)thiosemicarbazides for treating cancer in  
combination with)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 100 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:778718 CAPLUS

DN 137:289046

TI Methods and compositions for enhancing pharmaceutical treatments

IN Newman, Michael J.; Dixon, William Ross

PA USA

SO U.S. Pat. Appl. Publ., 47 pp., Cont.-in-part of U.S. Ser. No. 684,293.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002147197	A1	20021010	US 2002-104549	20020320
PRAI	US 1999-158322P	P	19991008		
	US 2000-684293	A2	20001006		
OS	MARPAT 137:289046				


IT 152459-95-5, Imatinib 152459-95-5D, Imatinib, derivs.,  
analog, and metabolites

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(methods and compns. for enhancing pharmaceutical treatments)


RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 101 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:675840 CAPLUS

DN 137:226590

TI Use of epothilone derivatives and a signal transduction inhibitor for the treatment of cancer

IN Buchdunger, Elisabeth; Heldin, Carl-Henrik; Oestman, Arne; Pietras, Kristian; O'Reilly, Terence; Rothermel, John David; Traxler, Peter; Wartmann, Markus

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.; Brandt, Ralf

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002067941	A2	20020906	WO 2002-EP2049	20020226
	WO 2002067941	A3	20031120		
	WO 2002067941	C1	20031218		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	CA 2439268	AA	20020906	CA 2002-2439268	20020226
	EP 1385522	A2	20040204	EP 2002-744903	20020226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002007649	A	20040309	BR 2002-7649	20020226
	CN 1511036	A	20040707	CN 2002-805608	20020226

10/519,722

JP 2004527493	T2	20040909	JP 2002-567308	20020226
NZ 527764	A	20060127	NZ 2002-527764	20020226
ZA 2003006404	A	20040607	ZA 2003-6404	20030818
NO 2003003769	A	20030825	NO 2003-3769	20030825
US 2004132754	A1	20040708	US 2004-469367	20040218
PRAI GB 2001-4840	A	20010227		
US 2001-339040P	P	20011030		
WO 2002-EP2049	W	20020226		

OS MARPAT 137:226590

IT 220127-57-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(STI 571; use of epothilone derivs. and a signal transduction inhibitor for the treatment of cancer)


RN 220127-57-1 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5


CMF C29 H31 N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S



L5 ANSWER 102 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2002:593669 CAPLUS

DN 138:198235

TI Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases

AU Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel; Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas; Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard

CS Molecular Pharmacology and Chemistry Program, New York, NY, 10021, USA

SO Cancer Research (2002), 62(15), 4244-4255

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research


DT Journal

10/519,722

LA English  
IT 220127-57-1, Imatinib mesylate  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(characterization of potent inhibitors of Bcr-Abl and the c-kit  
receptor tyrosine kinases and their antitumor effect)  
RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-  
pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA  
INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2002:465821 CAPLUS  
DN 137:47211  
TI Substituted 2-aryl-4-arylamino pyrimidines and analogs as activators of  
caspases and inducers of apoptosis, their preparation, and the use thereof  
as, e.g., anticancer agents  
IN Cai, Sui Xiong; Drewe, John A.; Nguyen, Bao; Reddy, P. Sanjeeva; Pervin,  
Azra  
PA Cytovia, Inc., USA  
SO PCT Int. Appl., 210 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002047690	A1	20020620	WO 2001-US47498	20011212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2002028922 A5 20020624 AU 2002-28922 20011212  
 US 2003069239 A1 20030410 US 2001-12444 20011212  
 US 6716851 B2 20040406  
 EP 1351691 A1 20031015 EP 2001-990048 20011212  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2004097503 A1 20040520 US 2003-704448 20031110  
 PRAI US 2000-254581P P 20001212  
 US 2001-12444 A3 20011212  
 WO 2001-US47498 W 20011212  
 OS MARPAT 137:47211  
 IT 438248-82-9P, 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[[2-(pyridin-4-yl)-6-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]benzamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of substituted aryl(arylamino)pyrimidines and analogs as caspase activators, apoptosis inducers, and anticancer agents)  
 RN 438248-82-9 CAPLUS  
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[2-(4-pyridinyl)-6-(trifluoromethyl)-4-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 104 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2001:686951 CAPLUS  
 DN 136:111944  
 TI Bcr-Abl inhibition as a modality of CML therapeutics  
 AU Buchdunger, E.; Matter, A.; Druker, B. J.  
 CS Research Oncology, Novartis Pharma AG, Basel, CH-4002, Switz.  
 SO Biochimica et Biophysica Acta, Reviews on Cancer (2001), 1551(1), M11-M18  
 CODEN: BBACEU; ISSN: 0304-419X  
 PB Elsevier B.V.  
 DT Journal; General Review  
 LA English  
 IT 220127-57-1  
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (STI 571; Bcr-Abl inhibition as modality of chronic myelogenous leukemia therapeutics)




10/519,722

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 152459-95-5 CAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

379.57

547.16


STN INTERNATIONAL LOGOFF AT 13:50:07 ON 29 SEP 2006

10/519,722

RN 220127-57-1 CAPLUS  
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 152459-95-5  
CMF C29 H31 N7 O



CM 2

CRN 75-75-2  
CMF C H4 O3 S



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 106 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 1996:380210 CAPLUS  
DN 125:114681  
TI Pyrimidine derivatives and processes for the preparation thereof  
IN Zimmermann, Juerg  
PA Ciba-Geigy Corporation, USA  
SO U.S., 18 pp., Cont.-in-part of U.S. Ser. No. 42,322, abandoned.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5521184	A	19960528	US 1994-234889	19940428
	CA 2148477	AA	19950413	CA 1994-2148477	19940921
PRAI	CH 1992-1083	A	19920403		
	US 1993-42322	B2	19930402		
	CH 1993-2966	A	19931001		

OS MARPAT 125:114681

IT 152459-93-3P 152459-95-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of phenylaminopyrimidine derivs. as antitumor agents)

RN 152459-93-3 CAPLUS